Type 1 ryanodine receptor interactions by English, Kathleen Kelly
Title Type 1 ryanodine receptor interactions
Author(s) English, Kathleen Kelly
Publication date 2015
Original citation English, K. K. 2015. Type 1 ryanodine receptor interactions. PhD
Thesis, University College Cork.
Type of publication Doctoral thesis
Rights © 2015, Kathleen K. English
http://creativecommons.org/licenses/by-nc-nd/3.0/
Embargo information No embargo required
Item downloaded
from
http://hdl.handle.net/10468/2238
Downloaded on 2017-02-12T07:04:29Z
i 
 
Type 1 Ryanodine receptor 
Interactions 
Kathleen Kelly English BSc. 
Thesis presented for examination for the degree of PhD. in Medicine (Physiology) to 
National University of Ireland, Cork. 
 
 
 
 
 
Department of Physiology, 
Head of Department: Prof. Ken O’Halloran 
Supervisor: Dr John Mackrill 
September 2015 
ii 
 
i 
 
Table of Contents  
Contents 
Type 1 Ryanodine receptor Interactions ......................................................................... i 
Table of Contents ............................................................................................................ i 
Declaration: ................................................................................................................ viii 
Papers: ........................................................................................................................... ix 
Abstracts: ...................................................................................................................... ix 
Acknowledgements ........................................................................................................ x 
List of figures ............................................................................................................... xii 
List of tables:.............................................................................................................. xvii 
Abbreviations .............................................................................................................. xix 
Abstract: ....................................................................................................................... 25 
Chapter 1: Introduction ................................................................................................ 27 
1.1: Ca
2+
 signalling in skeletal muscle ..................................................................... 28 
ii 
 
1.2: Skeletal muscle structure .................................................................................. 29 
1.2.a: Neural supply to skeletal muscle: .............................................................. 29 
1.2.b: Skeletal Muscle Cell Structure .................................................................. 30 
1.2.c: Sarcomere structure. ................................................................................... 31 
1.3 : Muscle fibre Types .......................................................................................... 34 
1.3.b: Muscle Fibre type determination ............................................................... 37 
1.3.a: Skeletal muscle contraction ........................................................................... 38 
1.3.b: EC coupling: role of the Ryanodine Receptor ........................................... 40 
1.3.c: Cross Bridge cycling: ................................................................................. 42 
1.3.d: Relaxation of skeletal muscle .................................................................... 44 
1.3.e: Skeletal Muscle Fatigue ............................................................................. 45 
1.4.a: Structure and function of RyRs ...................................................................... 46 
1.4.b: RyR interactions ........................................................................................ 50 
1.5: Regulation of RyR by small molecules and ions .......................................... 59 
1.6: RyRs in disease ................................................................................................. 65 
iii 
 
1.6.a: Malignant Hyperthermia ............................................................................ 65 
1.6.b: Central Core Disease ................................................................................. 66 
1.6.c: Multi-mini Core Disease ............................................................................ 67 
2.1: Aims and objectives: ............................................................................................. 69 
Chapter 3:Materials and methods ................................................................................ 70 
3.1. Cell culture ........................................................................................................ 71 
3.1.a: General Culture .......................................................................................... 71 
3.1. b: General methods: Cell culture. ................................................................. 72 
3.1. c: Subculture. ................................................................................................ 72 
3.1.d: C2C12 cells and Differentiation assay....................................................... 73 
3.1.e: siRNA Knock-Down of JPH1. ................................................................... 73 
3.1.f: A7r5 rat smooth muscle aortic cell line and calpian inhibition assay. ....... 74 
3.2: Animal tissue studies : ...................................................................................... 75 
3.2.a: CIH and Sham rat treatment: ..................................................................... 76 
3.2.b: Adult versus Aged animals: ....................................................................... 76 
iv 
 
3.3: Sample Preparation. .......................................................................................... 77 
3.3.a:Materials: .................................................................................................... 77 
3.4: Peptide array and Chromatography. ................................................................. 84 
3.5 : SDS-PAGE and Immunoblotting..................................................................... 90 
3.6: Statistical analysis ............................................................................................. 98 
3.7: Bioinformatic analysis: ..................................................................................... 99 
3.7.b: Calpain cleavage site approximation in JPH1 and JPH2: ........................ 100 
3.7.c: Rf measurement ........................................................................................ 100 
Chapter 4: Characterisation of potential RyR1-SH3 Binding domain interaction 
partners ....................................................................................................................... 102 
4.1:Introduction ...................................................................................................... 103 
4.2: Aims: ............................................................................................................... 106 
4.3: Results ............................................................................................................. 109 
4.3.a: Cell line screening for SH3B binding peptides ........................................ 109 
4.3.b: Peptide Assay ........................................................................................... 111 
4.3.c: Batch Chromatography ............................................................................ 112 
v 
 
4.3.d Hydroxyapatite Chromatography.............................................................. 113 
4.3.e: Isoelectric focusing .................................................................................. 116 
4.3.f: Biotin block of spurious reactions ............................................................ 118 
4.3.g: Novel RyR1 accessory proteins from Protein Interaction Databases. ..... 121 
4.4: Discussion: ...................................................................................................... 129 
4.5: Future Studies: ................................................................................................ 134 
Chapter 5: mAb VF1c Characterisation ..................................................................... 136 
5.1.: Introduction .................................................................................................... 137 
5.1.a:Junctophilin structure and function: .......................................................... 138 
5.2: Aims: VF1c Characterisation .......................................................................... 140 
5.3: Results ............................................................................................................. 141 
5.3.a: VF1c antibody characterisation ............................................................... 141 
5.3.b: JP1 and VF1c mAb comparison in mouse muscle . ................................ 144 
5.3.c: Investigation of JPH1 and 2 expression in organs from rat. .................... 145 
5.3.c: Comparison of JPH1 and 2 in various skeletal muscle from rabbit. ........ 148 
vi 
 
5.3.e and f: Characterisation of JPH1 protein expression and siRNA knock-down 
in C2C12 myotubes............................................................................................ 150 
5.3.g: Calpain Cleavage study using A7r5 cell lines and in silico analysis of 
likely calpain targets in JPH1 and 2. .................................................................. 153 
5.4: Discussion ....................................................................................................... 160 
5.5: Future Studies ................................................................................................. 170 
Chapter 6: Junctophilin 1 and 2 abundance in models of disease.............................. 173 
6.1. :Introduction .................................................................................................... 174 
6.2: Aims: ............................................................................................................... 183 
6.3: Results:............................................................................................................ 183 
6.3.a: JPH1 and 2 in 8 month old mdx and BL10 (WT )mouse strains ............. 183 
6.3.b: JPH1 and JPH2 in sarcopenia: effect of exercise. ................................... 190 
6.3.c: JPH1 and 2 expression in the 2 week CIH rat .......................................... 200 
6.4: Discussion ....................................................................................................... 207 
6.4.a: JPH1 and JPH2 abundance in mdx and WT mouse muscle. .................... 207 
6.4.b: JPH1 and 2 in exercised and unexercised adult and aged mice ............... 209 
vii 
 
6.4.c: JPH1 and JPH2 in CIH and sham treated rat EDL and Soleus Muscles .. 211 
6.5: Future studies .................................................................................................. 213 
Chapter 7: Discussion ................................................................................................ 216 
7.1: Introduction ..................................................................................................... 217 
7.2: GRB2-RyR1 interaction ................................................................................. 218 
7.3: Characterisation of mAb VF1c. ...................................................................... 221 
7.4: JPH1 and JPH2 in disease models. ................................................................. 228 
7.5: Conclusions:........................................................................................................ 233 
8.1: Appendices.......................................................................................................... 236 
8.2: Appendix II ..................................................................................................... 247 
8.3: Appendix III .................................................................................................... 254 
References .................................................................................................................. 261 
 
 
viii 
 
Declaration: 
I declare that all work in this thesis is my own (except where stated) and has not been 
presented for examination for any other degree. 
Signed: 
Kathleen K. English 
_________________________________ 
 
ix 
 
Papers: 
Closing a small gap in our understanding of excitation-contraction coupling: 
JSR90/JFP90 is Junctophilin 1 
Kathleen K. English, Vincenzo Sorrentino, Anna Carla Aiello,Maeve Kiely, Patrick 
A. Kiely, Brian Mcdonagh, John J. Mackrill. (2014) Calcium Signaling VOL.1 NO.1 
2373-1168 
 
Abstracts: 
Characterisation of Junctophilin 1 (JPH1) expression in rabbit skeletal muscle. 
Kathleen K. English, John J. Mackrill. Presented in poster form at the European 
Muscle Conference, September 2014. 
Closing a Gap in skeletal muscle Excitation-Contraction coupling: the 90 kDa 
Junctional foot protein is Junctophilin 1. K.K English, A. Carla, V. Sorrentino, J.J. 
Mackrill.Oral communication presented at Royal Academy of Medicine Biosciences 
meeting, June 2013.  
Characterisation of a putative SRC Homology 3 domain binding region in the Type 1 
Ryanodine receptor. K.K. English, W. Hu, D. Sheehan, J.J.Mackrill. Poster 
presentation and oral communication at RAMI Biosciences meeting, June 2011.  
 
x 
 
Acknowledgements 
First of all, I’d like to thank John Mackrill for taking me on as a student; from the 
minute I waltzed into the lab as a baby undergrad, I’ve loved working in there! I’d 
also like to thank the heads of department Patrick Harrison and Ken O’Halloran for 
allowing me to stay on. To say I’ve learned bucketloads would be an understatement! 
I’d also like to extend my gratitude to our collaborators in the McDonagh group, the 
Sorrentino group, Dave Sheehan’s Lab, the O’Halloran group and the Kiely group in 
UL, without whom this research would have been impossible: Thanks everyone!  
 I would also like to thank the staff in the Physiology department, especially 
Kieran, Miriam, Marcella, Greg, Tony, Jackie, Nora, Nicola, Maude and Verna, for 
all they do for us and making our lab-home feel like home! Thanks also to the 
academic staff, especially my panel for the interesting discussions, help and 
suggestions along the way.  
Extra-Special thanks to my fellow postgrads for making this the most fun four years 
ever. Lets face it, Physiology knows how to talk science while throwing a fabulous 
party! Special mention to everyone who donated the odd muscle: I realise I’m the 
department magpie, appearing in with the nitrogen “is anyone using that leg?!”, so 
big, huge thank yous to Dr. Maria, Elaine, Jenny, Cliona, Andy, Ciara, Nurullah, 
Julie, Philip and David (Sorry If I’ve forgotten anyone!); I owe ye big time! Special 
Mention to Dr Jen Hollywood, my lab-bestie, Elaine Barry, Fiona O Brien, Dr. Katrin 
Kaschig and Dr. Jenny Manning for all the support, help, kind words and generally 
being lovely, fabulous people. I’d also like to express my gratitude to the BSI crowd, 
especially Drs Will Pierce, Limian Zheng and Ciaran Lee, for their unwaivering 
patience and for all the help they gave me. 
xi 
 
 I cant write an acknowledgement section without mentioning the amazing staff 
of the Mercy hospital, without whom I definitely wouldn’t have managed, thanks for 
keeping me alive guys!  
 As always (she did put manners on me after all), I’d like to thank my lovely 
supportive family: Mom for minding me and always being in my corner; she takes full 
responsibility for my being a physiologist, after all, she bought me a how your body 
works book when I was 5, followed by years of watching ER and looking up the 
diseases. Thanks also to Dad, who always encourages me to bet on myself, and is 
never too busy to dole out sound advice or help jumpstart my car! Thank you Dr Tom 
English, for the many understanding chats and pep-talks. Thanks to Barry (and Aoife 
and Violet) for lightening the mood and all the support, and an extra big thank you to 
the best big little sister in the world, for her undying support, the many care packages 
and always having my back; thanks Gracie!  
 Finally, last but not least, to John Catchpole, my favourite human on the 
planet. Thank you for being kind, rational and amazingly understanding. I’m not sure 
how you put up with papers and wool all over the apartment, as well as my ranting 
about blotchey blots and cheeky undergrads, but you did, and frankly you deserve 
some sort of medal. I’m very excited about this new post-college part of our life, and I 
couldn’t wish for a more perfect better half!  
I would like to dedicate this thesis to my wonderful family, to John Catchpole, and to 
anyone who “just needs this last replicate to work!”  
 
xii 
 
List of figures 
Figure 1.2.b.i: Schematic of a skeletal muscle..............................................................7 
Figure 1.2.c: Schematic showing the structure of myofibrils is made up of 
sarcomeres....................................................................................................................8 
Figure 1.3.a: Schematic of the T-tubule and SR in the process of muscle 
contraction....................................................................................................................13 
Figure 1.3.b: Diagram of the location of RyRs and DHPRs in the triad ....................15 
Figure 1.3.c.i: Schematic of Cross bridge cycling in skeletal muscle. ......................16 
Figure 1.3.c.ii: Diagram of sarcomere shortening in cross bridge cycling. ...............17 
Figure 1.4.a: Diagram of RyR1 structure.....................................................................22 
Fig 1.3.c: Schematic of some of the known RyR1 interacting proteins. .....................28 
Figure 1.5.i:Diagram of RyR structure.........................................................................35 
Figure 4.1.1a: Cartoon of biotinylated peptides used in overlay and pull down 
experiments..................................................................................................................71 
Figure 4.1.2 b: Clustal Omega alignment of the Proline rich region (αα4462-4532) of 
Human, rabbit, pig, mouse, rat and chimpanzee RyR1. ..............................................72 
Figure 4.1.2a: Investigation of SH3B-interacting proteins in cell lines......................74 
Figure 4.1.4: SH3B peptide overlay optimisation. ......................................................75 
Figure 4.2.1: Batch chromatography of solubilised A549 homogenate. ...................76 
xiii 
 
Figure 4.2.2a: A549 homogenate subjected to hydroxyapatite chromatograpy and 
peptide overlay using SH3B peptide............................................................................78  
Figure 4.2.2b:Silver stained gel of A549 homogenate subjected to hydroxyapatite 
chromatography...........................................................................................................79  
Figure 4.2.2c: Peptide overlay of hydroxyapatite fractions from A549 cell line......80 
Figure 4.3.1a: IEF and peptide overlay using SH3B and SCRAM peptides...............82 
Figure 4.3.2a : Biotin-block of spurious reactions. .....................................................84 
Figure 4.4.1d: Coomassie stained rat brain and muscle samples subjected to 
solubilisation and pull down using FKBP12 –GST. ..................................................87 
Figure 4.4.1e: Rat brain and muscle samples subjected to solubilisation and pull down 
using FKBP12 –GST followed by western blot with H300 anti-RyR antibody. ........88 
Figure 4.4.1c: FKBP12 pull down using rat brain and muscle, probed with α 
Pleiotrophin (PTN) antibody........................................................................................89  
Figure 4.4.1.f: FKBP12 pull down probed with αPLCγ 1 antibody. .........................90 
Figure 4.4.1.g: Western blot of Brain and muscle samples from rat incubated with 
FKBP12 fusion proteins and probed with αGRB2 antibody. ......................................91 
Figure 5.1.1.a: diagram of JPH1 protein amino acid sequence. ................................100 
Figure 5.1.3 Yeast expressed fragments of JPH1 probed with A) mAb VF1c or B) aC-
terminal JP1 antibody. ...............................................................................................103 
Figure 5.1.1.b: Western blot experiment of Mouse muscle samples probed with pAb 
JP1 and mAb VF1c. ..................................................................................................105 
Figure 5.1.3 c: Expression pattern of JPH1 and JPH2 protein in rat. ......................106 
Figure 5.1.3.d: VF1c and JPH2 screen of Rabbit muscle types. ..............................109 
xiv 
 
Figure 5.1.3.f: JPH1 abundance in differentiating C2C12 myotubes. .....................111 
Figure 5.1.3.g siRNA knock down of JPH1 protein. ...............................................112 
Figure 6.1.1a: A diagram of the dystrophin associated proteins in complex at the cell 
membrane of skeletal muscle cells. ........................................................................122 
Figure 6.1.1.b: Overview of muscular effects caused by lack of Dystrophin 
expression. ..............................................................................................................123  
Figure 6.1.1.c.:diagram of factors involved in sarcopenia ....................................125 
Figure 6.1.3.a.i:  VL muscles of mdx and WT type mice were analysed via western 
blot for JPH1 and JPH2 expression using mAb VF1c and pAb JP2 antibodies .....129 
Figure 6.1.3.a.ii: analysis of JPH1 and JPH2 abundance in WT and mdx mouse 
diaphragm. ................................................................................................................130 
Figure 6.1.3.a.iii: Analysis of JPH1 and 2 in gastrocnemius muscle of WT and mdx 
mice. .........................................................................................................................131 
Figure 6.1.3.a.iv: analysis of JPH1 and 2 expression in mdx and WT soleus.........132 
Figure 6.1.3.b.i: JPH1 abundance measured in adult, aged, adult exercised and aged 
exercised quadriceps and soleus from mice via western blot using the mAb VF1c..134 
Figure 6.1.3.b.ii: Mouse quadriceps and soleus from adult (12 mth) and aged (24 mth) 
animals (exercised and non-exercised) assayed for JPH1 abundance using the mAb 
VF1c. .........................................................................................................................135 
Figure 6.1.3.b.iii: Screening of quadriceps and soleus muscle from adult, aged, (24 
months) adult exercised and aged exercised mouse muscle using pAb JP1. .........137 
Figure 6.1.3.b.iv: Western blots of quadriceps and soleus muscle from adult, aged, (24 
months) adult exercised and aged exercised mouse muscle using pAb JP1 .........138 
 
xv 
 
Figure 6.1.3.b.v: Graph depicting JPH2 levels (total protein) as detected by pAb JP2 
in soleus and quadriceps muscle from adult, aged, exercised adult and exercised aged 
mice. .........................................................................................................................140 
Figure 6.1.3.b.vi: Quadriceps and soleus muscles from adult, aged, adult exercised 
and aged exercised mice were analysed for JPH2 expression via Western blot......141 
Figure 6.1.3.c.i: CIH and sham rat EDL muscle analysed using mAb VF1c. ..........143 
Figure 6.1.3.c.i: EDL muscle from Sham and CIH treated rat was analysed for JPH1 
and JPH2 expression. ................................................................................................144 
Figure 6.1.3.c.ii: Sham and CIH treated rat soleus were analysed via western blot for 
JPH1 and JPH2 expression. .......................................................................................145 
Figure 6.1.3.c.iii: Graphs showing comparison of JPH1 (mAb VF1c and pAb JP1) and 
JPH2 (pAb JP2) abundance in EDL and soleus muscle from CIH and Sham–treated 
rats. ............................................................................................................................146 
Figure 8.1.a: Example of Rf measurement................................................................170 
Figure 8.1.b: MW calculation of cell culture screen: SH3B blot. ............................171 
Figure 8.1.d: Rf  calculations for FKBP12 pull down experiments...........................172 
Figure 8.1.e: FKBP 12 pull down of rat Brain and muscle, probed with anti- mouse or 
anti-Rabbit secondary antibody only. ........................................................................176 
Figure 8.1.f: OPHID search using “RyR1” as input method returns 38 known or 
predicted interactors. .................................................................................................178 
Figure 8.2.a:peptide array of amino acid fragments from JPH1 probed with VF1c and 
with secondary antibody only. ..................................................................................180 
Figure 8.2.b: Post antibody detection via ECl and Film, rabbit tissue blots were 
stained with Coomassie for densitometric analysis. .................................................182 
Figure 8.2.c: Rabbit muscle secondary only blots. ...................................................183 
xvi 
 
Figure 8.2.d : 3 hour incubation of A7r5 cells with calpain inhibitors. .................184 
Figure 8.2.e: 6 hour incubation of A7r5 cells with calpain inhibitors. ...................185 
Figure 8.2.f:A7r5 secondary only controls. .............................................................186 
Figure 8.2.g: Clustal Ω alignment of protein sequences from JPH1 and JPH2 from 
human, rabbit, rat and mouse...................................................................................187 
Figure 8.3.a: Western blot of rat muscle and organ tissue probed with anti-mouse 
secondary antibody only.. ........................................................................................189 
Figure 8.3.b: Rat muscle and organ samples probed with anti-rabbit antibody. .....190 
Figure 8.3.c: Anti-rabbit secondary control of Mouse organ and muscle tissue......191 
Figure 8.3.d: Anti-Mouse secondary control western blot of mouse organ and muscle. 
....................................................................................................................................192 
Figure 8.3.e: Quadriceps from adult and aged exercised and unexercised mouse 
probed with mAb VF1c and pAb JP1 antibodies......................................................222 
Figure 8.3.f:  Diagram of possible cleavage of JPH1 protein (dashed lines).............222 
 
xvii 
 
List of tables: 
Table 1.2 d: Differing cell components in slow and fast muscle types......................10 
Table1.4.d: well-known RyR1 interacting proteins and the effect of their ablation...32 
Table 3.1.f: Chemicals and concentrations used in calapin cleavage assays…….…43 
Table 3.3.d.i: Muscles excised from rodents………………..............................49 
Table 3.3.d.ii: Protease Inhibitors and Phosphatase Inhibitor used in Homogenisation 
and RIPA based sample preparation. .........................................................................49  
Table 3.3.e.i: BSA, distilled water and Bradford reagent concentrations and layout for 
Bradford assay ...........................................................................................................51 
Table 3.3.e.ii: Typical Sample dilutions, distilled water content and Bradford reagent 
volumes used in protein determination using the Bradford assay.............................51 
Table 3.4.a: Matrices used in batch chromatography and corresponding wash and 
elution buffers. ...........................................................................................................55 
Table 3.5.a: Components of stacking gels used in SDS-PAGE experiments. ............58 
Table 3.5.b: Components of resolving gels used in SDS-PAGE experiments. ..........59 
Table 3.5.c: Table describing the fragments of JPH1 expressed in yeast...................63 
Table 3.5.d. Antibodies used in western blot experiments. ........................................64 
xviii 
 
Table 4.3.a: List of cell lines used in pilot overlay experiment. ...............................74 
Table 8.1.a: average of molecular weights of proteins detected using SH3B peptide  
calculated from cell culture screen, peptide optimisation and hydroxyapatite 
experiments. ..............................................................................................................171 
Table 8.1.c: TagIdent (expasy.org) search using parameters defined by experimental 
results from section 4.3.1a-d......................................................................................173 
Table 8.2.a: Amino acids from JPH1 (VF1c interacting region 369-460) synthesised 
via fmoc chemistry and probed with VF1c antibody. ..............................................181 
Table 8.2.b: Calculated molecular weight of JPH1 and JPH2 in various rabbit skeletal 
muscle. .......................................................................................................................182 
Table 8.3.a: Rf of proteins analysed from rat muscle as detected with anti mouse 
secondary antibodies. ................................................................................................188 
 
xix 
 
Abbreviations 
αα: Amino acid. 
Ab: antibody 
AHX: Aminohexanoic acid 
ALL-N: N-acetyl-Leu-Leu-norleucinal, Ac-LLnL-CHO. Calpain inhibitor I. 
APS: Ammonium Persulfate. 
ARVD2: Arrymthogenic right ventricle Dysplasia 
ATP: Adeonsine Triphosphate. 
BSA: Bovine Serum Albumin.  
CaM: Calmodulin 
CaMKII: Calmodulin Kinase II.  
CASQ: Calsequestrin 
Cav1.1 channel:voltage sensitive calcium channel type one, also known as L-type 
voltage operated calcium channels or Dihydropyridine receptor. 
CAV3: Caveolin 3.  
CBC: Cross Bridge Cycling. 
CCD: Central Core Disease. 
CICR: Calcium Induced Calcium release. 
xx 
 
CIH: Chronic Intermittent Hypoxia.  
CHAPS: (3-((cholamidopropyl)dimethylammonio)-1-propane-sulfonate), 2 
CHERP: Calcium homeostasis endoplasmic reticulum protein. 
CLFS: Chronic Low Frequency Stimulation. 
CMC: Chloro-Meta-Creosol. 
CPVT: Catecholaminergic polymorphic ventricular tachycardia. 
CRU: Calcium release unit. 
DHPR: Dihydropyridine receptor (also known as L-type Voltage operated Calcium 
channels or Cav 1.1) 
DMD: Duchenne Muscular Dystrophy. 
DTT: Dithiothreitol. 
EC Coupling: Excitation Contraction Coupling. 
EDL: Extensor Digitorum Longus. 
EDTA: Ethylenediaminetetraacetic acid. 
EGCG: Epigallocatechin gallate 
ER: Endoplasmic Reticulum. 
EtOH: Ethanol. 
FBS: Fetal Bovine Serum. 
FKBP12, 12.6: FK 506 binding protein (12 or 12.6) 
xxi 
 
FMOC: Fluorenylmethyloxycarbonyl chloride. 
GRB2: Growth factor receptor Bound protein 2. 
GST: Glutathione-S-Transferase. 
IEF: Isoelectric Focussing. 
IPTG: Isopropyl β-D-1-thiogalactopyranoside. 
JPH 1,2,3 or 4: Junctophilin 1,2,3 or 4. 
JP-45: Junctional protein 45 
JSR-90: Junctional Sarcoplasmic Reticulum protein 90.  
KO: Knock out. 
Leup: Leupeptin. 
mAb: Monoclonal antibody. 
MALDI ToF: Matrix-assisted laser desorption/ionization Time of Flight analysis. 
mAKAP: Muscle A Kinase anchoring protein. 
MAPK: Mitogen activated Protein Kinase 
mdx mouse: Mouse model of Duchenne Musclar dystrophy.  
MeOH: Methanol. 
MG-29: Mitsugumin 29. 
MH: Malignant Hyperthermia. 
xxii 
 
MmD: Multi-minicore disease. 
MORN motif: Membrane opposition and Recognition Nexus. 
MW: Molecular weight. 
N-terminal: NH2 terminal end of a protein.  
NCK1: Non-catalytic region of tyrosine kinase adaptor protein 1. 
NCX: Sodium-calcium exchanger protein. 
NFAT: Nuclear factor of activated T-cells. 
NP-40: Nonidet P-40 detergent (octylphenoxypolyethoxyethanol). 
pAb: Polyclonal Antibody 
PATS assay: peptide array target screening assay.. 
Pep A: Pepstatin A. 
PBS: Phosphate Buffered Saline. 
pI: Isoelectric point. 
PKA: Protein Kinase A. 
PKC: Protein Kinase C. 
PLCγ1: Phospholipase C γ 1. 
PM: plasma membrane. 
PMCA: Plasma membrane Calcium ATPase Pump. 
xxiii 
 
PMSF: phenylmethanesulfonylfluoride. 
PTN1: Pleiotrophin 1. 
PVDF: polyvinylidene difluoride. 
Rf : Retardation factor. 
RIPA Buffer: Radio immunoprecipitation Assay buffer. 
ROS: reactive oxygen species. 
RyR 1,2 or 3: Ryanodine receptor (type 1,2 or 3). 
S100a: S100 calcium-binding protein A1. 
SCRAM: scrambled (peptide) 
SDS: Sodium Dodecyl Sulfate 
SDS-PAGE: Sodium Dodecyl Sulfate Polyacyrlamide electrophoresis.  
SEPN1: Selenoprotein N 1. 
SERCA: Sarcoplasmic/Endoplasmic reticulum Calcium ATPase pump. 
siRNA: small interfering RNA. 
SH2: SRC-Homology 2 domain 
SH3: SRC-Homology 3 Domain. 
SH3B: SH3 domain binding region. 
shRNA: small  hairpin RNA. 
xxiv 
 
SOCE: Store-operated Calcium entry.  
SR: Sarcoplasmic reticulum. 
TBS: Tris Buffered Saline. 
WT: Wild type. 
25 
 
Abstract: 
Excitation-contraction coupling is an essential part of skeletal muscle contraction. It 
encompasses the sensing of depolarisation of the plasma membrane coupled with the release 
of Ca
2+
 from intracellular stores. The channel responsible for this release is called the 
Ryanodine receptor (RyR), and forms a hub of interacting proteins which work in concert to 
regulate the release of Ca
2+
 through this channel. The aim of this work was to characterise 
possible novel interactions with a proline-rich region of the RyR1, to characterise a 
monoclonal antibody (mAb VF1c) raised against a junctional sarcoplasmic reticulum protein 
postulated to interact with RyR1, and to characterise the protein recognised by this antibody 
in models of skeletal muscle disease such as Duchenne Muscular dystrophy (DMD) and 
sarcopenia. These experiments were performed using cell culture, protein purification via 
immunoprecipitation, affinity purification, low pressure chromatography and western blotting 
techniques. It was found that the RyR1 complex isolated from rat skeletal muscle co-purifies 
with the Growth factor receptor bound protein 2 (GRB2), very possibly via an interaction 
between the proline rich region of RyR1 and one of the SH3 domains located on the GRB2 
protein. It was also found that Pleiotrophin and Phospholipase Cγ1, suggested interactors of 
the proline rich region of RyR1, did not co-purify with the RyR1 complex.  
 Characterisation of mAb VF1c determined that this monoclonal antibody interacts 
with junctophilin 1, and binds to this protein between the region of 369-460, as determined 
by western blotting of JPH1 fragments expressed in yeast. It was also found that JPH1 and 
26 
 
JPH2 are differentially regulated in different muscles of rabbit, where the highest amount of 
both proteins was found in the extensor digitorum longus (EDL) muscle.  
 JPH1 and 2 levels were also examined in three rodent models of disease: the mdx 
mouse (a model of DMD), chronic intermittent hypoxia (CIH)-treated rat, and aged and adult 
mice, a model of sarcopenia. In the EDL and soleus muscle of CIH treated rats, no difference 
in either JPH1 or JPH2 abundance was detected in either muscle. An examination of JPH1 
and 2 expression in mdx and wild type controls diaphragm, vastus lateralis, soleus and 
gastrocnemius muscle found no major differences in JPH1 abundance, while JPH2 was 
decreased in mdx gastrocnemius compared to wild type. In a mouse model of sarcopenia, 
JPH1 abundance was found to be increased in aged soleus but not in aged quadriceps, while 
in exercised quadriceps, JPH2 abundance was decreased compared to unexercised controls.  
Taken together, these results have implications for the regulation of RyR1 and JPH1 and 2 in 
skeletal muscle in both physiological and pathological states, and provide a newly 
characterised antibody to expand the field of JPH1 research.  
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Chapter 1: Introduction 
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1.1: Ca2+ signalling in skeletal muscle 
 As in any tissue, maintaining Ca
2+ 
homeostasis is crucial to the health of the cell, and 
consequently the entire tissue. Ca
2+
 is sequestered in discrete regions of the sarcoplasmic 
reticulum (SR), ready for release upon activation of contraction (see section 1.1.). Untimely 
or unwarranted entrance of Ca
2+ 
can have serious implications for the cell, including 
apoptosis, necrosis or cellular dysfunction. Calcium ions are utilised as a second messenger 
in a huge variety of cellular processes, including neurotransmitter release, gene expression 
and muscle contraction. Calcium regulated cellular processes involve changes in calcium 
concentration in both the cytoplasm and other cellular compartments (Cheng, Lederer, 2008).   
  Calcium release in the cell is tightly regulated. Calcium signalling can have long 
ranging (such as changes in gene expression) or short ranging effects, like brief contractions 
seen in skeletal muscle twitches. Internal calcium  ion concentrations are modulated by many 
proteins, which together are termed the Ca 
2+
 toolkit, described by Berridge, Bootman and 
Lipp. The Ca
2+ 
toolkit is a tissue specific set of proteins involved in the regulation of calcium 
inside the cell according to its needs. As dysregulated Ca
2+
 can be catastrophic for cellular 
fate; influx and efflux of this ion are tightly controlled. Calcium enters the cytosol from the 
extracellular milieu, and in muscle cells, from the SR and other cellular organelles. Calcium 
ions are in constant flux throughout all the organelles of the cell, particularly in muscle cells. 
The resting Ca
2+
 concentration of skeletal muscle is approximately 100 nM, while the replete 
29 
 
Ca
2+
 concentration in SR is approximately 0.5 to 1mM. (Baylor and Hollingworth, 2003; 
Calderón et al, 2014). Ca
2+
 release events from a single Calcium release unit (CRU)  
(discussed in section 1.1.c onwards) in muscle are known as sparks, and these localised Ca
2+ 
release events contribute to the formation of micro-signalling domains within cells. Skeletal 
muscle contraction cannot occur without Ca
2+
 release from intracellular stores (Berridge, 
2000; Berridge, Lipp and Bootman, 2000; Cheng and Lederer, 2008).   
1.2: Skeletal muscle structure 
Skeletal muscle is responsible for diverse processes such as locomotion, posture 
maintenance, respiration and vocalization. At the cellular level, muscle is made up of long 
chains of multinucleated cells called myofibres. These are organised into rods called muscle 
fibres and include the nerves and blood vessels supplying them. Groups of muscle fibres are 
bundled together to form fascicles, which themselves are assembled together to form muscle 
tissue. Skeletal muscle is usually attached at least one end to bone via a tendon (Lieber et al, 
2011).  
1.2.a: Neural supply to skeletal muscle: 
Most skeletal muscles are under both voluntary and involuntary control. Neural input to 
skeletal muscles arrives from the spinal cord via motor neurons. The main effectors of 
skeletal muscle contraction are α-motor neurons, most of which are monosynaptic. Each α- 
motor neuron innervates a specific number of muscle cells (ranging from few to several 
hundred). An α-motor neuron and the muscle fibres it stimulates are together termed a motor 
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unit. Motor units have varying numbers of muscle fibres; typically the lower the number of 
motor units, the finer the control of that muscle. Action potentials travel through these α-
motor neurons to their motor units to elicit contractions. α- motor neurons terminate at 
neuromuscular junctions (NMJ). 
 
 1.2.b: Skeletal Muscle Cell Structure 
Skeletal muscle cells are multinucleated, and contain mitochondria, a well developed 
endoplasmic reticulum (termed sarcoplasmic reticulum or SR in muscle), as well as other 
cellular components. Muscle fibres contain rows of sarcomeres, (comprised of thin filaments 
of actin, tropomyosin, troponin C, I and T, and thick filaments composed of myosin), which 
are attached to each other via the Z-line. The sarcomeres appear striated,  due to the repeating 
nature of the contractile proteins, and are surrounded by a well-developed network of the SR, 
which contains the main calcium store in skeletal muscle. The plasma membrane of muscle 
cells folds inward into what are known as TTubules, which abut the SR at specific junctions 
known as triads. A diagram of skeletal muscle structure can be seen in figure 1.2.b.i. Skeletal 
muscle cells have specialised infoldings of plasma membrane called transverse- tubules (T-
tubules), crucial to the spreading of the wave of depolarisation throughout the muscle cell. 
These T-Tubules interface with specialised, swollen regions of the SR called terminal 
cisternae. This enlarged SR interfaces with T Tubules at specific junctions called triads. T-
tubules and triads are crucial to muscle contraction (Stromer et al 1974). A schematic of this 
structure can be seen in Figure 1.2.b.i. 
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Figure 1.2.b.i: Schematic of a skeletal muscle cell. The diagram shows that the SR forms a 
well developed net around the contractile apparatus of the cell. Several nuclei and 
mitochondria are visible. The T-tubules are shown in yellow. This diagram also shows the 
interdigitation of thin (actin) and thick filaments (myosin ATPase seen here in red), which 
participate in cross bridge cycling (right hand side).  
1.2.c: Sarcomere structure. 
Sarcomeres are the contractile unit of skeletal muscle, and are made up of thin actin filaments 
and thick myosin filaments. The thin actin filaments are surrounded by a troponin C, troponin 
I and troponin T proteins, which occupy myosin binding sites in resting skeletal muscle. 
Myosin thick filaments have numerous heads, which in contracting muscle interact with the 
actin thin filaments to contract the sarcomere, and thus the muscle. A schematic of the 
sarcomere structure can be seen in figure 1.2.c.  Myosin can be seen as thick black lines, 
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while F actin is depicted in yellow. The A-band comprises F actin filaments (thin filaments) 
and the thick filaments (assembled myosin) in a lattice arrangement, which are packed 
slightly differently depending on the species: a haexagonal arrangement exists in insects 
flight muscle, but in vertebrates a tetragonal “super-lattice” of actin and myosin is more 
common. The A band also contains troponins T, I and C as well as tropomyosin, which play 
an essential role in regulating the thin-thick filament interaction crucial to muscle contraction 
(Squire, 1977; Craig and Woodhead, 2006). The I-band contains both the thin filaments and 
Z-line proteins. The Z line forms discs at the end of each sarcomere, attaching them linearly 
to each other, and is made up of primarily titin, nebulin and nebulette proteins. Z-line discs 
vary in size depending on the muscle fibre type: they are smaller in faster muscle types, about 
30-50 nm, while in cardiac and slower muscle fibres, Z line width can be 100 nm wide 
(Epstein and Davis, 2003).  As well as providing a structural scaffold for actin and α-actinin 
to bind to, Z-lines have important roles in passive force transmission and in stretch sensing in 
muscle cells (Luther et al, 2003; Luther, 2009; Lieber et al, 2011). Titin also participates in 
forming the M-line (the centre of the M-band, the region of thick myosin filaments without 
heads), and here provides a scaffold for myosin rod assembly in conjunction with obscurin. 
Obscurin also links other parts of the cyoskeleton such as the T-Tubule to the sarcomere, 
allowing quick communication between regions of muscle cells (Obermann et al, 1996; 
Kontrogianni-Konstantopoulos et al, 2003; Caldwell et al, 2015; Hu et al, 2015).  
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Figure 1.2.c: Schematic showing the structure of myofibrils is made up of sarcomeres. 
The A band (dark staining region) is made up of thick myosin filaments, and this contains the 
myosin ATPase heads necessary for interaction with the actin thin filaments (orange) in cross 
bridge cycling. The I band is comprised of these filaments and the Z disc, which link the 
sarcomeres together, end to end. The dark staining myosin and light staining actin thin 
filaments en masse give skeletal muscle its striated appearance.  
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1.3 : Muscle fibre Types 
In humans, muscle fibres are of three main types, type I, type IIa and type IIb. These 
were first classified as red and white muscles by Ranvier in 1874, based on the colour of the 
muscle, but it has since been discovered that muscle fibre types can be classified on the basis 
of contraction speed and protein expression. There are three main methods of classifying 
muscle: by histochemical staining of myosin ATPase, analysis of myosin heavy chain (part of 
the myosin ATPase molecule which interacts with the actin thin filament) expression in 
individual fibre types by immunohistochemistry or single fibre SDS-PAGE, or by enzymatic 
analysis of the oxidative state of muscle fibres being examined. There are four main fibre 
types in mammals, type I, type IIA, type IIX, and type IIB, as determined by ATPase- based 
histochemical staining. While all are expressed in varying proportions in smaller mammals 
such as mice and rats, humans do not express the type IIb fibre subtype (Scott et al, 2001; 
Westerblad et al, 2010). Confusion can persist in fibre type nomenclature based on fibre 
types determined by immunohistochemical staining, which uses antibodies to determine the 
exact myosin heavy stain isoform expressed in a muscle fibre. Multiple or a gradient of 
myosin heavy cahin isoforms can be expressed in some skeletal fibres, these are known as 
mixed fibres (Schiaffino, Reggiani, 2011).   
Type I fibres are the slowest isoform, meaning that they express type I myosin 
ATPase, giving them the slowest rate of cross bridge cycling, but they are highly fatigue 
resistant. Muscle comprised primarily of type I fibres (e.g. the soleus, an anti-gravity muscle 
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in the leg) are red because of their high capillary density and increased myoglobin 
concentration (compared to other muscle fibre types). Type I muscle needs high capillary 
density to provide oxygen to an increased number of mitochondria present within the muscle 
fibres, as the main energy source in these muscle is oxidative phosphorylation. It is for this 
reason that slow muscle fibres are also known as slow oxidative fibres. Slow fibre types have 
a less well developed SR, while fast fibre types have a highly structured SR. Slow fibre types 
have a lower power output than faster fibre types, and peak Ca
2+
 release is also lower in the 
former. Structurally, slow fibre types have a thicker Z line, which may be linked to stability 
under conditions of prolonged contractions. Crucially, slower muscle fibre types are more 
fatigue resistant, due to their increased capacity for oxidative metabolism, whereas faster 
fibre types are progressively less fatigue resistant from IIa-IIx to IIb, of which the latter 
almost totally reliant on glycolytic as opposed to oxidative metabolism.  The speed of 
calcium release from the SR in slow fibres is approximately three-fold slower than in fast 
twitch muscle fibres, and they typically express differing levels or isoforms of proteins such 
as DHPR, RyR, SERCA2a, and parvalbumin, an intracellular calcium buffer (Pette and 
Staron, 1997; Pette and Staron, 2000: Baylor and Hollingworth, 2003).  A list of comparisons 
between fast and slow muscle types can be seen in table 1.3.a.  
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Table 1.3.a: Differing cell components in slow and fast muscle types.  
Although fibre types can be readily distinguished on those criteria outlined above, it is 
not always clear cut which fibre type a motor-unit will contain. As fibre type composition is 
affected by activity level, it is possible for muscle fibres to express a range of fibre types, and 
under certain conditions to switch between them. Typically, fibre types blend with their next 
closest type, along the axis of Type I→I/IIa →IIa→IIa/IIx→IIx→IIx/IIb→IIb. Muscle fibres 
expressing a few types of myosin ATPase are known as hybrid or mixed fibres, and exist to 
provide shaped responses to the demand put on that particular muscle (Schiaffino and 
Reggiani, 2011). Type I to type II fibre shifts are common after spinal injury and a reduction 
of motor-neuron input to the muscle, under the effect of microgravity or in simple detraining. 
Shifts from type IIa to type IIb phenotypes are common, whereas a shift from type II to type I 
is less common, and has only experimentally been achieved using denervation and chronic 
low frequency stimulation (CLFS). Often, endurance training will induce a more oxidative 
phenotype (e.g. a hybrid fibre of type I/IIa) but total type II to I transitions are very rare 
(Aigner and Pette, 1992; Pette and Staron, 2001; Scott et al, 2001).  Endurance training exerts 
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this effect on skeletal muscle in a number of different ways: it increases mitochondrial 
biogenesis, thus increasing oxidative capacity and enhancing resistance to fatigue, and also 
causes an increase in protein synthesis. This in turn increases Ca
2+
 release, production of 
reactive oxygen species (ROS), and by way of mild hypoxia, angiogenesis. These changes 
culminate in a shift towards a more oxidative, fatigue resistant phenotype. 
1.3.b: Muscle Fibre type determination 
Muscle fibre type is determined by several mechanisms. The first is the satellite cells from 
which the muscle fibre originates, as this will partially determine the type of myosin ATPase 
produced by the cell (Kalhovde et al, 2005). Muscle fibre type is also shaped by the input 
each motor unit receives from its corresponding alpha motor neuron: constant low frequency 
stimulation will encourage the production of slow fibre type components (e.g. as seen in 
muscle used for maintaining posture), while high frequency input for short periods of time 
will encourage the production of fast fibre type proteins (such as that found in muscle used 
for sprinting). As motor neuron input determines the amount and frequency of Ca
2+
 release in 
skeletal muscle cells, it follows that calcium signalling can affect gene expression and so 
affect fibre type. As such, moderate but longer lasting Ca
2+
 release will induce the activation 
of the calcineurin phosphatase enzyme, which when interacting with calmodulin kinase 
(CaMKII) has been implicated in the maintenance of slow fibre type components (Parsons et 
al, 2003). Conversely, during high frequency stimulation, increases in Ca
2+
 release facilitate 
the interaction of CaMKII with other effectors, and induce the expression of fast fibre type 
proteins (Crabtree, 1999, Tavi and Westerblad, 2011). These mechanisms demonstrate how 
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spatial and temporal aspects of Ca
2+
 release in skeletal muscle can affect gene expression 
(Gundersun, 2001).  
1.3.a: Skeletal muscle contraction 
First, a stimulating action potential is propagated along the α-motor neuron unil it 
reaches the neuromuscular junction (NMJ). Here, the neurotransmitter acetylcholine (ACh) is 
released at the synapse between the motor neuron and the muscle cell, where it binds to 
nicotinic ACh receptors on the muscle cell membrane. This induces opening of the ACh 
receptors which allow an influx of sodium ions (as well as other ions) into the cell, causing 
depolarisation of the cell membrane (Almers, Stanfiel and Stühmer, 1983; Yarov-Yarovoy et 
al, 2012). This wave of depolarisation spreads down the T-Tubule, and causes the opening of 
voltage sensitive Ca
2+ 
ion channels, dihydropyridine receptors (DHPRs, also known as 
CaV1.1). DHPRs allow a small influx of Ca
2+
ions, and also cause the allosteric opening of the 
type 1 ryanodine receptor (RyR1), a Ca
2+
 channel located on the SR membrane. The opening 
of this channel increases the Ca
2+ 
concentration of the cytoplasm, which allows the initiation 
of cross bridge cycling (Franzini-Armstrong et al, 1991; Takehura et al, 1995).  
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Figure 1.3.a: Schematic of the T-tubule and SR in the process of muscle contraction. 
Depolarising waves travel down the T-Tubule, gating DHPRs. These allosterically open the 
RyR1 channel, allowing the release of Ca
2+ 
ions from the SR through RyR1. The increased 
Ca
2+ 
concentration in the cyoplasm activates cross bridge cycling by removing the inhibitory 
troponin complex from myosin binding sites on thin filaments. Relaxation occurs by re-
uptake of Ca
2+ 
into the SR via SERCA and by extrusion through NCX.  
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1.3.b: EC coupling: role of the Ryanodine Receptor 
Excitation contraction coupling (EC coupling) is the name given to the process of 
depolarisation induced calcium release from SR stores, which provides an intermediate step 
between membrane depolarisation and cross-bridge cycling in skeletal and cardiac muscles. 
EC coupling in skeletal muscle occurs at the triad, a specialised structure found in skeletal 
muscles, described in section 1.2.b. The dihydropyridine receptors (DHPRs) are L-type 
calcium channels which reside in the T Tubule membrane, and are made up of 5 subunits: 
α1S, the pore-forming unit, 1βa, a cytoplasmic subunit, and two transmembrane subunits α2δ 
and γ1 (Flucher et al, 2005). DHPRs provide the signal for RyR opening, by way of a 
physical interaction between the II-III cytoplasmic loop found  in the α1S subunit and RyR1. 
In essence, DHPR in the skeletal muscle acts as a voltage sensor for RyR1. Movement of 
DHPR’s II-III loop (and possibly junctophilin 1) causes the allosteric opening of RyR1. This 
allows calcium ions to flow from the SR, at a rate of approximately 200 μM/ms via the RyR 
and possibly  other SR membrane channels, and these Ca
2+ 
ions go on to participate in cross- 
bridge cycling and the generation of force by skeletal muscle as described in section 1.3.c 
(Calderon et al, 2014).  EC coupling cannot occur without these two proteins, as shown by 
the dysgenic (DHPR knock out) or dyspedic (“footless”- RyR knock out) animals or 
myotubes (Takehura et al, 1995; Buck et al, 1997).  Removal (by knockout or naturally 
arising  variant) of either protein proved  to be lethal, thus myotubes and cell lines from these 
animals have been used for characterisation of their interactions and calcium transients (Buck 
et al, 1997). Using these experimental tools, Franzini-Armstrong et al found that DHPR 
proteins were necessary for correct triad formation, while Avila et al found that RyR1-
mediated Ca
2+ 
release was necessary for DHPR expression in dyspedic myotubes (Franzini-
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Armstrong et al, 1991; Avila et al, 2001). In skeletal muscle, special arrangements of four 
DHPR channels arranged around one RyR channel exist, and are known as tetrads. Tetrads 
are abolished in the absence of RyR1, and are incorrectly formed when only RyR3 (another 
isoform of RyR) is expressed instead  (Protasi et al 1998; Protasi et al, 2000). The minimum 
specific regions for within RyR1 required for tetrad formation are residues 1272-1455, which 
were elucidated to be essential for this in studies using RyR1/3 chimeras expressed in 
dyspedic myotubes (Sheridan et al, 2006). It is plausible that this region of RyR1 interacts 
with the α1S subunit (specifically the II-III loop) and the 1βa subunit of DHPR, both of 
which have been shown to be important for tetrad formation and for orthograde and 
retrograde signalling between the two channels in EC coupling (Franzini-Armstrong et al, 
2009). A diagram of EC coupling is shown in figure 1.3.a, and a diagram of tetrad formation 
is shown in Fig 1.3.b. As discussed, cross bridge cycling cannot occur without release of Ca
2+ 
from the SR, and this process can be damaged by process that affect gating of any of the 
proteins involved or by EC-uncoupling, where the DHHPR and RyR proteins are uncoupled 
for a myriad of reasons. EC uncoupling is postulated to have a role in the pathology of 
sarcopenia and in muscle damage after strenuous exercise (Reganathan et al, 1997; Corona et 
al, 2010).   
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Figure 1.3.b: Diagram of the location of RyRs and DHPRs in the triad. The left panel 
shows RyR1 (green) and DPHRs (purple) as seen from the plane of the SR membrane One 
DHPR channel binds to each monomer of RyR, forming a tetrad. Every second RyR protein 
has a tetrad which interacts with it, and this forms a checkerboard-like pattern (right hand 
panel), as seen from the plasma membrane.  
 
1.3.c: Cross Bridge cycling:  
 Increased myoplasmic Ca
2+
 causes the formation of a troponin C-Ca
2+ 
complex, which 
moves the troponin away from myosin binding sites on the actin thin filament. The four main 
steps of cross bridge cycling are as follows: myosin heads (with bound ADP and Pi) bind to 
the actin thin filaments, with the heads perpendicular to the binding region (steps 1 and 2, fig. 
1.3.c.i). ADP and Pi are then released from the myosin heads, and this causes the myosin 
head to flex and to bind to the actin closer to the centre of the sarcomere. This pulls the ends 
of the sarcomere (the Z discs) closer together, and forms the “power stroke” of sarcomere 
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contraction (step 3 in figure 1.3.c.i). The myosin ATPase heads can now bind a fresh 
molecule of ATP, which is rapidly hydrolysed (step 4 in fig 1.3.c.i), setting up the myosin 
and actin filaments to go through the cycle again. The cross bridges of myosin and actin 
filaments will keep cycling as long as cytoplasmic Ca
2+
 remains high.  This model of cross 
bridge cycling is known as the Sliding Filament model (Huxley, Niedergerke, 1954; Gordon 
et al, 1966, Huxley, Simmons, 1971, Weber and Franzini-Armstrong, 1994; Cooke, 2004). 
The speed of ATP hydrolysis determines the rate of muscle contraction, and is in turn 
determined by the abundance and isoform of myosin ATPase expressed in each subtype of 
skeletal muscle.  
 
Figure 1.3.c.i: Schematic of Cross bridge cycling in skeletal muscle. Step 1 shows the 
hydrolysis of ATP into ADP and Pi (after the release of Ca
2+
 from the SR), which allows the 
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myosin head (red) to prepare for binding to the actin thin filament (yellow). Step 2 shows the 
myosin heads interacting with the actin thin filament at a 90º angle. Step 3 shows the 
swivelling of the myosin head to a 45º angle, which generates the force for sarcomere 
shortening, combined with the release of ADP. Step four shows the binding of a fresh 
molecule of ATP, allowing the cycle to begin again. 
Figure 1.3.c.ii: Diagram of sarcomere shortening in cross bridge cycling. Panel A shows 
a non-contracting sarcomere, where myosin heads are ready to interact with the actin thin 
filaments. Panel B shows a contracted sarcomere, where the power stroke of myosin heads 
swivelling has pulled the two z lines closer together, shortening the sarcomere. This is the 
basis of muscle contraction.  
1.3.d: Relaxation of skeletal muscle 
 Removal of cytoplasmic Ca
2+ 
is necessary for the relaxation of skeletal muscle. This 
is accomplished primarily by re-sequestering Ca
2+ 
ions into the SR by the SERCA 
(Sarcoplasmic/ Endoplasmic reticulum Ca
2+ 
pumps), which reside in the SR membrane. Some 
Ca
2+ 
is extruded through plasma membrane pumps such as the sodium-calcium exchanger 
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(NCX) or the plasma membrane Ca
2+  
pump, PMCA, although this is much less significant 
than that resequestered by SERCA (Brini and Carafoli, 2010).   
1.3.e: Skeletal Muscle Fatigue 
Fatigue is a major factor in skeletal muscle performance, and is mediated by several 
factors.  These include decreased myofibrillar sensitivity to Ca
2+
, increasing Pi content in the 
myoplasm, and the SR, where it decreases the pool of Ca
2+
 available for release, since it can 
buffer this cation. Fatigue due to high stimulation can also increase ROS production, which 
has knock on effects for signalling protein such as RyRs, and may act as an off-switch to 
prevent damage (see section 1.1.c.iv). Force generation and conduction speed are decreased, 
and relaxation speed is also affected (mediated by ATP via Ca
2+
 ion removal by SERCA 
pump). There is evidence the EC-uncoupling may also play a role in the decline in force 
production, especially after eccentric (muscle-lengthening) contractions (Evans and Lambert, 
2007; Westerblad et al, 2010; Corona et al, 2010).  
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1.4.a: Structure and function of RyRs 
Three isoforms of RyR exist, each encoded by a separate gene. RyR1 is found at highest 
levels in skeletal muscle, RyR2 is expressed predominantly in cardiac and smooth muscle, 
while RyR3 has a rather more diffuse expression pattern, and are found at their highest in 
brain and diaphragm muscle (Mackrill et al, 1997; Conti, Gorza and Sorrentino, 1996). RyRs 
have also been found in non-excitable cells, where they may have crucial roles in maintaining 
membrane potential and calcium homeostasis (Xue et al, 2000; Davis et al, 2013).  
RyRs are usually homotetrameric, forming complexes of molecular weight of 2.3 
MDa, rendering them the largest known ion channels. Each monomer is made up of 
approximately 5000 amino acids, with monomeric molecular weights of approximately 565 
kDa. Topologically, the RyRs are comprised of an N-terminal domain extending from amino 
acids 1-4500 which resides in the cytoplasm (the “foot structure”), a transmembrane region 
with 6 transmembrane segments and a cytosolic C-terminal domain (Zalk et al, 2014). The 
large N-terminal domain makes up about 80% of the proteins mass, and its large “square-
prism” surface of roughly 120Å serves as a massive interface with which many proteins and 
pharmacological agents interact, allowing them to exert effects on Ca
2+
 release from 
intracellular stores (Wagenknecht, Samso, 2002).  The N-terminal region has been divided 
into 15 domains based on appearance in cryoelectron microscopy (numbered 1-15) 
(Shersysheva et al 2008, Wagenknecht, Samsό, 2002). Domain 1 appears to form the link 
between the cytoplasmic and ER/SR luminal regions and may resemble columns, while 
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domain 2 may make up the Ca
2+
-traversing pore region. Domain 3 is of special interest, as it 
is not only the largest domain but also makes up the “handle”, which may allow inter-RyR 
interactions  and thus are important for the arrays of ryanodine receptors (the “checkerboard” 
pattern of RyRs, see Fig.1.3.b) seen in tissues like skeletal muscle and regulation by calcium 
ions (Yin et al, 2008: Zalk et al, 2014; Efremov et al, 2014).  
Domains 5-10 comprise the “clamp region” and facilitate many inter- and intra-
molecular interactions, and structural changes occur here which are associated with opening 
and closing of the channel (Samso et al 2009, Sherysheva et al 2008).  Inter- and intra-
molecular interactions are crucial for correct functioning of RyRs, and can be altered by 
pharmacological agents, such as dantrolene, and accessory proteins such as FKBP12 and 
FKBP12.6, which are discussed in sections 1.4.b and 1.5. The transmembrane assembly of 
the RyR is roughly 70Å in length, and is predicted to start at or near 4500, or more 
specifically, the stretch of amino acids extending from 4554-4575 are extremely 
hydrophobic, and are likely to be embedded in the SR membrane (Takeshima et al., 1989; 
Zorzato et al., 1990; Grunwald and Meissner, 1995). Between Wagenknecht et al and 
Efremov et al, the structure of the transmembrane region has been resolved using electron 
cyromicroscopy to a resolution of 6Å and this resolution has revealed the presence of 24 
transmembrane helices with two sets of four branch-like regions of high density, which 
extend from the cytoplasmic face toward the SR lumen (Samsó et al, 2005: Efremov et al, 
2015). These branches converge in two points to form negatively charged rings which make 
up the ion selectivity filter on the luminal side, and a gate structure near the cytoplasmic 
vestibule. This gives the transmembrane region an “inverted-tepee” structure, which is 
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comparable to the bacterial KscA K
+
 channel.  It is postulated that these branches can rotate 
based on open or closed state of the channel, because of the changes in angle of the luminal 
portion of the RyR relative to the cytoplasmic region upon opening and closing, in agreement 
with the “zipping and unzipping” model proposed by Ikemoto and Yamamoto (Ikemoto, 
Yamamoto, 2002). Selectivity is maintained by a well conserved –GVRAGGID- sequence (in 
RyR1, amino acid 4891-4900) as determined by comparison to K
+
 channel selectivity filters 
(Gao et al 2000). Mutations in highly conserved transmembrane and luminal portion of RyR1 
have been shown to cause slow Ca
2+
 leak form the SR associated with symptoms of 
hypotonia seen in central core disease (CCD) (Tilgen et al, 2001). The luminal portion of the 
RyR makes up of the remaining 10-20 % of the molecule. Although the very tail end of the 
C-terminus is located in the cytoplasm, the luminal face also has many interacting partners 
important for regulation of calcium release, and assessment of Ca
2+
 stores, such as 
calsequestrin, junctin and triadin (Mackrill et al, 1999) 
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Figure 1.4.a: Diagram of RyR1 structure: locations of handle, column and clamp regions 
are denoted by dashed lines. The large N-terminal region (located in the cytoplasm) is 
connected to the luminal region via the “columns”. A schematic of the column location when 
the channel is open and closed can be seen on the right hand side. When opening, the 
columns swivel out and downwards to allow ion flux (adapted from Samsó et al, 2005: 
Efremov et al, 2015). 
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1.4.b: RyR interactions  
RyR calcium channel function relies on the ability of these proteins to interact and be 
affected by endogenous and exogenous effectors, including natural ligands such as FKBP 
(FK506-binding proteins), calmodulin, junctin, CHERP (Calcium Homeostasis Endoplasmic 
Reticulum Protein), and triadin, as well as pharmacological agents such as ruthenium red, 4-
chloro-m-creosol, dantrolene, caffeine and natrin toxin (Mackrill, 1999, Mackrill 2010, Ryan 
et al, 2011). These interactions are vitally important for the elucidation of disease 
mechanisms (eg. RyR2-FKBP12.6 interaction in heart failure) and are also useful in studying 
the RyR. Protein ligands which interact with the RyR can fall into three broad categories: 
those that interact at the cytoplasmic, membrane, or SR/ER luminal face. 
Cytoplasmic and plasmalemmal interacting proteins include FKBPs, DHPR, CaM, protein 
kinases, sorcin, homer proteins and S100s. The dihydropyridine receptor (DHPR) forms the 
voltage sensor for Ca
2+
 release in skeletal muscle. It is a plasmalemmal voltage sensitive 
calcium channel, located in T-tubules, directly opposed to the SR.  This is described in 
section 1.3.b.  
FK506- binding proteins 12 and 12.6 (FKBP, also known as calstabins), named for their 
ability to bind the immunosuppressant macrolides FK506 and rapamycin and for their 
apparent molecular weights of 12 and 12.6 kDa, interact with RyR subtypes 1 and 3 or 2 
respectively (Mackrill, 2010). They are understood to stabilize the closed and open state of 
the channel, and may help mediate RyR-RyR interactions in array formation in skeletal 
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muscle (Gaburjakova et al, 2001; Samso et al, 2006; Efremov et al 2015; Zalk et al, 2014). 
One FKBP-molecule binds per monomer of RyR, i.e. four per receptor complex, and this 
interaction can be disrupted by addition of either of the macrolide drugs mentioned 
(Wagenknecht, Samsό, 2002). FKBP12 proteins are reported to bind at residue 2461-2462,  
and as well as stabilising the channel in the open or closed conformation, are said to be 
involved in coupling neighbouring RyRs to each other (Marx et al 1998). Although 
traditionally, FKBP12 was thought to bind only to RyR1, it has recently been found that 
FKBP12 can interact with RyR2, and that FKBP12.6 can interact with RyR1 and encourages 
channel opening, however there is little FKBP12.6 expressed in skeletal muscle. Further 
work is necessary to elucidate the wider effects of these interactions (Efremov et 
al,2014;Venturi et al, 2014).  
Calmodulin (CaM), like the FKBPs also binds one monomer of RyR per molecule CaM, and 
can exert two different effects on ryanodine receptors depending whether or not it is bound to 
calcium. In the presence of millimolar Ca
2+
 concentrations, Ca
2+
-CaM can behave as an 
inhibitor of RyR function, serving as an important “stop sign” for calcium release. At 
submicromolar Ca
2+
 concentrations, apo-CaM acts as an activator of various RyR isoforms. 
The binding site of CaM and apo-CaM are slightly different, but are located near each other, 
within the crevice formed at the junction of domain 3 and domain 5 for Ca
2+
-CaM and at 
domain 3 for apo-CaM, perhaps to allow quick movement and calcium status reporting 
during Ca
2+
 release cycling (Seiler et al, 1984; Ikemoto, Yamamoto, 2002; Wright et al, 
2008; Cornea et al, 2009; Huang et al, 2012). 
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Junctophilins are a group of four proteins expressed in various types of excitable cells. First 
described by Takeshima et al in 2000, there are four different isoforms (JPH1, 2, 3 and 4), 
expressed at their highest levels in skeletal muscle, cardiac muscle and neuronal tissues 
respectively. The main function of JPHs is to bring the t-tubule (in muscle) and  endoplasmic 
reticulum together, and thus they are crucial to maintaining essential membrane structures 
(Takeshima et al, 2000). This is facilitated by the three regions of JPH1. The most C-terminal 
part of the protein has a conserved SR/ER membrane insertion sequence, which effectively 
tethers the end of the protein. Following this is an α-helical segment, which acts like a spring, 
and at the N-terminal end, is a hook shaped area which contains up to eight MORN 
(Membrane Occupation and Recognition Nexus) motifs, which have an affinity for 
sphingocholine and other lipids, and thus allow binding of the proteins to the plasma 
membrane (Nishi et al, 2000). In this way the junctophilin family behave as scaffolding 
which effectively link the SR/ER and plasma membrane. In skeletal muscles, this especially 
important, as triads need to be tethered to the plasma membrane for effective calcium release 
from the SR. JPH2 is also expressed in skeletal muscle, but there is no evidence that it 
interacts with RyR1; however knock down of both JPH1 and 2 in myotubes does have an 
effect on SOCE and altered caffeine mediated Ca
2+
 release (Hirata et al, 2011). JPH1 knock 
out animals die perinatally due to a suckling deficiency, while JPH2 knock out was 
embryonically lethal. JPH1 knock out animals displayed deformed triads and impaired Ca
2+
 
signalling and force generation in skeletal muscle myotubes (Ito et al, 2001). Since then, it 
has been shown that as well as interacting with the plasma membrane of cells via their 
MORN motifs, JPH1 also interacts with DHPR and RyR1, and that it interacts with RyR1 in 
a redox-sensitive and conformationally dependent manner (Phimister et al, 2007; Golini et al, 
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2011). While JPH1 is confirmed to co-localise with RyR1 and DHPR in skeletal muscle, the 
subcellular location of JPH2 has been shown to be in discrete and separate areas of the SR 
membrane, indicating that in skeletal muscle, JPH2 may have more of a structural role 
(Jayasinghe et al, 2014).    
As well as those listed, protein kinases and glycolytic enzymes also bind to the 
cytosolic face of the RyR, and perform various different post-translational modifications 
which can have effects on ligand binding and calcium release. Integral membrane proteins 
such as triadin and junctin may help anchor the RyR complex in the SR membrane, and may 
also provide nearby binding sites for potential effectors. One of these effectors is likely to be 
calsequestrin, (CASQ) which binds to the tail of triadin and junctin, or directly to the RyR. 
CASQ is an acidic Ca
2+
 storage molecule which has intermediate capacity for Ca
2+
 binding. 
Depending on whether it is bound directly or indirectly to the RyR (via triadin or junctin, 
depending on isoforms), or its phosphorylation state, it can activate or inhibit Ca
2+
 release 
(Szegedi et al, 1999). CASQ is the main Ca
2+
 buffer in the SR, and can “sense” SR [Ca2+] 
because it polymerises with increasing [Ca
2+
], and its state of polymerisization and 
phosphorylation status can also affect Ca
2+
 binding (Beard et al, 2009). Two isoforms of 
CASQ are expressed in fast or slow muscle fibre types, CASQ1 is found in fast twitch muscle 
and can bind up to 80 mol/mol Ca
2+
; while the slow isoform, CASQ2 can bind up to 60 
mol/mol Ca
2+
, and is expressed in slow twitch and cardiac muscle cells. CASQ1 expression is 
found to increase in muscles that have been subjected to chronic low frequency stimulation 
(Froemming et al, 2000; Park et al, 2004). CASQ1 knock out animals have been generated, 
and have decreased SR Ca
2+ 
content, as well as decreased Ca
2+ 
release via RyR1 in fast fibres 
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(Olojo et al, 2011). CASQ1 knock out animals have also been reported to have an MH like 
phenotype (Paolini et al, 2007; Protasi et al, 2009).  
Junctin is a 33 kDa non-catalytic splice variant of the aspartate β-hydroxylase protein. 
It has a short N-terminal cytoplasmic region, a transmembrane domain and a long C-terminal 
tail found within the SR lumen.  Its main function is to anchor CASQ to RyR with triadin, 
although it binds to a separate region of RyR1. When added to the luminal face of bilayers 
containing RyR1 proteins, it can increase the opening activity of the channel, but when bound 
to CASQ it will decrease the open probability of RyR1 channels (Goonasekera et al, 2007; 
Dulhunty et al, 2009). Knock down of this protein indicates that it has a role in maintaining 
the calcium store of the SR (Wang et al, 2008). 
Triadin is a 95 kDa protein found in skeletal muscle. Like junctin, it helps to anchor 
CASQ to the lumenal face of RyR1. It has been shown to bind to the C-terminal end of 
RyR1, around the regions containing residues 4907, 4908 and 4878 (Kobayashi et al, 2000; 
Rezgui et al, 2005; Goonasekera et al, 2007). Knock out models have been created, and have 
shown a decrease in Ca
2+
 content in the SR, as well as a decrease in muscle strength, but no 
other major phenotype was observed (Oddoux et al, 2009).  Shen et al (2007) also found that 
knock out of triadin caused a decrease in junctophilin 1, junctin and CASQ expression in 
muscle cells. Triadin is also expressed in cardiac muscle, but here it is found at different 
molecular weights to that in skeletal muscle (Chopra et al, 2009). 
JP-45 (junctional protein 45) is an integral membrane protein of 45 kDa which 
interacts with the calcium release unit (CRU-described in section 1.3.b). Although at times 
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confused with JPH1 or 2, it is not the same protein. JP-45 interacts with CASQ and DHPR, 
and alters the sensitivity of the DHPR based on the SR store calcium content. It is found to be 
decreased in aged muscle compared to younger controls (Andersson et al, 2003; Yasuda et al 
2013).  
S100a is a calcium binding protein located in the cytoplasm of skeletal muscle cells. It 
has a molecular weight of 10-12 kDa, and contains an N-terminal EF hand, middle hinge 
region and a C-terminal EF hand. This middle hinge region becomes more hydrophobic when 
Ca
2+ 
ions are bound to the surrounding EF hand motifs, and this facilitates interaction with 
other proteins (Prosser et al, 2001). This hinge region interacts with the CaM binding region 
of RyR1, where it exerts an effect of increasing the open probability of the channel. It may 
also assist in the formation of the RyR1 tetramers. S100a knock out muscle fibres have 
decreased SR Ca
2+ 
release in response to changes in voltage, indicating that S100a has an 
important role in EC coupling (Wright et al, 2009).  
Mitsugumin 29 (MG-29) is a 29 kDa protein located in the SR membrane of skeletal muscle 
cells. It contains 4 transmembrane domains, and forms hexamers to exert its effect on RyR 
gating. Experimentally, MG-29 increases the open probability of RyR1, but has no effect on 
unitary conductance.  Knock out models have shown that ablation of MG-29 causes swollen 
T-Tubular membranes and misaligned triads, as well as rapid SR Ca
2+ 
content depletion and 
rapid fatigue. These results show MG-29 has a role in triad organisation, crucial for correct 
EC coupling (Nagaraj et al, 2000; Treves et al, 2009). 
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Selenoprotein N1 (SEPN1) is a 60 kDa protein that has been shown to be associated 
with RyR1, where it is necessary for full channel activity. It has a role in redox sensing and 
modulation of Ca
2+ 
release via RyR1 (Jurynec et al, 2008). SEPN1 mutants have been 
implicated in the pathogenesis of multi minicore disease (MmD, discussed is section 1.1.c.v) 
and this protein is essential to the process of muscle regeneration and satellite cell 
maintenance (Jungbluth et al, 2007; Castets et al, 2012).  
 
Fig 1.3.c: Schematic of some of the known RyR1 interacting proteins.  Many 
proteins are known to interact with RyR1, and assist in modulating calcium release from the 
SR. 
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Homer is an adapter protein expressed in brain, heart and skeletal muscle. Homer 1 
has been shown to modulate the response of RyR1 to Ca
2+ 
ions and to affect the response of 
RyR1 to voltage changes (via DHPR). Investigation of Homer 1 knock out has been 
performed in myotubes and in a mouse model, and Homer 1 KO results in a skeletal muscle 
myopathy with decreased myofibre cross-sectional area and decreased force generation. 
Homer 1 proteins have an N terminal EVH1 (Ena/vasodilator-stimulated phosphoprotein 
homology 1) domain which facilitates their interaction with many proteins. Homer 1 interacts 
with RyR1 via the EVH1 domain, which binds to a proline rich region located in the 
cytoplasmic region of RyR1 (Feng et al, 2002; Stiber et al, 2008). Homer 1 has a coiled-
coiled C-terminal domain, which facilitates dimerization, and interacts with other 
intracellular channels such as InsP3Rs and TRPC channels (Salanova et al, 2013).  
Other proteins that have been implicated in RyR1 regulation include caveolin 3 (CAV3) 
which has been found to co-localise and interact with RyR1 in skeletal muscle. CAV3 is 
responsible for the formation of caveolae in many cell types, and interacts with several 
proteins. CAV3 is also associated with the dystrophin complex at the plasma membrane of 
muscle cells, which is responsible for the correct transduction of force across muscle cells 
(see chapter 6). CAV3 KO animals have no perceptible caveolae, show T-Tubule 
deformation and altered dystrophin localisation. Mutations in the CAV3 gene have been 
associated with limb girdle muscular dystrophy (Galbiati et al, 2001; Whiteley et al, 2012).   
Recently, Ryan et al have detailed a novel interaction between RyR1 and CHERP (calcium 
homeostasis endoplasmic reticulum protein), identified using a histidine-tagged fragment of 
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RyR1 as bait expressed in HEK293 cells combined with mass spectroscopy. This protein is 
thought to participate in EC-coupling, and co-immunoprecipitation experiments show it is 
expressed in mouse soleus muscle fibres (Ryan et al, 2011). Taken together, one can surmise 
that a vast (and ever-growing ) list of protein interact with the RyR1 protein, which are 
necessary to shape the release of Ca
2+
 ions in response to the specific needs of the muscle 
being contracted. A diagram of some interactions that occur at the calcium release unit can be 
seen in figure 1.1.c.iii, while a table summarising the role of RyR1 interactors and the 
consequence of their ablation can be seen in table 1.1.c.iv.  Protein-protein interactions are 
not the only means of RyR regulation, as post translational modifications also aide the 
shaping of Ca
2+
 release from intracellular stores, as discussed in the next section. 
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Table 1.4.d: well-known RyR1 interacting proteins and the effect of their ablation.  
1.5: Regulation of RyR by small molecules and ions 
RyR1 is acted upon by a wide variety of pharmacological agents, most notably 
ryanodine, the plant alkaloid after which they are named. Other pharmacological agents 
which exert an effect on RyRs include dantrolene, ruthenium red, 4-chloro-meta-cresol 
(CMC) and caffeine.  
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Ryanodine exerts a biphasic effect on RyR channels, whereby concentrations in the 
submicromolar range activate a small Ca
2+
flux through the channel, via a subconductance 
state, while millimolar concentrations cause the irreversible closure and inactivation of  RyRs 
(Rousseau et al, 1987; Zimanyi et al, 1992; Ogawa et al, 1994). Labelled ryanodine  
([
3
H]ryanodine ) is widely used in single channel and Ca
2+
ion flux studies  (Hamilton et al, 
1989; Mackrill, 2010). Caffeine is also widely used in Ca
2+ 
release studies. It alters the 
sensitivity of RyR to Ca
2+
, on the luminal side, causing an increase in Ca
2+
release through the 
channel. Caffeine is thought to bind RyR1 near the D1 (divergent region 1) (Sitsapesan et al, 
1995: Du et al, 2000:Kong et al, 2008). 
CMC is a potent agonist of RyRs, and it interacts with type 1 and 2 but not type 3 RyRs. 
CMC may also have a role in shaping the store operated calcium entry response in skeletal 
muscle (Zeng et al, 2014).  Ruthenium red is a cationic chemical stain used in histological 
preparations. It is a potent inhibitor of RyR-mediated Ca
2+ 
release at nM to μM 
concentrations (Lukyaenenko et al, 2000).  Another inhibitor of RyRs is dantrolene, which 
has a clinical application during episodes of malignant hyperthermia, (see section 1.1.c.v.). 
Dantrolene inhibits Ca
2+
 release from RyRs, and some evidence exist to show that it may 
alter DHPR-RyR communication as well (Szentesi et al, 2001; Paul-Peltzer et al, 2002; 
Bannister 2013). Many other pharmacological agents have agonist or antagonistic effects on 
RyR gating, including procaine, Polychlorinated Biphenol  and epigallocatechin gallate, (a 
compound found in green tea) (Feng et al, 2008; Mackrill, 2010).   
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Calcium ions have a bi-phasic effect on RyR gating. At low concentrations (1-10μM), 
calcium ions have an activating effect on RyR. Concentrations in the range of 1-10mM have 
been found to inhibit RyR1 (Fill and Coppello, 2002). Recently, Efermov et al described a 
mechanism for Ca
2+
-mediated modulation of RyR1, whereby an EF hand motif located on the 
cytoplasmic side of RyR1 binds to Ca
2+
 and induces an allosteric regulation of the gating 
region of RyR1 (Efermov et al, 2014). 
Magnesium ions also modulate RyRs in two ways: at intracellular concentrations of 
600-1000 μM, Mg2+ can displace Ca2+ from the regulatory domain of RyR and when in 
complex with ATP, can enhance RyR activity by promoting channel opening. RyR1 appears 
to be more sensitive to Mg
2+ 
concentration fluxes than RyR2 or RyR3, and Mg
2+
 has been 
shown to be necessary for coupled gating of RyRs (Jόna et al, 2001; Porta et al, 2012). 
RyRs are known to be phosphorylated by many kinases, including Protein Kinase A (PKA), 
cGMP (cyclic guanosine monophosphate), Calmodulin Kinase and Protein Kinase C 
Phosphorylation by PKA results in the activation of RyR1, inducing Ca
2+ 
release from the SR 
(Coronado et al, 1994).  Ruehr et al found that PKA was localised to RyR1 via the MKAP 
tether (Ruehr et al, 2003). Marx et al have stated that “hyperphosphorylation” of the RyR1 
channels shifted its Ca
2+ 
sensitivity and resulted in “leaky” channels (Marx et al, 2000). 
Phosphorylation of RyR channels has been implicated in the effect of ionotropic factors 
during skeletal muscle contraction. In response to isoproterenol and muscle stimulation, the 
PKA mediated phosphorylation of serine-2844 of RyR1 was found to be increased. This 
phosphorylation event led to increased Ca
2+ 
release and increased force generation in treated 
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muscles, while an S2844A mutation abolished this effect (Andersson et al, 2012).  A serine 
residue at 2843 has also been implicated in increasing RyR1 channel “leakiness” in human 
vastus lateralis biopsies performed after a single bout of resistance exercise. Interstingly, the 
leaky RyRs were only found in type I fibres in the biopsies, indicating that fibre type specific 
regulation of RyRs may occur (Gehlert et al, 2012).  Phosphorylation events at the clamp 
region of RyR1 have also been found to be important. Yuchi et al (2012) found that 
phosphorylation of residues involved with the clamp region of RyR had tangible effects on 
interdomain allosteric interactions (Yuchi et al, 2012).  
Redox modulation of RyRs is hugely important in skeletal muscle. Redox 
modification of RyRs is accomplished by oxidation or nitrosylation of free thiol groups found 
within the RyR subunits, and is mediated by nitric oxide (NO) via nNOS (neuronal nitric 
oxide synthase)  or glutathione S transferase (GST) proteins among other mediators such as 
H2O2 and ROS.  Increasing the oxidation status of RyR decreases calcium release from 
intracellular stores, primarily by altering its sensitivity to activation and inhibition to Ca
2+ 
and 
Mg
2+ 
-ATP respectively. An increase in reduced thiols on the RyR1 protein increases Ca
2+ 
release, as determined in purified SR vesicles and single channel recordings (Sun et al, 2001). 
In this way RyRs can function as redox sensors in skeletal muscle, and may aid in the process 
of coupling SR Ca 
2+
release with mitochondrial output.  Oxidation and S-nitrosylation of 
RyR1 have been linked to the pO2 levels in muscle tissue, and may represent a matching of 
perfusion with contraction level (Sun et al, 2013). Redox modification of RyRs can also 
indirectly affect gating, as modification of free thiol content can alter both inter-subunit 
interactions within RyR1 and the interactions with FKBP12, JPH1, triadin and CaM, and may 
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have a role in shaping proteasomal degradation of RyRs, by affecting protease-RyR1 
interaction (Zissimopoulos and Lai, 2006). In pathological states such as sarcopenia, 
increased reactive oxygen metabolites can contribute to RyR modulation, and increased 
neuronal nNOS has been found to be associated with RyR1 in muscle from patients affected 
by rheumatoid arthritis, and these RyRs were also found to have increased peroxynitrate 
mediated damage as well as increased Ca
2+ 
transients (Andersson et al, 2011; Yamada et al, 
2014). Interacting proteins such as JPH1 are also affected by thiol content, and this in turn 
can regulate the interaction of JPH1 with RyR1 (Zissimopoulos and Lai, 2006: Phimister et 
al, 2011). 
 
 
64 
 
 
Figure 1.5.a: Diagram of RyR in open and closed state. The central columns which 
contain the selectivity filter splay outwards during channel opening, allowing Ca
2+ 
ions to be 
released from the SR. A list of modulators are presented underneath the channel diagrams. 
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1.6: RyRs in disease  
Since RyR complexes are so large and are crucial to proper Ca
2+
 homeostasis, perturbations 
of the macro- and micro-molecular interactions within and around the calcium release unit 
invariably cause some degree of channel dysfunction and disease. 
1.6.a: Malignant Hyperthermia 
Malignant hyperthermia is a pharmacogenetic disorder, where a patient has an unwarranted 
reaction to volatile anaesthetics or depolarising muscle relaxants, such as succinylcholine. An 
MH episode is characterised by a hypermetabolic crisis, and causes hyperthermia, muscle 
rigidity, acidosis, tachycardia, and rhabdomyolysis.  First described by Denborough in 1962, 
MH is a low penetrance disease i.e. it may not occur with every anaesthetic administration, 
and is diagnosed using an in vitro contracture test, which exposes a biopsied muscle sample 
to volatile anaesthetics or caffeine and monitors the contractile response (Denborough et al, 
1962).  Episodes can also be induced by high body temperatures (>37ºC). Malignant 
hyperthermia can be caused by over 200 point mutations in the RyR1 gene (MacLennan, 
Zvaritch, 2010), located on chromosome 19q13.2, which cause aberrant Ca
2+
release from the 
SR in response to depolarising anaesthetics. 
Epidemiological studies suggest that 1:60,000 adults or 1:15,000 children are affected by 
MH. Up to 70 % of cases are caused by autosomal dominant mutations in the RYR1 gene, 
many of which are clustered in three “hotspots” near the N-terminal end, the mid-region and 
C-terminal pore region of the protein (M
c 
Carthy, Mackrill, 2004).  Some of these mutations 
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have been shown to cause domain unzipping or faulty interdomain interactions, resulting in 
aberrant Ca
2+ 
release and the metabolic disaster that ensues. Dantrolene, the only available 
therapy for an MH episode (along with rapid cooling) reportedly re-stabilizes the faulty 
domain interactions (Kobayashi et al, 2005). The various mutations have been categorised as 
having four differing effects on RyR function causing either hypersensitivity, a leaky channel 
with depleted SR stores, the inability to release calcium at all or reduced expression of RyR 
(Treves et al, 2008, Canato et al, 2014). Many mutations found in RyR that are linked to MH 
are also linked to central core disease, thus the hot-spot regions 1-3 are also known as 
MH/CCD regions 1,2 and 3 (Monnier et al, 1997)  
1.6.b: Central Core Disease 
Central core disease  (CCD) is a disease of skeletal muscle where delayed motor 
milestones, hypotonia and atrophy are accompanied by the appearance of centrally located, 
amorphous cores in the musculature, which disrupt myofibrillar organisation and perturb both 
the mitochondria and the SR network (Jungbluth, 2007).  It presents with varying degrees of 
severity, with some patients completely unaware that they have it, while others have severe 
pathologies including proximal muscle weakness and or skeletal muscle deformities. Often it 
presents with type I fibre predominance, and diagnosis is made on the basis of biopsy and 
weakness, (Quinlivan et al, 2003). Causative mutations have been found in the C-terminal 
portion of RyR1 (Wu et al, 2006). It is thought that mutations here either cause leaky RyRs 
or EC uncoupling, leading to the pathological state seen in this disease (Treves et al, 2008). 
In a mouse model of one form of CCD, ( with a heterozygous expression of RyR1 I4898T 
mutation)  Boncompagnani et al  found that type 1 fibres (predominant in the soleus) display 
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Z-line streaming, and that type IIa, x and b fibres were relatively spared of this abnormality. 
In contrast, the faster type II a b and x fibres were found to have apparently swollen SR 
compartment compared to their WT counterparts.  This mouse model also displayed reduced 
Ca
2+ 
transients in response to electrical stimulation, and the authors suggest that the effects 
seen in this model are reminiscent of those found in aged muscle (Boncompagnani et al, 
2010).  
1.6.c: Multi-mini Core Disease 
Multi-minicore disease (MmD) is an autosomal recessive disorder which can be 
caused by mutations in RyR1 or the associated protein SEPN1, resulting in many small cores 
of non-oxidative material found along the length of muscle fibres (Jurynec et al, 2008). The 
pathological effects of the disease are varied, but spinal rigidity, hip girdle dislocation, 
opthalmoplegia, and respiratory insufficiency(which can cause secondary right ventricular 
heart failure) have been documented (Jungbluth, 2007). Mutations in the RyR1 gene linked to 
this disease have been found in the N-, C-terminal fragments and middle portion of the RyR1 
protein (Zhou et al, 2010). Decreased RyR1 expression has also been cited as a causative 
factor (Monnier et al, 2003). The SEPN1 protein associates with RyR1, and is mutated in 
certain forms of MmD, especially those causing scoliosis and respiratory impairment. SEPN1 
is postulated to participate in redox modulation of RyR1 (Ferrerio et al, 2002, Jurynec et al, 
2008).  Hirata et al suggest that “relatively relaxed” zebrafish, which carry a nonsense 
mutation in RyR1b, are a good model of MmD, and that they display decreased Ca
2+ 
 
transients in affected skeletal muscle compared to controls (Hirata et al,  2007).  
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 It is possible that as yet undiscovered interacting proteins or perhaps that fact that 
RyRs can form heteroteramers in some tissues could provide further information on diseases 
of skeletal muscle, and may explain the diverse pathological features seen in similar diseases 
(Murayama et al, 1997). Mutations of RyR2, or its associated proteins, expressed in heart are 
analogous to those which cause MH and CCD in RyR1 (i.e., occur in the same “hot-spot 
regions”) and have been linked with arrhythmogenic right ventricular dysplasia type 2 
(ARVD2) and catecholeminergic polymorphic ventricular tachycardia (CPVT) (Leenhardt et 
al, 1995; Priori et al, 2001;Tiso et al, 2001; Kobayashi et al, 2009, MacLennan, Zvaritch, 
2010). ARVD2 results in cardiomyocytes being replaced by fatty and fibrotic tissue, and 
ARVD2-associated mutations in RyR2 cause a persistent Ca
2+
 leak via the channel, elevating 
cytoplasmic [Ca
2+
], which can result in ventricular arrhythmia (Corrado et al, 2000: Tiso et 
al, 2001). CPVT has many forms but may involve hyperphosphorylation of RyR2 by either 
PKA or CaMKII after β-adrenergic stimulation, leading to stress-induced ventricular 
tachycardia. Another mechanism involves a mutation of Arg-4496-Cys in the C terminal 
region of RyR2, resulting in a lower affinity binding site for the RyR-associated protein, 
FKBP12.6 (discussed in section 1.5) which stabilizes RyR2 in the open conformation 
(Kobayashi et al, 2009). 
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2.1: Aims and objectives: 
As the information presented in this literature review demonstrate, a considerable 
amount of knowledge has been generated regarding the Type 1 RyR in the past few decades, 
particularly with regard to its role in health and disease. However, further work is necessary 
to elucidate the nature of novel interactions with the RyR1 complex, such as those suggested 
by in silico analysis. To rectify this, we sought to confirm or refute some of these interactions 
in vitro using a biotinylated peptide mimetic of the proline rich region of RyR1 coupled with 
chromatography and SDS-PAGE based detection to identify any interacting proteins. The 
results of this analysis can be found in chapter 4. 
Attempts were made to clarify and expand upon a suggested interaction between 
RyR1 and an unknown protein termed JSR-90, which was reported using the VF1c mAb. To 
do this we characterised mAb VF1c using western blotting based experiments.  The results 
can be seen in chapter 5. 
 We also sought to clarify the role of Junctophilin 1, (a protein known to interact with 
RyR1 in skeletal muscle) in different types of skeletal muscle and in models of disease whose 
pathology extends to skeletal muscle tissue, such as Duchenne muscular dystrophy, chronic 
intermittent hypoxia and sarcopenia. The results of this study can be found in chapter 6.  
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Chapter 3:Materials and methods 
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3.1. Cell culture 
3.1.a: General Culture 
Materials:  
Unless otherwise stated, all cell culture plasticware, was purchased from Sarstedt 
(Sarstedt Ltd., Drinagh, Wexford, Ireland), Sigma-Aldrich (Sigma-Aldrich Ireland Limited, 
Vale road, Arklow, Wicklow, Ireland), MyBio Ltd.(MyBio Ltd., 
Hebron Business Park, Kilkenny) or GIBCO ® (C/O:Bio-Sciences,3 Charlemont Terrace 
,Crofton Road, Dun Laoghaire,  Dublin).  
Reagents used include Dulbeccos modified Eagles medium (DMEM, Cat. No. D5796, 
Sigma-Aldrich), supplemented with penicillin/streptomycin (cat no. 15070-063, GIBCO®, 
and Fetal bovine serum (FBS) (Sigma, cat no: 12003C). For subculture, 0.25% (w/v) 
Trypsin-EDTA (GIBCO®) and Trypan blue (0.4%(w/v), from Sigma, Cat no T6146) was 
used.  
Equipment: Thermo CL10 Centrifuge (Thermo-Fischer Scientific Incorporated, 
Basingstoke, Hampshire RG21 6YH). Haemocytometer (AC1000 Improved Neubauer, 
Hawksley Medical and Lab Equipment, Lancing, Sussex, BN15 8TN) 
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3.1. b: General methods: Cell culture. 
Cells were typically grown in Dulbecco’s Modified Eagles Medium (DMEM, Sigma-
Aldrich) supplemented with 10% heat-inactivated fetal bovine serum and 1% penicillin and 
streptomycin solution, and were maintained at 95% O2 with 5% CO2 in a humidified Thermo 
Scientific Water-Jacketed incubator. 
3.1. c: Subculture. 
Subculture of cells was performed as needed or weekly, based on cell confluency. 
Culture medium was aspirated from the cell monolayer, which was then washed with 2 ml of 
0.01% trypsin/EDTA solution. This was removed by aspiration and cells were incubated at 
37˚C for 3-5 minutes in 4 ml trypsin solution to detach adherent cells. This cell suspension 
was centrifuged in a Thermo scientific CL10 swing bucket rotor at 500 gmax for 5 minutes, 
and the supernatant was removed.  Fresh media, warmed to 37˚C was added and the pellet 
dispersed with gentle trituration through a 10 ml pipette. Cells were then either counted using 
a haemocytometer for plating or diluted (1 volume of cell suspension: 10 volumes of media 
for A7r5 myocytes or 1:20 for A549 or C2C12 cells, depending on cell doubling time). Cells 
were transferred to a new vessel and the growth media replenished as needed. 
The A549 adenocarcinoma cell line was maintained in DMEM, supplemented with 
10% foetal bovine serum and 1% penicillin and streptomycin (Sigma). Cells were grown to 
80% confluency or above, and removed from flasks using two washes of cold 10 mM EDTA 
in PBS and a cell scraper.  The cell suspension was centrifuged in a Thermo scientific 
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centrifuge CL10 at 500 gmax for 5 min, and cell pellets were either snap frozen in liquid 
nitrogen or used immediately (see homogenate preparation, section 3.3). 
3.1.d: C2C12 cells and Differentiation assay. 
Materials: DMEM with 10% FBS, differentiation medium (DMEM with 0.5% FBS), 
10 mM EDTA in PBS (EDTA from Sigma, cat no E6758). Cell scrapers and 100mm cell 
culture plates from Sarstedt.  
C2C12 cells were subcultured in 100 mm dishes and maintained in 10% FCS-DMEM. 
Upon reaching 80% confluency, the media was changed to DMEM containing 0.5% FCS to 
encourage myotube formation. Media was replaced daily and cells/myotubes were harvested 
from between 24 h and 8 days after addition of differentiation media. Cells and myotubes 
were detached by washing twice in room temperature 10 mM EDTA in PBS and scraping 
with a cell scraper. Samples were then flash frozen or used immediately, and were processed 
as described in section 3.3. 
3.1.e: siRNA Knock-Down of JPH1. 
Reagents: N-ter™ Nanoparticle siRNA Transfection reagent, (Sigma: N2913) JPH1 
silencer RNA (Sigma, EHU078801).RNAse Zap decontamination solution (Sigma R2020). 
RNAse-free water, DMEM (with and without 10% FBS), 6 well plates, C2C12 cell line.  
C2C12 cells were seeded at a concentration of 5x 10
4 
cells per well in 6 well plates. 
The cells were differentiated until myotubes were seen on visual inspection (day four). All 
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tubes used were autoclaved at 121º C for 15 min and the working area of the bench liberally 
sprayed with RNAse Zap decontamination solution. NTer nanoparticles were diluted into a 
16% working solution and (using RNAse free water) and incubated with 10 or 20 nM of 
JPH1 silencer esiRNA or Flourescein esiRNA (negative control) for 30 minutes at 37°C to 
allow complexes to form. N-TER nanoparticles interact non-covalently with the siRNA 
particles, and then, by interacting with lipids in the plasma membrane, allow the whole 
complex to enter cells (Sigma Aldrich Technical Bulletin N0788). After the complex 
formation step, siRNA-N-TER nanoparticle complexes were added to C2C12 cell layers and 
covered in 1.5ml of serum-free or 0.5% serum content DMEM, and replaced in the incubator 
for 24 hours. Experiments were performed in duplicate. After a 24 hour incubation, the cells 
were scraped in 50 μl of ice cold RIPA buffer (with protease inhibitors, see sample 
preparation section3.3) and flash frozen using liquid nitrogen. Samples were stored in a -80
o
C 
freezer until analysed for JPH1 protein content via western blotting (see section 3.5).  
 
3.1.f: A7r5 rat smooth muscle aortic cell line and calpian inhibition assay. 
Materials: ALL-N calpain 1 inhibitor (N-acetyl-Leu-Leu-norleucinal, Ac-LLnL-
CHO) Cat. No. A6185, Sigma. A23187, (calcium ionophore, Cat. No. C7522, Sigma) 
BAPTA-AM, (1,2-bis(2-aminophenoxy)ethane-N,N,N′,N′-tetraacetic acid, A4926, Sigma) 
DMSO (Dimethylsulfoxide, (Cat. No. D2650, Sigma)).SDS-PAGE sample Buffer: (250 mM 
Tris HCL pH 6.8, 10% SDS, 30% glycerol, 0.4% bromophenol blue.) 
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A7r5 cell lines were maintained and subcultured as described in section 3.1.1. For 
calpain inhibition assays, cells were seeded in 6 well plates and allowed to grow until 70-80% 
confluency. Cells were incubated with a range of concentrations of ALL-N, A23187, the 
esterified calcium buffer BAPTA-AM, 0.1% DMSO  in final volume of 2 ml and control 
DMEM solutions with 2 ml of media per well. The cells were incubated for 1, 3, 6 and 24 h, 
after which they were incubated on ice in 50 µl of 2X reducing SDS-PAGE sample buffer per 
well and scraped into 1.5ml tubes. Samples were either snap frozen or boiled at 100˚C for 7 
min and loaded onto 7.5% SDS-PAGE gels 
. 
Table 3.1.f: Chemicals and concentrations used in calapin cleavage assays. A7r5 
cells were incubated with the outlined chemicals in 6 well plates (in triplicate) in 2 mls of 
DMEM for 3 or 6 hours.  
3.2: Animal tissue studies : 
 All named researchers possessed the required animal licenses and the protocols were 
approved by the University College Cork Animal experimentation ethics committee or the 
corresponding regulatory body for their respective instituitions. For FKBP12-Glutathione S-
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Transferase affinity purification and rabbit muscle western blot experiments, male Wistar rats 
and ex-breeder male white New Zealand rabbits were housed on 12 hourly day and night 
cycles in the Biological Services Unit, UCC with ad libitum access to food and water. Rats 
were anesthetised by either CO2 inhalation or euthetal administration (performed by and 
under care of Dr Maria Buckley, or Ms. Elaine Barry (Department of Physiology, UCC) and 
Dr Cliona O Mahoney (Department of Parmacology, UCC). Rabbits were sacrificed by 
cervical dislocation. Muscle tissue (see table 3.3.1) was excised and flash frozen in liquid 
nitrogen.  
3.2.a: CIH and Sham rat treatment: 
Under the supervision of Prof Ken O Halloran at the Department of Physiology, University 
College Dublin, male Wistar rats were housed in 12 hr light and dark cycles with free access 
to food and water. Chronic intermittent hypoxia was achieved by placing the rats in chambers 
with alternating room air/5% O2 (CIH animals, n= 6) or alternating room air-room air every 
90 seconds (Sham animals, n=5) for 8 hrs per day for two weeks(essentially as described in 
Shortt et al 2013). Animals were sacrificed (By K O’Halloran) via administration of 5% 
isoflurane followed by cervical dislocation, after which muscles were excised and flash 
frozen. Extensor Digitorum Longus (EDL) and Soleus muscles were analysed for JPH1 and 2 
expression via western blot.  
3.2.b: Adult versus Aged animals: 
 In the laboratory of Dr. Brian McDonagh (University of Liverpool, Department of 
Musculoskeletal Biology, Institute of Aging and Chronic Disease), male C57BL/6 mice were 
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housed in 12 hr light/dark cycles with free access to food and water. At 12 and 25 months of 
age, mice were anesthetised using 0.15 mg/ml Dormitor and 20mg/ml Ketaset, followed by 
cervical dislocation. Soleus and a portion of quadriceps were excised and either underwent an 
isometric contraction protocol (in vivo isometric contraction) or were snap-frozen and sent to 
this laboratory, where the experiment was blinded by JJM. The muscle samples were 
homogenised as described in section 3.3. 
The isometric contraction protocol performed by Dr. McDonagh was as follows: mice 
were anesthetised and surface electrodes were placed on the ankle and around the upper leg 
of both hindlimbs. Contractions were elicited for 15 minutes duration using a square wave 
pulse 0.1 ms in duration at 100 Hz and 70 V for 0.5 s every 5 seconds as described in 
(McArdle et al, 2001). Following the isometric contraction protocol the mice were sacrificed 
and the muscles were excised and snap frozen in liquid nitrogen.  
3.3: Sample Preparation. 
3.3.a:Materials:  
Protease inhibitors: aprotinin (Cat. No. A1153, Sigma), leupeptin (Cat. No. L2884, 
Sigma). Pepstatin A (Cat. No. P5318, Sigma). Phenylmethanesulfonyl Fluoride, (PMSF, Cat. 
No. P7626, Sigma).Trizma HCL (T5941, Sigma) Sodium Deoxycholate (D6750, Sigma) 
Sodium dodecyl sulphate (SDS, L4390, Sigma). Sodium chloride (NaCl, S7653, Sigma). 
Sucrose (S903, Sigma). Homogenisation Buffer I: 25mM Tris-HCl pH7.4 and 0.5M MgCl2. 
Homogenisation Buffer II: 25mM Tris-HCl pH 7.4, 0.5M sucrose, and 0.3M KCl. Radio 
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Immunoprecipitation assay (RIPA) Lysis buffer: 150 mM NaCl, 1% NP-40, 0.5% sodium 
deoxycholate, 1% SDS, 50mM Tris-HCl pH 8.8 plus freshly added protease inhibitors Ultra 
Turrax Homogeniser with 10 mm probe (Model Z722464GB, Sigma), Omni Prep GLH 
homogeniser (Model GLH 115, Omni International) with 5 mm probe (Model B5-075, Omni 
International), Spectramax  Multimode Spectrophotometer (Molecular Devices), Sanyo MSE 
Soniprep 150  (Model B-052, Sanyo), Eppendorf  5810 centrifuge, (Model 5810. 000.327, 
Eppendorf). 
3.3.b: Homogenisation 
Homogenisation of cell pellets was performed using pre-chilled buffers I and II, with 
freshly added protease inhibitors leupeptin, pepstatin A, aprotinin and PMSF (for 
concentration used, see table 3.5.b).  Briefly, cell pellets were homogenised by 50 strokes in a 
loose-fitting glass Teflon homogeniser in 1.25 ml of buffer I, followed by the same volume of 
buffer II and underwent another 10 strokes (adapted from Chen et al, 1993). This crude 
homogenate was aliquoted and used immediately or snap-frozen and stored at -80°C.  
3.3.c: RIPA lysis 
Cell pellets were incubated in ice-cold RIPA buffer and kept on ice for 30 min. 
Lysates were sonicated using a Soniprep 150 (Sanyo MSE) for ten s at a probe amplitude of 
5µm and centrifuged at 10,000 g for 30 min in a pre-cooled (4°C) Eppendorf 5810 centrifuge. 
The supernatant was retained, separated into aliquots, labelled and assayed for protein 
concentration according to the method of Bradford (Bradford, 1976). Bradford reagent was 
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used as it was the most cost-effective way to accommodate the varying buffer needs of the 
lab.  
3.3.d: Muscle preparation: 
The muscle tissue samples listed in Table. 3.3.d.i were obtained in the following 
manner: animals were sacrificed either by sodium pentobarbital administration and/or 
cervical dislocation (see section 3.2). Skeletal muscle and heart samples were excised and 
snap frozen in liquid nitrogen. Muscle samples were weighed and placed in five to ten 
volumes of modified RIPA buffer (15mM NaCl, 0.1% NP-40, 0.05% sodium deoxycholate, 
0.1% SDS, 5mM Tris-HCl pH 8.8 plus freshly added protease inhibitors (table 3.3.d.ii)), and 
were then homogenised by three thirty second bursts of an OMNI Probe (≥ 200 µl per 
sample) or Ultra Turrex homogeniser (≤ 1 ml sample volume). Total lysate/homogenate 
samples were then centrifuged at 13000 gmax for thirty minutes to pellet any debris. The 
resulting supernatant was divided into 0.5ml aliquots, a separate sample was taken for 
determination of protein content by the Bradford assay and the remaining aliquots were snap-
frozen in liquid nitrogen and stored at -80°C until use. 
. 
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Table 3.3.d.i: Muscles excised from rodents. 
 
Table 3.3.d.ii: Protease Inhibitors and Phosphatase Inhibitor used in Homogenisation 
and RIPA based sample preparation. 
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3.3.e: Bradford assay 
  Bradford assays were performed in 96 well plate format using a 1:100 dilution of 
samples prepared with deionised water and vortexed for thirty seconds. Samples, or standards 
and deionised water (made up to 100μl) were pipetted into wells of 96 polystyrene clear plate in 
duplicate and mixed with Bradford reagent (100 μl) (Sigma, Cat. No. B6916) in the manner 
described in tables 3.3.c and d. The Bradford method of protein quantification is a colorimetric 
reaction which works on the premise of Coomassie brillliant blue interaction with proteins 
(Bradford, 1976). In an acidic solution, Bradford reagent (in its unbound state a reddish brown 
colour) binds to arginine and aromatic amino acids within proteins and causes the absorbance 
of the solution to shift from 470nm to 595 nm peak absorbance, giving a blue colour, which can 
be read using a spectrophotometer. The Bradford assay was used as it is a quick and simple 
method for determination of the protein content of samples. Detergent-containing samples must 
be diluted before protein quantification can occur using the Bradford method, as SDS and other 
detergents can interfere with detection. Samples are compared and their protein content 
intrapolated using a standard curve of known protein concentrations, frequently albumin. Plates 
were read using a Spectramax photometer at a wavelength of 595 nm, and compared to bovine 
serum albumin standard curve (BSA, Sigma, A7906). 
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Table 3.3.e.i: BSA, distilled water and Bradford reagent concentrations and layout for 
Bradford assay. 
 
Table 3.3.e.ii: Typical Sample dilutions, distilled water content and Bradford reagent 
volumes used in protein determination using the Bradford assay. 
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3.3.f: Over expression of FKBP12-GST protein for affinity purification assays 
  Generation of a PGEX-2TK plasmid containing a GST tagged FKBP12 sequence was 
performed by JJM and is described by Carmody et al.  (Carmody et al, 2001).This plasmid or 
a GST only plasmid was transfected into competent DH5α’ E. coli cells, stocks of which 
were and maintained at -20°C.  Cultures of FKBP12-GST or GST only transfected bacteria 
were used to inoculate 5 ml of LB broth (containing 100 μg/ml ampicillin) overnight (New 
Brunswick Scientific Excella E24 incubator). These cultures were then expanded by addition 
of 1 ml of overnight culture to 50 mls of LB broth and grown at 37°C until an Optical density 
of 0.6 was obtained at 600nm (using an Eppendorf Biophotometer). Bacteria were then 
induced to synthesize GST or FKBP12-GST protein by addition of 1 mM isopropyl β-D-
thiogalactoside (IPTG) followed by incubation for approximately 2 hours at 27 °C. The 
bacterial suspension was collected by centrifugation at 3000×gmax for 10 min at 4°C in 
Eppendorf Centrifuge 5810 rotor. The bacterial pellet was then lysed in lysis solution 
containing 0.1% Triton X-100 and 100 μg/ml lysozyme in ice-cold PBS and sonicated in 
three 10 s bursts (on ice). The lysate were then cleared by centrifugation at 20,000 gmax in a 
pre-cooled Jouan MR 1822 centrifuge for 60 min at 4°C.  
The resulting supernatant was then incubated glutathione Sepharose 4B beads (GE 
healthcare) in FKBP wash buffer (300 mM sucrose,170 mM NaCl, 0.1% CHAPS 
(3(cholamidopropyl)dimethylammonio)-1-propane-sulfonate), 2 mM dithiothreitol, 20 mM 
Tris–HCl pH 7.4 and protease inhibitors) in 15 ml tubes fixed onto a shaker overnight at 4°C.  
After incubation, the beads were pelleted using a Labnet bench top microfuge for 1 minute at 
16,600 gmax and washed using ice cold FKBP WB with added protease inhibitors (as used in 
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sample homogenisation). This was repeated three times. GST or FKBP-GST bound beads 
were either used immediately or stored at 4°C. 
 For use in affinity purification experiments, rat brain or quadriceps muscle was 
homogenised as described in section 3.3. The total membranes fraction was solubilised for 1 
hour at room temperature in 2% CHAPS, 500mM NaCl, with 20 mM Tris HCl pH 7.4 with 
added protease inhibitors, and then centrifuged at 20,000 g for 1 hour at 4°C (Jouan MR 1822 
refrigerated centrifuge). The resulting supernatant was aliquoted, diluted to five times its 
volume (to dilute NaCl to 100 mM) with Tris HCl pH 7.4  and 10 ml of this solution was 
incubated with glutathione Sepharose 4B beads, GST-bound beads or FKBP12-GST bound 
beads overnight with rotation at 4°C. Following incubation, the samples were cleared by 
centrifugation in 1.5 ml Eppendorf tubes at 16,600 gmax and samples of supernatant and 
pelleted bead-protein complexes were taken for subsequent analysis by SDS PAGE and 
Western blot. 
3.4: Peptide array and Chromatography. 
3.4.a: Materials: 
 Hydroxyapatite matrix (Calbiochem, now distributed by Sigma, cat no 
55497)Heparin agarose matrix(H6508, Sigma) reactive red matrix(R0503, Sigma) Phenyl 
Sepharose Matrix(P7892, Sigma) Concanavalin agarose (C7555, Sigma). Wash and elution 
buffers, as described in table 3.4.a. Solubilisation buffer (1% Triton-X 100, 0.5M NaCl, 
20mM Tris-HCl pH 7). Hyd Ap column buffer (10mM NaH2PO4, 100µM CaCl2, 0.1% 
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Triton-X100, 20% glycerol, and 100mM NaCl).Triton-x-100 detergent (T8787, Sigma). 
CHAPS (3-((cholamidopropyl)dimethylammonio)-1-propane-sulfonate), 2) C5070, Sigma). 
Phosphate buffered saline (137.5 mM NaCl, 2.68 mM KCl, 10.14 mMNa2HPO4 , 1.76mM 
KH2 PO4.) Tris Buffered saline (140 mM NaCl, 20 mM Tris-HCL pH 7.4). Methanol 
(179957, Sigma). Bovine serum albumin, fraction V (Sigma, O5479). Streptavidin 
peroxidase, ultrasensitive (S23438, Sigma). Isoelectric focussing equipment (Amersham 
Biosciences) and IPG strips were from GE healthcare life sciences, Amersham Place, Little 
Chalfont, Buckinghamshire, HP7 9NA UK). Biotinylated peptides as described in section 4.1. 
SDS-PAGE reagents as described in section 3.5.  
3.4.b: Batch Chromatography 
A549 homogenate (2 mg protein/ml, prepared as described in section 3.3.b) was 
solubilised for 1 hour at room temperature in 1% Triton-X 100, 0.5M NaCl, 20mM Tris-HCl 
pH 7.4 and freshly added protease inhibitors.  The solubilised samples were then cleared in a 
Beckman Avanti JA 25-50 rotor for 1 h at 75,600 gmax at 4°C and the resulting supernatant 
and pellet were diluted with Tris-HCl  pH 7.4 to 100 mM NaCl concentration and incubated 
overnight at 4°C with 40 l of resuspended concanavalin A, heparin agarose, hydroxyapatite, 
phenyl sepharose and reactive red matrices.  These were collected by centrifugation using a 
tabletop microcentrifuge (Labnet microfuge) and washed repeatedly with ice-cold wash 
buffer (see Table 3.4.a for wash/elution buffers below) between clearing via centrifugation 
for 5 min at 14500 gmax. After washing, proteins were eluted using various elution buffers 
(see table 3.4.a).  Pellet and supernatant samples were dissolved in 1X SDS-PAGE sample 
buffer, heated to 100
o
C for 7 min and loaded onto 7.5% polyacrylamide gels with 4% 
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stacking gel as described in Section 3.5 (see table 3.5a and b).  Samples were either 
transferred to PVDF membranes for Western blotting or stained in Coomassie brilliant blue. 
 
Table 3.4.a: matrices used in batch chromatography and corresponding wash and 
elution buffers. 
3.4.c: Hydroxyapatite chromatography: 
  One gram of Hydroxyapatite matrix was prepared by re-suspension followed by at 
least three washes of PBS to remove any fine particulate matter. The slurry was then loaded 
into 25 ml columns, to a depth of 1-2cm bed height, and tapped to remove air bubbles. The 
column was equilibrated with 3 rinses of wash buffer containing 10mM NaH2PO4, 100µM 
CaCl2, 0.1% Triton-X100, 20% glycerol, and 100mM NaCl. Solubilised A549 sample (1-2 
mg protein/ml) was diluted with 5 volumes of Tris pH 7.4 to lower NaCl concentration to 
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100mM, and the pre-cooled solute was loaded onto the column. Samples of all flow-through 
and eluents were collected, and the column was kept at approximately 4°C using ice-packs. 
Proteins were eluted from the column using a stepwise NaCl gradient from 100mM to 2M 
concentration, and the column was washed between elution steps with 2 column volumes of 
wash buffer. Elution Buffer contained 50mM NaH2PO4, 100µM CaCl2, 0.1% Triton-X100, 
20% glycerol and 100mM-2M NaCl. After sample collection, 200µl of each fraction was 
incubated overnight at -20°C in 1ml acetone to concentrate any proteins present, after which 
samples were centrifuged at 16,600 gmax for 10-30 min at 4 ˚C, the acetone removed and 
pellet dried briefly. Twenty microlitres of 2X reducing SDS-PAGE sample buffer was added 
to each sample, which were then boiled at 95°C and centrifuged before loading onto 10% 
polyacrylamide gels for SDS-PAGE and subsequent staining or transfer as described in 
section 3.3. 
3.4.d: Peptide Overlay 
Peptide assay was performed to determine optimum signal to noise ratio for the 
biotinylated peptides. Three hundred micrograms of protein from crude A549 homogenate 
was subjected to 10% polyacrylamide SDS-PAGE with a 4% stacking gel. Gels were 
transferred and blocked as described previously, except 5% BSA in TBS was used as 
blocking and incubation buffer.  The blots were incubated in varying amounts of either 
SH3B, SCRAM peptides or 5% BSA in TBS using a multiscreen system from Biorad. 
Peptide concentrations used for both SH3B and SCRAM peptides were 10, 5, 2, 1, 0.1, 0.05, 
0.02, 0.01 µM, diluted in 5% BSA in TBS, and were incubated overnight at 4°C with rotation 
(SH3B and SCRAM peptides were custom ordered from Genscript and are described in 
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section 4.1). The membranes were washed using TBS with 0.1% CHAPS (3 x 10 minute 
washes). Blots were incubated in 1:10,000 Streptavidin peroxidase HRP in 5% BSA in TBS 
with 01% CHAPS for 1 hour at room temperature. They were then developed as described in 
section 3.5.c. Subsequent peptide overlays were performed in the same manner using the 
optimised amount of SH3B peptide, as described in section 4.1.  
3.4.e: Biotin Blocking of spurious reactions 
Materials: as for peptide overlay, Streptavidin (unlabbelled-Sigma Cat no S4762), Biotin 
(Sigma, Cat no B4501).  
After peptide overlay blots were transferred to PVDF membranes and blocked as normal, a 
second blocking step was performed to occupy any natural biotin-containing proteins. This 
was performed by incubating the blot using 0.5-1 mg/ml streptavidin in TBS at room 
temperature for 30 minutes to 1 hour, followed by washing twice in plain TBS. To prevent 
biotinylated peptides binding to the streptavidin, the blots were then incubated in a four-fold 
amount of Biotin (e.g.: if 1 mg/ml of streptavidin was used, a concentration of 4 mg/ml of 
biotin was employed) in TBS for 1 hour, rinsed with standard wash buffer twice and the 
peptide assay was continued as described in section 3.4.d. 
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3.4.f: Isoelectric focusing: 
 Isoelectric focusing was performed in the Biochemistry Department of University 
College Cork, in collaboration with and under the supervision of Prof. David Sheehan and 
Dr. Wentao Hu. Pooled 2M NaCl-eluents from hydroxylapatite chromatography were 
concentrated using acetone to 300μg/μl and dissolved 125µl of IEF rehydration buffer, 
containing 2µl destreak solution and 5µl carrier ampholytes from Sigma and Amersham, 
respectively. Samples were vortexed and centrifuged briefly to ensure they were thoroughly 
mixed, and 125µl of the sample was used to rehydrate iso-electric focusing strips of either 7 
or 18cm length, with a pH gradient from 3-10 or 4-7, overnight.  During focusing, strips in 
the rehydration tray were covered in mineral oil to prevent dehydration and sample loss. 
After rehydration the strips were focused at 500 V (1 h), 1000 V (8 h) and held at 5000V (8 
hours. Strips were flash-frozen using liquid nitrogen for storage or used immediately. 
3.4.g: Press-Blotting of IEF Strips: 
Defrosted 18cm IEF strips with a pH gradient of 4-7 were transferred directly to 
PVDF membranes. The PVDF was pre-soaked in methanol and equilibrated in press-blot 
solution (500mM NaCl, 200mM Tris HCl pH7.4) for 5 minutes. The membranes were then 
laid onto the IEF strips and weighed down with filter papers soaked in press-blot solution. 
Dry filter papers were stacked on top of the IEF strip-PVDF sandwich, which was then 
covered and weighed down for 15-30 min. After transfer the blots were washed TBS with 
0.1% CHAPS for 5 minutes and blocked as described previously. 
90 
 
 
3.5 : SDS-PAGE and Immunoblotting 
3.5.a: Materials: 
Biorad Tetra electrophoresis apparatus and transfer system. Sample buffer: 250 mM 
Tris HCL pH 6.8, 10% SDS, 30% glycerol, 0.4% bromophenol blue. 10X SDS PAGE 
running Buffer (1L): 10 g SDS, 30.3g Tris Base, 144g Glycine.10X Transfer Buffer (1L): 
3.7g SDS, 25.22g Tris Base, 112.6 g Glycine. Precision Plus Protein™ All Blue Standards, 
Bio-Rad, (Cat. No. 161-0373), Pierce prestained Molecular weight marker, Thermo-
Scientific, (Cat. No. 26612) or “Colorburst” electrophoresis marker, (Sigma  Cat. No. 
C1992), Methanol, Sigma (Cat. No. 322415). Thermo Scientific Enhanced chemiluminesence 
substrate (catalog no: PL-32106), homemade ECL substrate (H2O2 (cat no.216763), p-
Coumaric acid(cat no. C9008)  and luminol (cat no. 123072) from Sigma) (ECL component 
1: 0.5mM luminol  0.4mM p-Coumaric acid, 10 ml 0.5M Tris HCL pH 8.5, made up to 50 
ml. ECL component 2: 0.02% H2O2,10ml 0.5M Tris pH 8.5, made up to 50 ml total volume 
with deionised water.) Kodak Carestream film, 5 x 7’, (Sigma, Z30428). AGFA developer 
(CP1000) Licor C-Digit blot scanner, (Cat. No. 980-13723,  LICOR Biosciences UK Ltd, St. 
Johns Innovation Centre, Cowley Road, Cambridge, CB4 0WS, United Kingdom). 
Coomassie brilliant blue R250 (Sigma Cat. No.B8522). Immobilon-P PVDF membrane 
(IPVH00010, Merck Millipore, Tullagreen, Carrigtwohill, Cork, Ireland).  
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3.5.b: SDS-PAGE 
All samples were subjected to electrophoresis on either 7.5% or 10% resolving gels 
with a 4% stacking gel, with the exception of RyR blots (3% stacking gel with a 5 or 6% 
resolving gel, see tables 3.5a and b below). The polyacrylamide gels were fixed into the 
electrophoresis rig and the wells were washed with 1X running buffer. The chambers of the 
electrophoresis rig were filled with the same buffer. DTT (50 mM) was added to 2X sample 
buffer (250 mM Tris HCL pH 6.8, 10% SDS, 30% glycerol, 0.4% bromophenol blue) and 
added to samples containing 30-60μg of protein Samples were then boiled for 7 min at 100°C 
in 1.5ml Eppendorf tubes and centrifuged for 1 min in a benchtop Labnet microcentrifuge at 
16,600gmax  at room temperature. Samples were immediately placed on ice and 20-30 μl of 
supernatant were loaded slowly into wells of 1.5 mm gels.  
SDS-PAGE gels were run at 20 mA per gel for approximately 90 min, or until the 
dye-front was within 5 mm of the bottom of the gel. After electrophoresis gels were either 
briefly rinsed in deionised water and stained for 1-4 hours in Coomassie brilliant blue R250 
in a scrupulously clean staining tray, or transferred to Immobilon-P Polyvinylidene Flouride 
(PVDF) membranes. 
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Table 3.5.a: Components of stacking gels (4 ml total volume) use in SDS-PAGE 
experiments. The stacking gel uses a lower pH and larger pores (due to lower acylamide 
percentage) to evenly stack the proteins before they are electrophoresed into the resolving 
gel. The 3% gels have glycerol added to stabilise them due to low acrylamide content. 
 
Table 3.5.b: Components of resolving gels (8ml total volume) used in SDS-PAGE 
experiments. Gels were overlaid with 200 μl of 70% isopropanol to smooth the top of the 
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gel. This was washed off with distilled water prior to pouring the stacking gel. Higher 
percentages of acrylamide were used to separate lower molecular weight proteins.   
3.5.c: Immunoblotting 
Transfer of proteins from SDS-PAGE gels to PVDF membranes was performed for 70 
min at 70 V in a pre-cooled Biorad wet transfer apparatus. Upon removal from transfer 
apparatus, membranes were rinsed in dH2O, stained in 0.1% Ponceau S solution in acetic acid 
(Cat. No. 78736, Sigma) to ensure transfer of proteins to the membrane was successful, 
washed with PBS and blocked for two hours at room temperature in 5% milk in PBS on a 
shaking platform at approximately 30 rpm. Blots were then incubated in different antibodies 
(Table 3.2.e) in blocking buffer overnight at 4°C in plastic sheets sealed with a heat sealer. 
As many bubbles as possible were removed prior to sealing in the membranes. Following 
primary antibody incubation, blots were separately washed thrice (ten min per wash) in PBS 
or PBS with 0.1% Tween-20, and incubated with secondary antibody/peroxidase conjugates 
(anti-rabbit, Sigma Aldrich catalog number O545) anti-mouse (A9917) or anti-goat IgG 
(A8919), 1:1000 dilution)  in blocking buffer for 1 h at room temperature (18-22
o
C). Blots 
were then re-washed as described and developed via incubation with 0.5 ml each of ECL 
reagent 1 and 2 for 1 min followed by exposure to X-ray film (Kodak) in a developing 
cassette, followed by development on an AGFA developer, or by scanning with a Licor Blot 
scanner. 
  Enhanced chemiluminsecence has widely replaced colourimetric detection of protein 
on western blots. ECL buffers typically involve two buffers, one which contains H2O2 and the 
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other which contains luminol, a substrate for horse radish peroxidase (HRP) HRP-linked 
antibodies react with H2O2 in buffer A and luminol in buffer B to facilitate the production of 
light. In this laboratory, ECL reagents were either from Thermo Scientific or homemade 
using (H2O2 (cat no.216763), p-Coumaric acid (cat no. C9008)  and luminol (cat no. 123072) 
from Sigma) (ECl component 1: luminol (0.5mM),  0.4mM p-Coumaric acid, 10 ml 0.5M 
Tris HCL pH 8.5, made up to 50 ml. ECL component 2: 0.02% H2O2, 10ml 0.5M Tris pH 
8.5, made up to 50 ml total volume with deionised water and stored in the dark at 4ºC. Blots 
were rinsed briefly in PBS or TBS containing no detergent after third wash following 
secondary antibody incubation. Meanwhile, 1 ml of buffers A and B (per blot) or components 
1 and 2 were pipetted on to an acetate sheet fixed to an X-ray blot cassette.  Blots were placed 
protein-side down and gently moved from side to side to properly mix buffers A and B using 
a plastic tweezers. After a 1 min incubation period, excess buffer was removed using paper 
towel placed at the edge of the blot and lifting the cassette at a 45
o
 angle. The blot was 
flipped to display the protein-side up, an acetate sheet was quickly placed on top and bubbles 
were removed from the sandwich using a roller or heavy bottle. The cassettes were then 
brought to the dark room and exposed to Kodak X-ray film. X-ray films are covered with an 
emulsion of silver halide crystals which react with light producing a latent image which when 
developed is reduced to a black image on the film.  
 After development, films were marked with locations of molecular weight 
markers (Thermo scientific, Biorad All Blue precision plus or Sigma Colorburst) and washed 
with PBS.  X-ray films were then imaged by use of a Vilbur Lourmat light box and UVIPro 
transilluminator box and camera, and images were taken and recorded as JPEG files using 
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UVI Photo MW software (UVI Tech, UVItec Limited, Unit 36, St John's Innovation Centre, 
Cowley Street, Cambridge CB4 0WS, United Kingdom). For many blots, reprobing with a 
second or third antibody was performed as follows: blots were washed in either PBS or TBS 
thrice for 10 minutes. To strip off the bound antibodies, blots were incubated in either 
stripping buffer (0.75g Glycine, 0.05g SDS, 500 μl Tween 20; made up to 50 ml with 
distilled water and brought to a pH of 2.2) at 50°C for thirty minutes in a sealed bag, or 
incubated in a clean tray with approximately 30 ml of 0.2M NaOH for 3 minutes at room 
temperature. After stripping blots were re-blocked in 5% milk in PBS/TBS (as appropriate) 
for 1 hour and re-probed overnight at 4°C in a new primary antibody solution.  
3.5.d: Coomassie staining of blots 
Upon completion of western blotting procedures, PVDF membranes were stained 
with a solution containing 0.1% Coomassie Brilliant blue R250 (Sigma Cat. No.B8522) in 
methanol and distilled water (50:50 ratio) for 3 minutes in a tray cleaned with ethanol, as 
described in (Welinder and Ekblad, 2011). Destaining was completed using a solution of 
ethanol, acetic acid and water (Acetic Acid: EtOH: dH2O ratio of 1:5:4). Destaining solution 
was changed after thirty minutes or until protein bands were clearly visible. Membranes were 
then air dried and imaged using a UVIPro transilluminator box and camera, as described in 
the western blotting section. 
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3.5.e: Peptide synthesis 
Spot synthesis of peptides onto nitrocellulose membranes was completed in the 
laboratory of Dr. P.A Kiely at the University of Limerick, Ireland. 18-mer fragments of rabbit 
JPH1 were synthesised by Ms. Maeve Kiely with FMOC (9-Fluorenylmethyloxycarbonyl) 
chemistry using an automatic spot synthesis program and an Autospot Robot ASS 222 (from 
Intavis Bioanalytical Instruments). Peptides were synthesised on a continuous nitrocellulose 
support and were detected under UV light.  Upon receipt of the peptide arrays in UCC, they 
were treated essentially as described for Western blot experiments using mAb VF1c, except 
that all buffers employed Tris buffered saline, and washes were increased to 15 minutes per 
wash. Peptide arrays were developed using both fluorescent secondary antibodies (Cy2 
TM 
and Cy3 conjugated AffiniPure Donkey Anti-rabbit and anti mouse IgG Secondary antibody, 
Cat. No.711225-152 and 715225-150, Jackson ImmunoResearch Europe Ltd. 1:10,000 
dilution in 1% milk in TBS) and HRP-tagged secondary antibodies (1;2000 dilution, in 1% 
milk in TBS) using thermo ECL reagents and film from Sigma. 
 
3.5.f: Over- expression of Junctophilin fragments in Yeast. 
In the laboratory of Prof V. Sorrentino in Sienna, fragments of human JPH1 were 
expressed in Saccharomyces cerevisiae strain Y153 by Ms. Anna Carla, as described in 
(Bagnato et al, 2002) except using cDNA fragments corresponding to amino acids 1-233(a) 
232-369 (b), 141-278(c), 141-278 (d), 229-460(e), 154-278 (f), 229-550(g, 154-635 (h) of 
human JPH1.These were cloned into a pGBKT7 vector and expressed under the control of a 
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GAL4-BD promoter using a Matchmaker III system from Clontech. Positive clones were 
selected by β-galactosidase assays.  The positive yeast clones were expanded, lysed and run 
on 10% SDS PAGE followed by transfer to PVDF membranes which were dried and sent to 
our laboratory. Upon receipt of the membranes, they were rehydrated using a 15 s immersion 
in methanol and were blocked as described in section 3.5.b in 5% milk in PBS. 
 
Table 3.5.c: Table describing the fragments of JPH1 expressed in yeast. These were 
generated by Ms. Anna Carla of the University of Sienna, Italy, these were synthesised to 
confirm or deny the interaction of mAb VF1c with JPH1 protein. 
 
Table 3.5.d.: Primary Antibodies used in western blot experiments. 
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3.5.g: Western blot quantification 
After development, blot films were marked with location of molecular weight 
markers, and photographed using a Ulight box and UVItec CCD camera and acquisition 
software. The images were saved on to a removable disc in JPEG format. Images were 
analysed using Image J software (http://imagej.nih.gov/ij/). Bands of interest were located 
and sealed off using the straight line tool, and the area under the curve was measured for each 
band.  For coomassie stained blots, the entire lane was measured and the sum of all peaks 
measured to give a reading for total protein per lane.  For normalising to tubulin or total 
protein per lane, the intensity for each band of interest was divided by the intensity of the 
corresponding actin, tubulin or Coomassie stained lane. These manoeuvres were performed 
using Microsoft excel.  
3.6: Statistical analysis 
All statistical calculations were performed using Microsoft Excel or GraphPad Prism 
software with the exception of power calculations, which were performed using an online 
calculator (http://statpages.org/proppowr.html see appendices).  Data from densitometry of 
blots was prepared in Excel, and then Prism was used to generate graphs and compare means 
in statistical tests. Unless otherwise stated, means of protein abundance as detected via 
western blot in test group were normalised to the control group (e.g. mdx JPH1 abundance in 
diaphragm was normalised to JPH1 abundance in wild type diaphragm etc.), and compared 
using a Students’ T-Test (two-tailed). Significant differences were acknowledged when the p 
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value was found to be less than 0.05. For comparisons of multiple parameters, a one way 
analysis of variance was completed, again taking significance as a p value of less than 0.05.  
3.7: Bioinformatic analysis: 
Materials: Uniprot protein database (http://www.uniprot.org/), Protein Blast local 
Alignment tool (http://blast.ncbi.nlm.nih.gov/Blast.cgi). Online human predicted interaction 
database (OPHID - http://ophid.utoronto.ca/ophidv2.204/), Expasy Proteomic tools server 
(http://www.expasy.org/proteomics). TagIdent (http://web.expasy.org/tagident/). Clustal 
Omega protein alignment software (http://www.clustal.org/omega/) (Sievers et al, 2011)  
Bioinformatic analysis were performed as described in sections 4.3, and 4.4. In most 
cases, FASTA sequences or accession numbers of desired proteins were obtained from the 
Uniprot website and used as input where necessary in Clustal Omega alignments. For 
identification of potential RyR1 interactors, the RyR1 protein was screened using the OPHID 
database, and potential interactors were tested experimentally (Chapter 4, section 4.4.1). To 
assemble a list of potential interaction partners based on experimental data (chapter 4, section 
4.3), molecular weight, cellular location and isoelectric point and selected species were 
entered into the TagIdent database, which then generated a list of possible proteins of interest, 
or in this case a list of potential interactors. The results can be seen in Appendix I. 
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3.7.b: Calpain cleavage site approximation in JPH1 and JPH2: 
Materials: Uniprot protein database, Site Predictor calpain cleavage prediction software 
(http://www.dmbr.ugent.be/prx/bioit2-public/SitePrediction/) (Verspurten et al, 2009). 
 FASTA sequence of JPH1 and 2 from  rat, rabbit, mouse and human were obtained from 
from the Uniprot database. The sequences were separately inputted into the site predictor 
engine and analysed for calpain I or calpain II cleavage sites. Results were compared across 
the defined species, and calpain cleavage sites common to all were compiled into the tables 
seen in chapter 5. 
3.7.c: Rf measurement 
Materials: ruler, molecular weight standards (ThermoPierce molecular weight markers, cat 
no: 26612, Colourburst® Molecular weight markers, Sigma, cat no:C1992 or  All-Blue 
Prestained protein plus,: Biorad cat no 1610373), Light box, CCD camera, SDS PAGE 
Coomassie or silver- stained gel or Blot (as in section 3.5 and 3.6),  Microsoft Excel software 
(Microsoft, 2007).  
Blots and gels were measured on the lightbox by placing te ruler as close as possible and in a 
straight line next to the molecular weight standards. The distance between the top of the gel 
(the beginning of the resolving gel) and the bottom of the gel (the dye-front) were noted. The 
distance travelled by each molecular weight marker was then measured, and the ratio of the 
distance travelled over length of gels or blots were used to generate a curve using Excel 
software.  Bands of unknown or undetermined molecular weight were also measured and  
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their molecular weight was extrapolated from the curve generated by the standards. An 
example is shown in Figure 3.5.a 
  
Figure 3.5.a: Example of Rf measurement. The distances travelled by molecular weight 
markers are treated as standards and used to extrapolate the apparent molecular weight of 
proteins of interest. 
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Chapter 4: Characterisation of 
potential RyR1-SH3 Binding 
domain interaction partners 
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 4.1:Introduction 
 The type 1 Ryanodine receptor (RyR1) is a large homotetrameric protein with many 
different regions, as described in section 1.4.a, one of which is a proline rich region between 
the amino acids of 4254 to 4631. This proline rich region is has so far been poorly 
characterised, but due to its position in divergent region 1 of RyR1, has the potential to be 
important to protein-protein interactions and may be the site of regulation of Ca
2+
 inactivation 
in this channel (Benacquista et al, 2000).  
  Based on the in silico analyses of Wu et al in 2007, peptide array target screens identified a 
region of RyR1within the proline rich area which interacts with a candidate Src Homology 3 
(SH3) binding domain. Wu et al used modular expression of SH3 domains from 8 proteins as 
“prey” and screened them with over 1000 potential interacting peptides (used as bait) in what 
was termed a peptide array target screening (PATS) assay. It was found that the proline rich 
region near the C terminal end of RyR1 (amino acids 4521-4533) could interact with the 
modular SH3 domains from PLCγ1 (amino acids 791-851), NCK1 and GRB2 in the array. To 
further characterise this interactions, and identify any other interacting protein(s), biotinylated 
peptides were designed by JJM to mimic the RyR1 proline-rich region, and were used in s 
series of over lay experiments (see results section 4.3.a to 4.3.f). 
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SH3 domains are non-catalytic domains, first identified by Mayer in 1988 (Mayer et al, 
1988). They are small protein modules of approximately 50-70 amino acids, with the average 
SH3 domain being 60 αα residues in length (Sudol, 1998). While they are non-catalytic, they 
are crucial in cell signalling pathways as they mediate protein-protein interactions, and can 
thus increase local concentrations of effector molecules and enzymes with their relative 
binding partners.  
Roughly 400 SH3 domains are encoded within the human genome, and are known to be 
expressed in at least 350 proteins (Larson et al, 2000, Jia et al, 2005). SH3 domains are 
typically comprised of 5 β-pleated sheets, termed βa-βe, which are linked by the RT-Src loop 
between βa-βb, the n-Src loop between βb-βc and the distal loop separating the βc and βd 
helices. The β-pleated sheets and loops fold into two perpendicular sheets, which have been 
named sheet 1 and 2 for clarity. Sheet 1 is comprised of βa, βe and the first half of βb. At a 
90º angle to this, sheet 2 is formed from βc, βd and the second half of βb, which has a 
conserved kink in the middle of it, allowing it to participate in the two sheets via hydrogen 
bonding, known as the “β-bulge” (Larson, Davidson, 2000). The overall structure is 
important for creating “binding pockets”, three of which exist in SH3 domains, and they form 
an indented space into which ligands can fit, and helps maintain the structural integrity of the 
interaction. The conserved RT and N-Src loops contribute to the specificity of binding with 
ligands. It should be noted that SH3 domains are able to fold and unfold within a biologically 
relevant timescale, which is to say that the folding and unfolding of SH3 domains have been 
measured at 1 second up to 1 hour, and this unfolding can be important for structure 
maintenance and allowing access to other domains within the protein (Wales and Engen, 
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2006). SH3 domains are known to bind Class I, II or II ligands, of which Class I and II both 
have the canonical –PxxP motif but with N- or C-terminal positive amino acids flanking 
them, which determines their binding orientation with respect to the RT-Src Loop. Class III 
ligands also exist, and are less specific. The location of the proteins themselves also 
contributes specificity upon the binding region (Mongiovi et al, 1999; Bartelt et al, 2015). 
The RyR1 proline rich region lies between amino acids 4462-4532, an area close to the ER 
membrane, and any interaction here could have important effects on gating, and thus on 
disease associated with calcium channel dysregulation. This area is also contained within the 
divergent region 1, a large, poorly conserved region of RyR1 (compared to RyR2 and 3) 
which has been implicated in the regulation of Ca
2+
 - inactivation of the channel, and thus it 
is imperative to confirm and validate any interactions which occur in this region (Benacquista 
et al, 2000). 
To ascertain if any protein binds to this region of RyR1, two synthetic peptides were 
designed. The SH3B peptide mimics a class I (-AxPxxP-) SH3B binding region, 
corresponding to the sequence -PPKKQAPPSPPK- (amino acids 4520-4532 of RyR1, see Fig 
4.1.a, which shows a species comparison of RyR1 proline rich regions and the fit of each 
orientation of the peptide as an SH3 binding region) with a biotin moiety at the N-terminal 
region and a linker region to allow flexibility; while the SCRAM control peptide has the 
same amino acids in a randomly scrambled order. Scrambling of the control peptide was done 
by assigning each amino acid in the SH3B peptide a number from 1-12, and an online 
random number generator was used to pick these out and so generate a peptide sequence 
without bias. The peptides also have an Aminohexanoic acid group (AHX) which allows 
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flexibility of the peptides and maintains distance between the streptavidin-biotin interface. 
This means the two peptide probes have the same amino acid composition and molecular 
weight, but different sequences. The biotin moiety facilitates detection using streptavidin 
peroxidase, as the biotin-streptavidin has been shown to have a dissociation constant of 4 x 
10
-14 
M, and requires temperatures of 70°C to break the interaction (Holmberg et al, 2005).  
A cartoon of these peptides can be seen in Fig. 4.1.a. For these reasons, SH3B and SCRAM 
peptides were used to attempt to identify potential novel binding partners for RyR1. 
4.2: Aims: 
The aim of this research was to characterise the protein-protein interactions of the 
proline rich region of RyR1 using biotinylated mimic peptides SH3B and a scrambled 
version, SCRAM in overlay and pull down experiments. Cell culture screens were used to 
identify a suitable RyR1-expressing raw material, followed by overlay experiments using 
SH3B and SCRAM peptides to determine optimum working concentrations for these 
peptides. Chromatography matrices (reactive red, phenyl sepharose, heparin agarose, 
hydroxyapatite and concanavalin a, described in detail in the material and methods section) 
were used to further isolate potential interaction partners, and finally RyR1 complexes were 
isolated using bacterial overexpression of  FKBP12 in immuoaffinity experiments followed 
by western blot analysis to test the validity of RyR1-protein interactions suggested by Wu et 
al (2007) and the Online Human Protein Interaction database (OPHID).  
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Figure 4.1: Cartoon of biotinylated peptides used in overlay and pull down experiments. 
The peptides have a C terminal Biotin moiety and an N-terminal amidation group to help 
stabilize the peptide. 
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Figure 4.2: Clustal Omega alignment of the Proline rich region (αα4462-4532) of 
Human, rabbit, pig, mouse, rat and chimpanzee RyR1.  
The Clustal Omega suite of EMBL was used to generate an alignment of the proline 
rich region believed to be involved in interactions with an SH3 domain-containing protein. 
(http://www.ebi.ac.uk/Tools/msa/clustalo/). SH3 domain ligands usually have either a class I 
(R/KxxPxxP), Class II (PxxPxR/K) or Class III structure (P-rich segments without the 
surrounding charged amino acids), but RyR1 has a proline rich region which could contain all 
three classes (Tonikan et al, 2009).  RyR1 from Homo sapiens has both class I and II ligands, 
which are highlighted (yellow and blue boxes). It is possible that these putative SH3 domain 
ligands could interact with one or more SH3 domain containing proteins (Kang et al, 2000).  
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4.3: Results 
4.3.a: Cell line screening for SH3B binding peptides 
To determine if any proteins which could interact with SH3B peptide were detectable 
in a range of human and rodent cell types, homogenates from A549, JEG3, rat A7r5, SH-SY-
5Y,  Jurkat, U937, HL-60 and mouse C2C12 cell lines were subjected to peptide overlay as 
described in section 3.4. A summary of these is provided in table 4.3.a. Cell types were 
chosen based on their availability and expression of RyR1. 
  The resulting peptide overlay shows two bands at 150 kDa and 90 kDa (calculated 
molecular weight using Rf  ,see section 3.6.c) are detectable in A549, JEG-3, A7r5, SH-SY-
5Y and C2C12 cell lines. Molecular weights were estimated based on retardation factor (Rf) 
using the molecular weight markers as standards (graphs of Rf can be found in the appendix). 
Bands of 80kDa apparent molecular weight were detected in U937 and HL60 cell lines, with 
a possible band at 75 kDa in the Jurkat cell line. While C2C12 and A7r5 cell lines are from 
mouse and rat respectively, and do not have the same SH3 binding region on RyR1 as that 
found in humans,(see figure 4.3.a), they do display bands at 90 and 150 kDa. 
Based on band intensity, A549 lung adenocarcinoma cell line was chosen for further study. 
A549 cell lines also had the advantage of growing quickly, thus enabling up-scaling of 
purification. Optimisation experiments were performed using A549 homogenate to determine 
the best signal to noise ratio for biotinylated peptide overlay. 
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Table 4.3.a: List of cell lines used in pilot overlay experiment. Cell lines (A549, A7r5, 
C2C12, HL-60, JEG-3, JURKAT, SH-SY-5Y, and U-937) which all express at least one 
isoform of RyR were subjected to peptide overlay using the biotinylated SH3B peptide. All 
cell lines express RyR1, except for HL-60, which express RyR2.  
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Figure 4.3.a: Investigation of SH3B-interacting proteins in cell lines. Cell lines were 
homogenised, or were used to prepare lysates, and were subjected to SDS-PAGE and transfer 
to PVDF membranes, followed by peptide overlay with the SH3B biotinylated peptide. Using 
this technique, a band was detected at 150 kDa in A549, JEG-3, A7r5, SH-SY-5Y, and 
C2C12 cells. A band at 90kDa in molecular weight was detected in all cell lines except Jurkat 
and U937 cells. 
 
4.3.b: Peptide Assay 
  To determine the optimum working concentration of SH3B peptide for use in 
overlay experiments, multiscreen experiments were performed with a range of concentrations 
of SH3B peptides. This was performed to find the optimum signal to noise ratio. A549 
homogenate was screened via peptide overlay with 5-0.1 µM of SH3B peptide, and the 
lowest signal to noise ratio was found using a concentration 0.1 µM.  At this concentration, 
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two clear bands were visualised at approximately 120 and 75 kDa, as seen in figures 4.3.b, 
however the 2 and 5 µM panels are difficult to make out due to high background.  
 
Figure 4.3.b: SH3B peptide overlay optimisation:  Varying concentrations of  SH3B 
peptide used in overlay experiments to probe A549 homogenate for interacting proteins. 
Bands are seen at approximately 125 and 75 kDa with the greatest clarity at 0.1µM SH3B.  
 
4.3.c: Batch Chromatography 
  To further characterise the 125 and 75 kDa proteins, a selection of matrices were used 
in chromatography assays to remove contaminants. Solubilised A549 homogenate was 
incubated with various matrices on a small scale format as described in section 3.4.b, in an 
attempt to purify any novel interacting proteins for further analysis, e.g. by mass 
spectroscopy. While all matrices seemed to enrich the protein, hydroxyapatite and heparin 
agarose were found by visual inspection to have the greatest amount of 125 and 75 kDa 
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proteins, thus these matrices were chosen for larger scale purification of the proteins of 
interest. 
 
Figure 4.3.c: Batch chromatography of solubilised A549 homogenate. Matrices loaded 
were concanavolin A (Con), hydroxyapatite (Hyd A), heparin agarose (Hep A), phenyl 
sepharose (Pen) and reactive red (Reac R) matrices. The highest amount of protein detected 
from equal amounts of A549 homogenate with 0.1μM of SH3B peptide was in heparin 
agarose and hydroxyl apatite samples. 
4.3.d Hydroxyapatite Chromatography 
   Hydroxyapatite chromatography was chosen as it provided a good yield of protein as 
detected using SH3B overlay (Heparin agarose also also tried, however the perotein could not 
be eluted at specific times using our buffer system, (data not shown) thus Hyproxyapatite was 
chosen for further analysis) Low-pressure column chromatography was performed using a 
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rehydrated hydroxyapatite matrix from Sigma, in the manner described in section 3.4. 
Hydroxyapatite was chosen for further study as this matrix yielded the highest amount of 
protein in the batch purification. Proteins were eluted from the column using a 100mM-2M 
NaCl gradient, and in the case of hydroxyapatite, the 75 kDa protein was eluted at 2M NaCl 
concentration (Figure 4.3.d.i). The proteins present in each fraction were compared using 
SDS PAGE and silver staining, and at 2M NaCl, several proteins were eluted, as seen in Fig 
4.3.e, however only one of these proteins was detected at 75 kDa using an overlay experiment 
with the SH3B peptide. This protein was also found, along with another protein at 120kDa in 
the “Flow-through” sample.  Hydroxyapatite was thus used for further isolation of these 
interaction proteins. 
For convenient execution of SH3B, SCRAM and BLANK (Steptavidin-HRP-only controls), 
and to increase protein concentration, fractions were pooled into four samples. A549 
homogenate (control sample), flow-through, 0.1-1M NaCl wash and 2M samples were 
subjected to peptide overlay, shown in Fig. 4.3.d.iii. In the 0.1-1M and 2M fractions, a band 
of 75 kDa apparent molecular weight was detected in all three blots (SCRAM, BLANK and 
SH3B), indicating that this protein was revealed to be a  non-specific interaction. The SH3B 
panel also depicts a band at 125 kDa in all four fractions. If this protein does indeed bind to 
the SH3 binding domain of RyR1, further studies would have to be performed to confirm this 
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Figure 4.3.d.i : (top) A549 homogenate subjected to hydroxyapatite chromatograpy and 
peptide overlay using SH3B peptide or Silver stained(bottom).  Solubilised and diluted 
A549 homogenate (1.5mg/ml A549 homogenate per solubilisation, 30 μg protein loaded per 
lane) was subjected to hydroxyapatite chromatography followed by peptide overlay with 
SH3B peptide. Equal volumes (10 mL) of each sample were concentrated using acetone 
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preciptitation at -20 ºC overnight, then resolved by SDS-PAGE, transferred by western 
blotting and probed with the SH3B peptide in an overlay assay.  A protein of 75 kDa apparent 
molecular weight was detected in the homogenate, solubilised material, flow-through, and in 
the 100 mM, 200 mM, 300 mM and 2M NaCl elution steps. The flow-through and 100mM 
fractions also contain a band at approximately 100 kDa (upper arrow).  The 100 kDa protein 
is not seen in the 2M fraction. The bottom image shows Silver stained gel showing the A459 
homogenates, post sol, flow-through, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1M, and 2M 
fractions in lanes 3-15 respectively. There is a strong band in the 2M fraction at 75 kDa 
4.3.e: Isoelectric focusing 
 Isoelectric focusing is the process of separating a protein or set of proteins according 
to their differing isoelectric points (pI). As each protein has a different isoelectric point based 
on its amino acid composition and post-translational modifications, this technique can 
theoretically be used to identify or narrow the identity of an unknown protein, as long as 
there are adequate detection methods. For this reason concentrated samples eluting at 2M 
NaCl from pooled hydroxyl apatite chromatography experiments were subjected to isoelectric 
focussing using strips with a pH gradient of 4-10. These strips were then press-blotted on to 
PVDF membranes and probed using the SCRAM and SH3B peptide. The results (Figure 
4.3.e.i) show that the SH3B peptide detected a protein with an isoelectric point in the region 
of 5-6, with another band visible at an approximate pH between 6-7 pH units. These are 
likely to correspond to the two bands found using peptide overlay experiments (based on 
comparisons with stained gels, which show that many contaminants have been removed) and 
thus narrow the identity of these proteins to those within the given pI ranges. Using this 
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information, combined with knowledge of the molecular weight and the fact that this protein 
is more likely to only be expressed in humans, a “TagIdent” search was performed using 
these parameter to generate a pool of possible identities for this novel RyR1-interactor, the 
results of which can be seen in appendix I, Table 8.1.c. 
In the SCRAM probed strip, multiple bands were detected, indicating that the SCRAM 
peptide or biotin moiety attached to it has interacted with several proteins, resulting in a 
“smeared” appearance. This demonstrates a non-specific interaction of this peptide with 
many proteins in the “2M” fraction, or it could be due to incomplete blocking of free sites on 
the membrane resulting in non-specific interactions. 
In an attempt to gain more information about these potential RyR1 interactors, isoelectric 
focussing was performed using concentrated 2M fractions from the same experimental setup. 
The concentrated fractions were focussed on 7 and 18 cm strips with a pH gradient of 4-10, 
and were transferred to PVDF membranes by capillary transfer method. This allowed the 
direct imaging of protein locations along the length of the IEF strip, and thus gives an 
approximate indication of the isoelectric point (pI) of these peptide binding proteins. In this 
case, the SCRAM peptide gave many results along the length of the IEF strip, while the 
SH3B peptide gave a more specific result, with one major band at the positive end of the 
strip, which is closer to a pI of 4. This is interesting, as elution from a hydroxyl apatite 
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column at 2M NaCl would imply that the protein was basic in nature. 
 
Figure 4.3.e: IEF and peptide overlay using SH3B and SCRAM peptides. Peptide overlay 
probe of 2M fractions (1.5 to 2 mg.ml total protein concentration) for hydroxyl apatite 
chromatography subjected to IEF along a pH gradient of 4-10. Three bands can be seen in the 
SH3B panel (top), while the SCRAM panel has many indistinct bands.  
4.3.f: Biotin block of spurious reactions 
 When increasing the concentration of protein loaded on gels for peptide overlay from 
40 to 60 µg per well, the “BLANK” and SCRAM panels had very similar bands to those seen 
previously only in the SH3B labelled panels. This implied that streptavidin peroxidase was 
binding to a biotin-containing or biotin like protein, and could thus be competed away from 
the (possibly very weak) interaction of SH3B and SCRAM peptides with potential targets. To 
mitigate this, and to resolve the problem of false positives, peptide overlay blots were 
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performed as described previously, but including an additional step in which blots, were 
incubated with streptavidin to occupy any biotin or biotin-like proteins. Because streptavidin 
has four biotin binding regions (Sano and Cantor, 1995), biotin was then incubated with the 
PVDF membrane to fill these sites and prevent the peptide from interacting here (described in 
section 3.4.e).  The membranes were then treated as for a standard peptide overlay using 
SH3B, SCRAM and BLANK (Streptavidin-HRP only control). This method partially blocked 
the bands seen at 120 kDa in homogenate and cytosolic samples (lanes 1 and 2), indicating 
that these bands are due to spurious interactions with streptavidin-HRP,  however biotin 
block treatment does not alleviate the spurious band seen at 75 kDa. This indicates that 
another method of detection may be more suitable to identifying proteins using these 
peptides.  
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Figure 4.3.d.iii: Peptide overlay of hydroxyapatite fractions from A549 cell line.  To 
increase detectable protein levels, pooled Hydroxyapatite fractions from solubilised A549 
cell homogenate with A549 homogenate, flow through, 0.1-1M and 2M fractions (lanes 1-4 
respectively) incubated with 50 nM Peptides or 5% BSA in TBS (BLANK, secondary only 
control). 
 
Figure 4.3.f.i: Biotin-block of spurious reactions. A549 samples (60µg of protein per well 
of homogenate, cytosol and total membranes, lanes 1, 2 and 3 respectively) were subjected to 
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peptide overlay as described, except after blocking, blots were incubated in 0.1mg/ml 
Streptavidin in TBST, followed by three 10 min washes to remove any unbound streptavidin. 
This was followed by the addition of 0.5mg/ml biotin in TBST for 60 minutes at room 
temperature, after which the peptide overlay was performed as described previously. 
Taken together, the blots and gels shown in figures 4.3.b-f show that hydroxyapatite matrix 
could be used to isolate two proteins from A549 homogenate in the SH3B-probed blot. The 
proteins were detected at approximately 100-120 kDa and 75 kDa and at an isoelectric point 
of  roughly  5-7. Both proteins appears in SH3B, SCRAM and BLANK control blots, thuis 
are most likely spurious reactions with the streptavidin-HRP.Attempts to block this reaction 
were undertaken using a niotin block protocol, however these were not successful. Although 
attempting to purify novel interactors of RyR1, Hydroxyapatite chromagtraphy inadvertently 
purified contaminants. Other methods were thus employed to characterise novel interaction 
partners for this region of RyR1.    
4.3.g: Novel RyR1 accessory proteins from Protein Interaction Databases. 
 In an attempt to further characterise the interactions suggested in Wu et al (2007), 
experiments were performed to confirm or deny the interaction of RyR1 with PLCγ1 and 
Pleiotrophin1 (PTN-1) as suggested by as OPHID  (Online Human Interaction database, 
http://ophid.utoronto.ca/ophidv2.204/: Brown and Jurisica, 2005). The use of in silico 
analysis of protein-protein interactions has proven invaluable to the understanding of cellular 
physiology as a whole, but care must be taken to validate any putative interactions. Many 
RyR1 interactions described in online databases such as OPHID are from in silico data only, 
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or a combination of predicted and high-throughput experimental results, so it would be useful 
to purify these proteins in complex with RyR1 to validate these in silico interactions.(A table 
of interactions described using RyR1 as the input protein in OPHID can be seen in appendix 
1, Fig 8.1.f). This in turn could determine the functional effect they have, if any, on RyR1 
function, and also any other cellular pathways that they may interact with. Two such 
interactions were that with phospholipase C gamma 1 subunit, (PLCγ1), a widely expressed 
signalling protein with varied roles in MAPK and Ca
2+
 signalling, and pleiotrophin (PTN), a 
ubiquitous cytokine with phosphatase inhibitor implicated in bone growth, muscle 
regeneration and angiogenesis (Camarino et al, 2013). Interactions between these proteins 
and RyR1 would be very interesting, based on their role in the cell. PLCγ1 is a 147kDa 
member of the phospholipase C enzyme family whose function is to hydrolyse 
phosphatidylinositol-4,5 bisphosphate (PI(4,5)P2) into the widely utilized second messengers 
inositol 1,4,5  triphosphate and diacylglycerol (Ins (1,4,5) P3 and DAG respectively). These 
second messengers go on to mediate Ca
2+ 
release from internal stores and PKC activation. 
PLCγ1 is thus known to have roles in diverse processes like signal transduction and gene 
expression regulation (Fukami et al, 2010). Pleiotrophin is an 18 kDa heparin binding protein 
which is involved bone formation, angiogenesis and neurite outgrowth, and is highly 
expressed in developing animals or tumors. Usually a secreted protein, it has recently shown 
to be translocated to the nucleus upon interaction with the protein nucleolin (Koutsioumpa et 
al, 2012). Due to its widely diverse roles in signalling cascades, and its implication as a 
tumor promoter, an interaction with RyR1 could be very important.  
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 To study these interactions, isolation of the RyR1 complex was performed via an affinity 
purification ‘pull down’ experiment, followed by western blot analysis with antibodies of 
potential interacting proteins. To this end, GST tagged FKBP12 fusion protein was used to 
isolate the RyR1 complex from rabbit skeletal muscle microsomes. As described in section 
1.4.b, FKBP12 is a 12 kDa protein which interacts with RyR1. FKBP12 (and its cardiac 
homolog FKBP12.6)  have been successfully expressed in bacterial cells with an added GST 
tag and used in affinity based isolation of RyR complexes (Mackrill et al, 2001). Skeletal 
muscle (leg muscle from rat) was used as RyR1 is expressed in at its highest levels in this 
tissue (Mackrill et al, 1997). Pilot experiments revealed that very low levels of PLCγ1 were 
expressed in skeletal muscle, but was detectable in brain homogenates from rat, so solubilised 
brain and muscle samples were used in the FKBP12 pull down assay. Although the main 
isoform expressed in neural tissue is RyR3, RyR1 is also expressed, although in much lower 
levels (Mackrill et al, 1997).  A Coomassie stained gel showing these fractions with the 
appropriate controls (GST only brain, GST only muscle) is shown in Fig. 4.3.g.i. These 
complexes were probed with anti-RyR antibodies to confirm presence of RyR protein 
followed by αPLCγ 1, αPTN, αGRB2 and αJPH1 antibodies, as outlined in Chapter 3. Results 
can be seen in Fig. 4.3.g.ii-v.  The αPLCγ 1, αPTN and αGRB2 antibodies were used as Wu 
et al (2007) suggest that these proteins (as well as NCK1) interact with RyR1 via the proline 
rich region located between amino acid 4520-4532. The FKBP12 pull down experiments 
were used to validate these interactions in vitro.  
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Figure 4.3.g.i: Coomassie stained rat brain and muscle samples subjected to 
solubilisation and pull down using FKBP12 –GST beads run on a 6% SDS PAGE gel. 
Rat brain and muscle (VL) samples (40 μg total protein per lane,  3.5 mg/ml protein per 
solubilisation experiment) were solubilised and incubated with either GST bound beads or 
FKBP12-GST beads generated using bacterial fusion proteins. (Hom: Homogenate, PO: post 
solubilisation, FT: Flow through) 
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Figure 4.3.ii: Rat brain and muscle samples subjected to solubilisation and pull down 
using FKBP12 –GST followed by western blot with H300 anti-RyR antibody. Rat brain 
and muscle were subjected to FKBP12 pull down as described above and transferred to 
PVDF followed by staining with H300 anti-RyR antibody. Little if any RyR is detectable in 
any of the brain samples, however an enriched band can be seen in the FKBP12-Muscle pull 
down lane, at (approximately 350 kDa- above range of MW markers) as well as a degraded 
band in the muscle homogenate and post solubilised fraction. This demonstrates that the RyR 
complex is isolated using this assay, and is enriched compared to muscle homogenate or post 
solubilised samples.  
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Figure 4.3.g.iii: FKBP12 pull down using rat brain and muscle, probed with α 
Pleiotrophin (PTN) antibody. Bands can be seen in rat brain homogenate and post 
solubilised fractions at approximately 60 kDa and 50 kDa. 50 kDa bands can be seen in the 
GST and FKBP12 flow through (GST, FKBP12 FT) lanes, indicating that PTN has not bound 
to the RyR1- FKBP12 complex in this instance. A different banding pattern is seen in muscle, 
where PTN is undetectable in muscle homogenate but appears enriched in the post solubilised 
sample (muscle PO). This could be due to nuclear translocation of PTN. No PTN is seen in 
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the GST-Muscle or FKBP12-Muscle samples, indicating that PTN has not been isolated by 
the control or FKBP12 binding complex. 
 
Figure 4.3.g.iv: FKBP12 pull down probed with αPLCγ 1 antibody. Rat and brain 
samples incubated with FKBP12 as described above were run on 10% SDS PAGE gels 
followed by transfer to PVDF and probing with αPLCγ 1 antibody. Bands are detectable in 
brain homogenate, brain post sol, muscle homogenate and post sol at an apparent molecular 
weight of 180-200 kDa. As the predicted molecular weight of PLCγ1 is 150 kDa, this is 
likely to be the correct band. No PLCγ1 was detected in either brain or muscle FKBP12 pull 
down fractions, indicating that under these conditions, PLCγ1 cannot be isolated in complex 
with RyR1. 
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Figure 4.3.g.v: Western blot of Brain and muscle samples from rat incubated with 
FKBP12 fusion proteins and probed with αGRB2 antibody. Rat brain and muscle samples 
were treated as described above and incubated with FKBP12 fusion proteins expressed in 
bacteria or GST only controls. Little if any GRB2 is detected in brain samples, but is detected 
at 40 kDa in muscle homogenate and at 160 kDa in muscle post-sol samples. An enriched 
band is visible at 40 kDa in the FKBP12 –muscle pull down lane, showing that GRB2 can be 
isolated with the RyR1 complex under these conditions. 
These results indicate that under these conditions, PTN 1 and PLC γ1 do not interact with 
RyR1, or that the interaction is not strong enough to allow isolation using recombinant 
FKBP12.  These two results highlight the need to thoroughly validate in silico or high 
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throughput experiments. Fig 4.3.g.v shows the same FKBP 12 pull down experiment probed 
with αGRB2 antibody. The results show a visible, enriched band at approximately 30 kDa, 
the correct weight for GRB2 (marked with an arrow). (McPherson et al, 1994) There is a 
lower background band at 25 kDa (marked with an asterisk), which is a result of non specific 
interaction with the secondary antibody (controls can be seen in appendix I, Fig 8.1.e). This 
interaction is interesting, as GRB2 is an adapter protein, it is likely to be allowing the 
interaction of RyR1 and other proteins, and due to its role as a tyrosine kinase activator, this 
interaction could have huge implications for the regulation of calcium signalling in muscle. 
Further studies will have to be performed to confirm this, and should include 
immunoprecipitation of either RyR1 and or GRB2 with cross probing with antibodies to 
confirm the interaction, and perhaps siRNA knock down of GRB2 followed by functional 
studies of Ca
2+ 
release from the RyR1 to monitor effect. 
4.4: Discussion: 
It remains important to investigate this region of the type 1 RyR. As it is close to the 
transmembrane domain, allosteric or posttranslational modifications here could have vast 
implications for cellular Ca
2+ 
homoeostasis. In 1993, Treves et al found that a polyclonal 
antibody targeted to the amino acids 4425-4621 of RyR1 could have an effect on the 
regulation of the channel by Ca
2+ ions. This region of RyR1 also encompasses the “divergent 
region 1”, which may confer a very specific function to any proteins interacting in this area. 
(Treves et al, 1993, Benaquista et al, 2000)  
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Although the SH3B peptides did not give visible results that were not apparent contaminants, 
it would have been really useful to study this interaction. As the SH3 domain can have less 
than stringent binding partners, the -PxxP- motif may not be strong enough to interact on its 
own, without the rest of the protein. The –PxxP- motif may also be only a portion of the 
binding region, or not involved at all. It has been found that SH3 require the cooperation of 
residues outside the –PXXP- motif for binding to occur (Bartelt et al, 2015). Along the same 
lines, the peptide probe may not be long enough to confer specificity, leaving all available 
streptavidin molecules to bind to contaminants.  
The results outlined above demonstrate that biotinylated peptide overlay is an 
unreliable method for protein interaction discovery. Although faint bands in the SH3B 
overlay panels existed outside the main contaminants at 120 and 75 kDa, they were not 
consistent and some of them were visible in the SCRAM and blank panels. Bands of a similar 
molecular weight were found in Yeow-Fong et al, who expressed SH3 domains from SNX9 
as GST fusion proteins and used them as “prey” in an overlay experiment to screen rat brain 
and testis tissue for interactors of the SNX9 protein (Sorting nexin 9, involved in mitosis). 
This indicates that the non -specific interactions are not exclusive to cell culture, and that 
very careful raw material choice and experimental design are necessary to gain meaningful 
information from overlay experiments. Stringent controls must also be employed (Yeow-
Fong et al, 2005, Kim et al 2010). A more reliable method must be used to investigate any 
binding partners which interact with this region of RyR.1 Kim et al suggest removal of 
contaminants via passing solubilised material through a streptavidin-sepharaose column 
before proceeding with biochemical detection with biotinylated peptides, however this adds 
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another step to sample preparation which could significantly increase cost, sample loss and 
degradation. Confounding results also appeared with the IEF purification experiments, which 
based on the estimation of isoelectric point gave a result at a pI of 4-6. This contradicts the 
estimated pI of proteins eluted using increased NaCl gradients from hydroxyl apatite 
columns, which are usually basic under the conditions used (Cummings et al, 2009), although 
this is disputed by Hou et al (2011) who state that there was no correlation between protein 
retention and isoelectric point of that protein with elution using increasing NaCl gradients 
and constant phosphate concentration (Cummings et al, 2009; Hou et al, 2011). Taken 
together, these results demonstrate that either contamination of samples has occurred or more 
likely, that several contaminants are detected from the streptavidin peroxidase-HRP alone. 
Although intended as a purification step, in this instance Hydroxyapatite chromatography 
acted as an enriching step for contaminants, and thus could be used to remove this from 
future analyates.  
 Further attempts to characterise interactions with RyR1 and proteins suggested in the 
OPHID database were carried out using the FKBP12 fusion protein pull down of RyR1 
complexes followed by probing with αPLCγ1, αPTN, and αGRB2 antibodies. RyR complex 
isolation was achieved, as demonstrated by the αRS4 western blot, however neither the 
αPLCγ1 and α-PTN antibodies showed any bands in the pull down sections. This does not 
exclude the possibility of either of these proteins interacting with RyR1, however, it has not 
worked in this experimental set up. It is possible that the αPLCγ1 antibody (generated against 
rabbit) does not have the required specificity (although BLAST searches of the human and 
rabbit PLCγ1 show little variation  in the immunogenic peptide as described on the suppliers 
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website). Pleiotrophin may have not have been detected in the 6 or 7.5% SDS PAGE gel, but 
subsequent experiments showed that both PLCγ1 and PTN1 were detected in the brain 
homogenate using 10 and 15% gels respectively, indicating that their absence in the pull 
down fractions is not due to poor antibodies. However, a band was visible at 60kDa, 
indicating that it may have been in complex with a larger protein (despite rigorous sample 
boiling and addition of DTT, this is not unheard of, and may not have been amenable to other 
interactions.   It is also possible that the starting material was degraded, leaving very little to 
be detected, or that the PTN antibody actually detercts some other protein. Future efforts to 
validate these interactions could be improved by using the most recent muscle samples 
available and the use of varied complex purification techniques, as well as a gradient gel to 
maximise protein resolution and detection.  
 The GRB2-RyR1 complex interaction, seen in Fig. 4.3.g.v is a potentially novel 
result, and has interesting ramifications for calcium signalling in muscle cells. GRB2 has an 
SH2 domain in the middle region of the protein, flanked by a SH3 domain on either side 
(Maignan et al, 1995).  As these data are essentially preliminary results, careful validation 
must be performed to validate this interaction, and determine the effect this interaction has on 
the cell. The first step would be to confirm that the GRB2 antibody does in fact bind to 
GRB2, perhaps by use of an inhibitory peptide mimetic of the antigen used to generate the 
antibody and then to confirm GRB2–RyR complex interaction, by co-immunoprecipitation 
and incubation with RyR and GRB2 antibodies. Regrettably, such experiments were outside 
the time constraints of this study.  Current theory states that not only does GRB2 have a role 
in Ras –MAPK signalling, but also as an adapter for receptor Tyrosine kinases. As an adaptor 
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protein, GRB2 uses its SH2 and 3 domains to bring other proteins closer together. In the case 
of the Ryanodine receptor, this may mean that the GRB2-RyR1 interaction is facilitating the 
close apposition of another molecule which may exert some sort of regulation on RyR gating. 
In permeabilised T lymphocytes, GST-GRB2 incubation had no effect on RyR mediated Ca
2+
 
release, however a known associate of GRB2, p59
fyn 
, a non-receptor tyrosine kinase 
associated with T-cell receptors, did cause transient phosphorylation of RyRs and an increase 
in Ca
2+
 ion release from cADPR and ryanodine sensitive stores in permeabilised Jurkat T 
cells . (Guse et al, 2001).This could mean that GRB2 could link p59
fyn 
and RyR for quick 
regulation of calcium signalling based on signal transduction through T-Cell receptors in 
immune cells. In muscle, as RyR1-mediated Ca
2+
 release is so specialized and tightly 
regulated, it is feasible that tissue-specific-tailoring (the specialisation of the Ca
2+
signalling 
toolkit) of this interaction could occur (Berridge, 2000: Bootman et al,2001). A functional 
GRB2 knock out has been generated by Maina et al, and it showed drastic reductions in 
muscle development, particularly in limb buds (Maina et al, 1996). Taken together with its 
potential interaction with RyR1, this hints that GRB2 may have a role in the regulation of 
calcium release and possibly in the regulation of skeletal muscle growth. GRB2 knock out 
animals are not viable, but GRB2 knockdown in C2C12 cells display increased insulin uptake 
(Maina et al, 1996; Liu et al, 2009) and in B cells, GRB2 knock down was seen to lead to 
“hyperreactive” receptor signalling, and these cells showed abnormal congregation behaviour 
in the spleen. (Liu et al, 2009; Jang et al, 2011) Thus, in muscle cells, the GRB2-RyR1 
interaction could have vast implications for muscle cell growth and differentiation as well as 
insulin related signalling. As GRB2 is also implicated in the formation of artherosclerotic 
lesions (Proctor et al, 2007) and is a potential target for anti-proliferative drugs (Zhang et al, 
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2003), further study of this interaction is necessary to understand  the many signalling 
pathways which could be affected by aberrations in this interaction, and the potential for 
these are discussed in section 4.5.  
4.5: Future Studies:  
 The biotinylated peptides were used as a way of mitigating the time and labour intensive 
purification of intact RyRs, however overexpression of the SH3-binding region with one or 
more tags to facilitate purification of any complexes formed in a suitable cell line model 
might be a more effective strategy. This strategy was employed by Kobayashi et al , who 
engineered a “multifunctional GFP”  (mfGFP) protein with built-in streptavidin binding 
peptide, c Myc and an 8x Histidine tag for visualisation and tandem affinity purification of 
both clathrin and RyR1 from HeLa cell lines with minimal contamination products. The 
mfGFP tagged RyR1 was also easily visualised via confocal microscopy, and no mis-
localisation was observed (Kobayashi et al, 2008). Ryan et al used a similar experimental 
design where a large fragment of RyR1 (amino acids 1-4243) was expressed in HEK-293 
cells with a 6x-Histidine tag attached. This fusion protein and associated interacting proteins 
were then purified by Ni-NTA metal affinity chromatography, and the resulting proteins 
characterised by liquid chromatography mass spectrometry (LC-MS). Interacting proteins 
were validated by western blotting and Calcium homeostasis endoplasmic reticulum protein 
(CHERP) was found to be a novel component of the RyR1 complex (Ryan et al, 2011). This 
experimental set up demonstrates that novel interactors of RyR1 can be found, but using a 
combined approach of purification followed by proteomic applications will yield the most 
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accurate results. A caveat of this study is the choice of raw material, as HEK-293 cells may 
not actually express all the proteins capable of interacting with RyR1. In the same manner, 
future studies could focus on the SH3 binding region or RyR1 using both a muscle and non-
muscle cell type/ tissue as a raw material, as this could provide more meaningful data on the 
role of any specific interactors.  
  In terms of the GRB2-RyR1 interaction, further analysis needs to be 
performed to fully characterise this partnership. Such studies should include a comprehensive 
study of the areas of each protein which interact with each other, and could be done by 
mutating the putative binding regions (e.g. changing key proline residues in the PRR of RyR1 
etc) or by deleting fragments of either of the SH3 domains found in GRB2.  This could be 
followed by functional effects of blocking this interaction either by mutational studies or by 
knock down of the GRB2 protein and looking at the effect this has on calcium signalling and 
growth of the cell. Recently, Simister et al  discovered a novel small molecule inhibitor of 
GRB2, and this could prove really usefull in altering GRB2 interactions in vitro and 
monitoring the effects, thus giving a quick and non-cytotoxic method of studying GRB2-RyR 
complex interactions (Simister et al, 2013). 
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Chapter 5: mAb VF1c 
Characterisation 
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5.1.: Introduction 
  In 1987, Campbell et al performed a series of experiments designed to 
characterise the proteins involved in EC coupling (Campbell et al, 1987). This study led to 
the generation of several widely used antibodies targeted against several proteins involved in 
the EC coupling proteins, including XA7, a monoclonal antibody which interacts with RyR1. 
One of the antibodies generated, VF1c, was shown to interact with a 90 kDa protein, found in 
the terminal cisternae of muscle (determined by differential centrifugation of rabbit muscle 
homogenate followed by western blotting), which was termed “ Junctional sarcoplasmic 
reticulum protein-90” or JSR-90. This protein was shown to interact with RyR1, and was 
known to be phosphorylated by an unknown endogenous kinase protein. Subsequent analysis 
of this protein revealed that it was found at higher abundance in fast twitch muscle (ATPase 
and immunostaining experiments) of rabbit, and that its expression was higher in the vastus 
lateralis muscle of aged men compared to their younger counterparts (Olhendieck, 1990, 
Campbell et al, 1987). Despite the generation of a large amount of data about this JSR-90 
protein, it was never identified nor was the antibody fully characterised. To address this, 
studies in the laboratory of JJM were undertaken to characterise this antibody and identify its 
target. Immunoprecipitation experiments followed by MALDI-ToF analysis revealed the 75 
and 90 kDa bands identified by the VF1c antibody to be two fragments of the Junctophilin 1 
(JPH1) protein, separated by a calpain cleavage site (a PEST motif, as delineated by 
ePESTfinder software). A diagram of the results obtained are shown in Fig. 5.1.3.a.  
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 Junctophilins are a family of four proteins (JPH1, 2, 3 and 4), encoded by four 
separate genes. They span the gap between the endo-or sarcoplasmic reticulum and plasma 
membrane of excitable cells, at subplasmalemmal junctions. JPHs are also expressed in some 
non-excitable tissue such as mammary and prostate epithelia, as shown by gene array studies 
(Pawłowski et al, 2011; Marin-Aguilera et al, 2012). Discovered in 2000 by Takeshima et al, 
(2000), JPHs are especially important in skeletal and cardiac muscles, where JPH1 and 2 are 
the predominant isoforms respectively, and where failure of interaction between the PM and 
SR can lead to failure of EC coupling. As implications of diseases such as MH show, the 
misfiring of Ca
2+ 
ions can be catastrophic in excitable tissues. JPH subtypes 3 and 4 are 
mostly found in neuronal tissue, and JPH3 is implicated in Huntingtons-like syndrome and 
motor discoordination (Nishi et al,2002).  
5.1.a:Junctophilin structure and function:  
Junctophilins share approximately 38% amino acids identity (JPH1, 2, and 3 only, 
Nishi et al, 2001), but all have essentially the same predicted structure: an N-terminal region, 
containing between 5 and 8 MORN (Membrane Occupation Recognition Nexus) motifs  
which facilitate interaction with lipids on the inner leaflet of the plasma membrane. 
(Takeshima et al 2000;Nishi et al, 2000). Distal to these motifs, a spring-like, highly 
conserved alpha helix region permits a gap between the plasma membrane and the SR, and 
allows for a 12 nm space. The COOH terminal contains the transmembrane domain which 
inserts into the SR membrane. (Takeshima et al 2000: Garbino et al, 2009)  
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Various knock-out and knock-down animals have been generated to analyse the 
function of JPH. JPH4 KO mouse appears to have no deficit, whereas a JPH1 knock out died 
shortly after birth due to feeding and breathing irregularities. (Ito et al, 2003). As the JPH1 
knock out animals were unviable, inducible knock down via virally delivered shRNA against 
JPH1 and 2 were utilised in skeletal muscle fibres from mice, and reducing the expression of 
these proteins lead to decreased store operated Ca
2+ 
entry (SOCE), disrupted triad structure, 
defective Ca 
2+ 
release from SR and a decreased Ca 
2+ 
pool within the SR. This implicates 
JPH1 not only in RyR1 regulation but also in the maintenance of correct cellular Ca
2+
 
concentrations, crucial to proper muscle function (Hirata et al, 2006). JPH1 negative 
myotubes were also found to have decreased expression of STIM and ORAI proteins, which 
play an important role in SOCE, and to have decreased TRPC3 and 1, but not TRPC 4 or 6 
expression. (Li et al, 2010). As well as mediating contact between the DHPR and RyR1, 
JPH1 has also been found to interact with caveolin 3, (CAV3) a scaffolding protein located at 
caveoli of the plasma membrane (Golini et al, 2011). JPH2 knock-out mice are embryo-
lethal, but analysis of cardiac muscle found irregular dyad formation and impaired Ca
2+ 
release (Takeshima et al, 2000), and mutations in JPH2 have been linked to hypertrophic 
cardiomyopathy in both humans and mice (Landstrom et al,2007). 
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Figure 5.1.a: diagram of JPH1 protein amino acid sequence: with the amino acid 
sequences found by MADLI-ToF analyses of bands immunoprecipitated from rabbit skeletal 
muscle using the mAb VF1c. The sequences obtained from the 90 kDa band appear in green 
box, while the sequences from the lower 75 kDa band appear in the pink box. A potential 
PEST motif, a consensus site of calpain cleavage, lies between the two, and may explain why 
there are two bands (original data generated by JJM: English et al, 2014). 
 
5.2: Aims: VF1c Characterisation 
The aims of this work were to confirm the interaction of mAb VF1c with JPH1 and to 
characterise this interaction. To this end, yeast-expressed fragments of JPH1 were probed 
with mAb VF1c and an antibody known to target the C-terminal end of JPH1. This 
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determined the region of JPH1 that mAb VF1c interacts with. Further experiments were 
performed to assess the amount of JPH1 in rabbit and rat tissue of muscle and non-muscle 
origin.  As it was suggested by Murphy et al  suggest that both JPH1 and JPH2 undergo 
calpain mediated proteolytic cleavage, experiments were carried out to determine if this could 
be prevented by the chelation of calcium or using a calpain inhibitor in a cell culture model 
(A7r5 cells, known to express JPH1, Hammoud et al, 2013) (Murphy et al, 2013). 
5.3: Results 
5.3.a: VF1c antibody characterisation 
In a collaborative effort with the laboratory of Prof. Vincenzo Sorrentino in Sienna 
Italy, fragments of rabbit JPH1 were expressed in yeast, resolved by SDS-PAGE, transferred 
to PVDF membrane and sent to this lab, where the blots were screened with the VF1c and 
JPH1 ( targeted to the C-terminal region) antibodies. The JPH1 fragments expressed in yeast 
contained amino acids 1-233, 232-369, 369-571,141-278, 229-460, 154-278, 229-550 and 
154-635. The VF1c mAb bound to four fragments: 229-460, 369-571, 229-550 and 154-635. 
This confirms that VF1c binds to JPH1, and indicates that the epitope for this antibody is 
between residues 369- 460. To confirm the validity of this approach, another antibody, raised 
against the C-terminal portion of the protein was used to probe a duplicate experiment. This  
pAb JP1 antibody bound only to the fragment expressing the most C-terminal amino acids, or 
fragments 154-635. These results can be seen in Fig. 5.1.3 a and b, which also show how 
mAb VF1c and pAb JP1 antibodies interact along the length of the protein. In an effort to 
narrow down the binding region of mAb VF1c even further, peptide arrays expressing 
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gradually decreasing fragments of the 369-460 region of JPH1 were synthesised on 
nitrocellulose membranes by the laboratory of Dr. Patrick Kiely, at the University of 
Limerick. These peptides arrays were then probed with the VF1c antibody, and these results 
(Figure 8.2.a, appendix ) show multiple peptide spots interacting with this antibody. Thus, the 
secondary antibody could be binding to the peptides, giving false positive signals, or VF1c 
could bind a conformational epitope of the JPH1 protein, which would not be represented on 
a peptide array.  
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Figure 5.3.a: Yeast expressed fragments of GST-tagged JPH1 probed with A) a poly 
clonal C-terminal JP1 antibody. or B) mAb VF1c Fragments of JPH1 protein (amino acids 
1-233, 232-369, 369-571, 141-278, 229-460, 229-550 and 154-635 of JPH1)  were expressed 
in yeast , resolved by SDS PAGE , transferred to PVDF membranes and  probed with  pAb 
JP1 (panel a) and mAb VF1c (panel b). The JP1 antibody bound only to the most C-terminal 
B 
A 
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fragment(amino acids 154-635 of JPH1), while mAb VF1c bound to fragments expressing 
amino acids 369-460. A 60 kDa band is present in all lanes of panel b, including the yeast 
only control lane, indicating that this is an artefact (n=1, two technical replicates). 
5.3.b: JP1 and VF1c mAb comparison in mouse muscle .  
 To further confirm that mAb VF1c interacts with JPH1 protein, mouse muscle 
samples (intercostal, soleus, sternocleidomastoid, tibilias anterior, and vastus lateralis (termed 
Sterno Mast, TA and VL respectively) were excised, homogenised,  subjected to western blot 
using these antibodies. Rabbit skeletal muscle (latissimus dorsi) was utilised as a control. The 
results show that mAb VF1c detects two bands in mouse skeletal muscle, at 100 and 85 kDa 
in all tissues except intercostal muscle, where mAb VF1c detects two bands at a slightly 
higher molecular weight of 120 and 90 kDa, and soleus, which shows no detectable JPH1 in 
these experiments (see Rf measurement, appendix II). The bands have a similar appearance to 
that seen in rabbit muscle control. The pAb JP1 panel shows a strong interaction with a 
protein at 60 kDa and a fainter interaction at 85 kDa in rabbit tissue. This band aligns with 
that detected by mAb VF1c. Taken together with the antibody characterisation experiments 
(section 5.1.1.b), this implies that in mouse and rabbit skeletal muscle, JPH1 is cleaved 
somewhere in the region of 369-460, and that as mAb VF1c interacts with this region of 
JPH1, two bands are detected. As pAb JP1 antibody interacts with the C-terminal end of the 
protein, this detects a faint amount of full length JPH1 and a cleaved portion at 60 kDa in 
rabbit skeletal muscle. Possibly due to poor transfer, pAb JP1 did not interact with any 
proteins in mouse skeletal muscle, even though mAb VF1c did, showing that JPH1 is 
detectable in these samples. 
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Figure 5.3.b: Western blot experiment of Mouse muscle samples probed with pAb JP1 
and mAb VF1c. Mouse intercostal, soleus sternomastoid, tibilis anterior and vastus lateralis 
(with rabbit skeletal muscle as positive control) muscle were probed with pAb JP1 and mAb 
VF1c. No bands were detected in the mouse samples using the pAb antibody, however two 
bands at 120 and 90 kDa were detected using mAb VF1c. The blots were both probed with 
anti-tubulin antibodies as a control.   
5.3.c: Investigation of JPH1 and 2 expression in organs from rat.  
Detection of JPH1 in Rat Muscle and organs using VF1c mAb.:  
Several muscle groups and organs from rat were excised, frozen in liquid nitrogen and 
subsequently homogenised and probed with mAb VF1c and pAb JP2 antibodies by western 
blot, and the results are shown in Fig. 5.1.3.c. The VF1c antibody detects proteins at 91 and 
80 kDa (marked with arrows) in vastus lateralis, soleus, diaphragm, sternohyoid, and 
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intercostal muscle samples, while no JPH1 is detected in brain, heart, lung, liver, pancreas, 
spleen or adrenal gland. The asterisks mark bands indistinguishable from those seen in 
secondary only controls. Although not shown in this data, VF1c does detect JPH1 in the A7r5 
cell line, and it has been shown to express JPH1 (Hammoud et al, 2013).The pAb JP2 
antibody interacts with two bands, at 96 and 70 kDa in all skeletal muscle types as well as 
heart. This indicates that JPH2 is also cleaved by some form of cellular protease (likely a 
calpain, (Murphy et al, 2013)). As JPH2 is visible at 90 kDa in heart samples, this intimates 
that JPH2 is less susceptible to proteolytic cleavage in this tissue.    
 
Figure 5.3.c: Expression pattern of JPH1 and JPH2 protein in rat tissues Rat VL, soleus, 
diaphragm, sternohyoid (SH), intercostal, brain, heart, lung, liver, pancreas, spleen, adrenal 
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gland and A7r5 cell line lysates (35μg protein /well )were subjected to SDS PAGE and 
western blotting using VF1c and JP2 antibodies. Asterisks mark bands seen in secondary 
antibody only controls, while arrow mark those found only in mAb VF1c or pAb JP2 blots.  
These results show that JPH1 (VF1c blot) is not detectable in the organs tested, but JPH1 is 
present in rat skeletal muscle at an apparent molecular weight of 90 and 80 kDa (arrows) (for 
Rfs and secondary-only controls see appendix III) JPH2 was detected in all muscle samples 
(extremely low levels of JP2 in soleus in this instance) as well as heart and A7r5 (rat 
embryonic smooth muscle cell line) at an apparent molecular weight of 96 and 70 kDa. 
Coomassie stains of PVDF membrane are shown as loading control (n=2) 
 
JPH2 is the main isoform in the heart and possibly smooth muscle, as the A7r5 cell 
line also expresses JPH2 as a 90 kDa band, which implies that it may be less susceptible to 
proteolytic cleavage. Although a faint band is visible in VF1c at 220 kDa in the A7r5 lysate 
sample, it was not different to that seen in secondary only controls (figure 8.3.a, Appendices). 
Interestingly, varying levels of both JPH1 and 2 were detected in the skeletal muscle samples, 
and this result was further analysed using rabbit muscle.  
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5.3.d: Comparison of JPH1 and 2 in various skeletal muscle from rabbit. 
 Fig 5.3.d  shows a screen of different muscle types from  rabbit, which were analysed 
via western blot using mAb VF1c. The purpose of this blot was to confirm whether or not 
JPH1 is expressed in higher amounts in in type II muscle fibres, as suggested by Guo et al 
(Guo et al, 1994). As shown in Fig 5.1.3.c, EDL muscle (a predominantly type II muscle) has 
the highest amount of VF1c immunoreactivity, followed by latissimus dorsi and TA muscles. 
Remarkably, the diaphragm muscle (a mixed fibre type muscle that is in constant use) and 
soleus muscle (which in humans perform as anti-gravity muscles) have the lowest amount of 
JPH1 abundance, and in these muscles JPH1 migrates at a lower molecular weight. This 
could be the result of different specialised post translational modification or indeed cleavage 
of these proteins, which may be necessary in long-acting muscles. There is also a disparity in 
the amount and the molecular weight of JPH1 and 2 seen in intercostals muscle, another set 
of muscle which undergoes frequent use. Here, JPH1 was found at a molecular weight 90 and 
100 kDa, while JPH2 was found at a molecular weight of 95 kDa. To determine the relative 
amounts of JPH1 compared to JPH2 in different muscle types, the same tissues were probed 
with an antibody against JPH2. These blots show a similar trend to that seen with JPH1, but 
the differences in expression between muscle types were less marked and were not 
significant. 
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Figure 5.3.d: VF1c and JPH2 screen of Rabbit muscle types. Muscles from male rabbits 
(lat. Doris, diaphragm, Intercostal, EDL, Soleus, Gastrocnemius, Vastus lateralis, 
Sternomastoid and sternohyoid, 45μg/protein per lane) were screened for JPH1 and JPH2 
expression using VF1c and JP2 antibodies. Intercostal muscles show a higher molecular 
weight form of JPH1 and 2, while diaphragm and soleus show decreased amounts of JPH1. 
The highest amount of JPH1 was seen in EDL muscle.Diaphragm has significantly less JPH1 
abundance compared to Intercostal muscle (p=0.0089,one way analysis of variance, n =3)  
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5.3.e and f: Characterisation of JPH1 protein expression and siRNA knock-down in 
C2C12 myotubes. 
C2C12 mouse myotubes were grown and differentiated using 0.5% FCS-containing DMEM 
for up to 7 days, and JPH1 protein levels were compared to undifferentiated controls by 
western blot. JPH1 shows a biphasic expression pattern , whereby it peaks between day 2 and 
4 of differentiation and decreases again by day 7 (Fig 5.3.e). The JPH1 blot shows increased 
cleavage at day 2 (band visible at  60 kDa, in contrast to the 100 kDa bands seen in other 
lanes , figure 5.1.3.f). This diffuse banding pattern vould be due to the JPH1 antibodies 
binding site occuring distal to the predicted calpain cleavage site within the JPH1 protein. 
However, it should be noted that consistent results were difficult to obtain, and it seems likely 
that there is either no peak in JPH1 expression in C2C12 myotubes or that it is highly 
sensitive to cell passage number and condition.  
Attempts to down regulate JPH1 were performed using siRNA knock down of the protein, 
(Fig 5.3.f) Apparent down regulation was achieved, particularly under serum free conditions, 
however, JPH1 exression was raised in NFS (Vehicle, N-TER peptides transfection reagent) 
only and fluorescent siRNA negative controls. Results were also obfuscated by differences in 
antibody binding. Fig.5.3.f shows attempted knock down of JPH1 protein using N-TER 
peptides and siRNA mixes from Sigma. These results show that although a small decrease 
was achieved (particularly using the serum free set-up) , the knock down of JPH1 was 
inconsistent, and actually increased in fluorescent-only controls and in cells incubated with 
20 nM of siRNA mix. These blots do show the difference in binding capabilities between the 
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JPH1 and VF1c antibodies, and show that mAb VF1c has an apparent higher affinity for 
JPH1 protein  
 
Figure 5.3.e: JPH1 abundance in differentiating C2C12 myotubes: C2C12 mouse 
myotubes (30μg protein/lane) were analysed for JPH1 abundance via western blot. The 
highest abundance was found between day 3-4, although results were highly variable.(3 
replicates).  
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Figure 5.3.f: siRNA knock down of JPH1 protein. N-TER peptides were used as 
transfection reagents with siRNA targeting the JPH1 mRNA, theoretically causing a down-
regulation in the protein (25 μg/protein lane). Fluorescent and non siRNA (NFS only) 
controls were used to monitor effects (n=3). 
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5.3.g: Calpain Cleavage study using A7r5 cell lines and in silico analysis of likely 
calpain targets in JPH1 and 2. 
Aim: to characterise the proteolytic cleavage of JP1 and 2 by calpain proteins in the A7r5 rat 
smooth muscle cell line and to use in silico analysis of JPH1 and 2 sequences to pin-point 
potential calpain cleavage regions. These experiments were performed to ascertain whether 
calpain inhibition or exacerbation (via treatment with ALL-N, a calpain I and II inhibitor, 
BAPTA-AM, a calcium chelator or A23187, a calcium ionophore), would have an effect on 
the abundance of total JPH1 and 2 levels as detected by western blot using pAbs JP1, JP2 and 
mAb VF1c 
Murphy et al, (2012) performed calpain activation experiments on JPH1 and 2 by incubating 
muscle homogenate and skinned muscle fibres in high concentrations of calcium, to activate 
calpains I and II. They found that both JPH1 and 2 were cleaved by proteases after incubation 
in high calcium concentrations, but this does not exclude the effect of other proteases nor 
does it confirm the action of calpains on JPH1 and 2.  To expand on this and to see if a 
timeframe of calpain cleavage on JPH proteins could be determined, calpain cleavage 
experiments were performed using the A7r5 cell line (the mouse muscle cells line C2C12 was 
tried for this assay but due to uneven growth, A7r5 rat aorta cell lines were used instead) 
Although a smooth muscle cell line, A7r5s express calpains I and II, similar to skeletal 
muscle and both Junctophilin 1 and 2 (Jiang, et al ,2008: Hoummod et al, 2013)  
A7r5 cell lines were grown in 6 well flasks and treated with BAPTA-AM, ALL-N, A23187 
and DMSO as vehicle control. BAPTA-AM is a cell permeable calcium ion-chelator, and in 
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this instance was used to decrease the cytoplasmic calcium ion concentration and thus inhibit 
calpain activation (Mandic et al, 2002). ALL-N (N-Acetyl-L-leucyl-L-leucyl-L-norleucinal, 
also known as calpain inhibitor I) is a pharmacological inhibitor of calpain I and calpain II 
(Wang and Yuen, 1994: Waters et al, 1997). A23187 is a calcium ionophore which facilitates 
the entrance of calcium ions into the cell as it traverses them membrane, thus it increases the 
intracellular calcium concentration (Watson, 1978: Katusic et al, 1988). It was used to 
encourage the activation of calpains in A7r5 cells. Using this experimental set up, It was 
hypothesised that cleavage of JPH1 and 2 could be inhibited by incubation with BAPTA AM 
or ALL-N, while cleavage of these proteins could be induced by incubation with A23187, 
which would raise the intracellular calcium concentration. Experiments were carried out as 
described in materials and methods section 3.1.1.f. An in silico study was also undertaken to 
try and identify likely calpain targets on JPH1 and JPH2 proteins using online databases. The 
results can be seen in figures 5.1.3.g and h. 
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Figure 5.3.g.i: 3 hour incubation of A7r5 cells with calpain inhibitors. Western blot of 
A7r5 cells incubated with 0.1% (total concentration) of DMSO (vehicle), 20 μM ALL-N, 
A23187 and BAPTA –AM for 3 hours, analysed for JPH1 and 2 expression.JPH2 abundance 
is significantly increased in A23187-treated cells, which may imply that increased Ca
2+ 
concentration may increase JPH2 abundance. Conversely, an increase in JPH1 abundance 
(detected with mAb VF1c) is found after incubation with a calcium ion chelator BAPTA-
AM. This could imply that JPH1 and 2 are differentially regulated (n=3, one-way analysis of 
variance with Dunnetts multiple comparison post test: all values were compared to DMSO) 
At 3 hours, no significant results were seen with the pAb JP1, however using the VF1c mAb, 
western blot detection of JP1 protein abundance showed a significant increase in total 
abundance after treatment with 20μM BAPTA –AM, a calcium chelator, compared to vehicle 
156 
 
treated controls (p=0.0312).  This means that removal of calcium ions from the cytosol of 
A7r5 muscle cells may lessen the amount of calpain cleavage undergone by JPH1. One 
would have expected an increase in JPH1 abundance in cells treated with ALL-N, a calpain I 
inhibitor, however this increase was non-significant (as determined by One-way ANOVA 
followed by Dunnetts multiple comparison tests). It is likely that ALL-N inhibition was 
ineffectual in these experiments. Surprisingly, A23187 (a calcium ionophore) treatment 
caused an increase in both JP1 and JP2 detection after three hours, and in JP2-probed blots 
this increase was significantly higher (p= 0.036) than in vehicle-treated controls. JP1 probed 
blots showed increased abundance in A23187 treated samples, but a decrease in BAPTA-AM 
treated samples, in stark contrast to the results seen using the VF1c antibody. It should be 
noted that there was stubborn background on JP1 pAb treated blots, and this is likely to have 
interfered with analysis.  
Due to the confounding results obtained after three hours, it was postulated that 3 hours was 
too short a treatment time, thus treatment with ALL-N, A23187 and BAPTA-AM and DMSO 
only and media-only controls were extended to 6 hours in the same cell line. In 6 hour treated 
samples, again, pAb JP1 treated blots were swamped in persistent high background, which is 
likely to have partially obscured the analysis using this antibody. The panel probed with JP1 
pAb shows the highest abundance of JPH1 protein in media only control lanes, with steadily 
decreasing abundance in DMSO-, ALL-N, A23187- and BAPTA-AM-treated cells. Detection 
of JPH1 protein using the VF1c mAb showed a significant increase in JPH1 abundance in 
DMSO (vehicle) treated samples compared to media only controls, which is interesting as 
DMSO should not have any effect. ALL-N treatment (Calpain I/ μ-Calpain inhibitor) caused 
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a significant decrease in JPH1 abundance compared to DMSO treated controls (p= 0.005), 
hash mark on graph), while A23187 and BAPTA-AM treated JPH1 levels were not 
significantly different from vehicle treated controls. It should also be noted that when JP1 
blots and VF1c blots were run in tandem, the corresponding films could be perfectly aligned 
when overlaid, further corroborating the fact that JPH1 is detected by the VF1c antibody. In 
pAb JP2-probed blots, again, there was a significant difference in vehicle and media only 
controls, so all data was normalised to the vehicle, DMSO, by way of Dunnets multiople 
comparison tests. JPH2 was detected as a doublet at 100 kDa in molecular weight, with 
background bands visible at higher molecular weights. ALL-N incubation showed no 
difference in JPH2 abundance, while A23187 incubation caused a significant decrease in 
JPH2 abundance (p=0.02, hash mark on graph), as expected. BAPTA-AM treatment for 6 
hours caused a massive decrease in JPH2 abundance compared to vehicle only controls, 
(p=0.003, black diamond on graph). 
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Figure 5.3.g.ii: 6 hour incubation of A7r5 cells with calpain inhibitors. JPH1 and JPH2 
abundance were measured in A7r5 cells incubated with media only, vehicle (0.01% DMSO), 
ALL-N, A23187, BAPTA-AM for 6 hours via western blotting with pAb JP1, JP2 and mAb 
VF1c. JP1 abundance was decreased in ALL-N incubated samples compared to vehicle 
incubated controls, in mAb treated blots, however this was not found in pAb JP1 treated 
samples. JPH2 abundance was decreased in A23187 and BAPTA-AM treated samples 
compared to controls. 
 
159 
 
 
 
Table 5.3.i: In silico analysis of Rabbit, mouse, rat and human JPH1 and 2 sequences 
using online Calpain-cleavage predictors. Online and freely available programs (Site 
predictor) were used to calculate the potential calpain cleavage sites on JPH1 and JPH2 
proteins. 
JPH1 and 2 protein sequences were also analysed using online software (Site Predictor-
http://www.dmbr.ugent.be/prx/bioit2-public/SitePrediction/) (Verspurten et al, 2009) and a 
species comparison was performed between rabbit, rat, mouse and Human isoforms. The 
results, seen in table 5.1.3.j, show that both JPH1 and 2 have the potential to be cleaved by  
calpains I and II. Looking at cleavage events mediated by Calpain I, JPH1 has one very likely 
calpain cleavage site across all four species (indicated by the score of 99.99% or higher, dark 
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grey box), while JPH2 has two very likely sites, between 230-235 and 237-244 ( purple 
boxes, table 5.3.j). The highest scoring calpain II cleavage sites on both JPH1 and JPH2 
occur in a similar region, (amino acids 161-166 and 157-162 for JPH1, and 152-162 and 161-
172 for JPH2). It is very possible that these regions are conserved across junctophilins, which 
lead to a Blast alignment of JPH1 and 2 sequences from rabbit, rat, mouse and human (see 
appendix II, Figure 8.2.g). In agreement with (Garbino et al, 2009) the alignments show that 
the region of JPH1 and 2 which are most likely to be cleaved by calpains I and II are in fact 
conserved across the four species analysed here. It is important to note that although the 
FASTA sequences for JPH 1 and 2 (which were analysed here) give computed molecular 
weights of 75 kDa total, in SDS PAGE JPH1 or 2 are rarely if ever found at that apparent 
molecular weight (this is discussed in detail in chapter 6, section 6.4). It should also be noted 
that the fragment readouts given here assume one cleavage event per protein, and that this 
many more cleavage events may occur in vivo.    
 
 
5.4: Discussion 
Fig. 5.1.3a and b show that mAb VF1c interacts with JPH1, and that it interacts at 
within the region of 369-460 amino acids, near the mid-section of the protein. As this 
antibody has previously been used to detect a protein termed JSR-90, current knowledge on 
JPH1 can now be coalesced with previous studies of JSR-90. This reveals that JPH1 is 
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phosphorylated by an endogenous kinase (Guo et al, 1994), is preferentially stained in fast 
fibres and under non-reducing conditions migrates at 170 kDa, indicating potential dimer 
formation or, its participation in a protein complex. Froemming’s study in 1999 show that 
JSR-90 is sharply down-regulated after chronic low frequency stimulation, (a model of fast to 
slow fibre type transition) of rabbit muscle, and was most abundant in EDL muscle 
(Froemming et al, 2000). These results are supported by the work presented here. Although 
the peptide array experiments failed to provide definitive data, cumulatively they hint that 
mAb VF1c may bind to JPH1 in a conformational manner. It is noteworthy that the mAb 
VF1c interacts with JPH1 in an area very close to its DHPR binding region (residues 232-
369, with a faint interaction seen in pull down experiments using residues 369-571(Golini et 
al, 2011)). Knowing that the mAb VF1c can detect JPH1 will provide novel avenues of study 
for the interaction of JPH1 with RyR and DHPR, as well as novel interactors which together 
shape the release and regulation of Ca
2+ 
ions in the cell.   
Rat and mouse tissue were analysed for expression of JPH1 and JPH2 via western 
blot. Using pAb JP1, only 1 band, a positive control band in rabbit skeletal muscle lane was 
detected, and it had an apparent molecular weight of 45-50 kDa. This is different to the 
staining pattern observed using mAb VF1c, which detected two bands at 85 and 60 kDa. 
Consideration must be given to the binding regions of the antibodies used, as it has been 
shown that mAb VF1c interacts with the middle region of JPH1, while pAb JP1 interacts only 
with the C-teminal region. It is likely that the C-terminal of the protein has been cleaved off 
and may have run off the gel, and thus could not be detected by pAb JP1. Future analysis 
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could employ higher percentage gels or ideally a gradient gel would optimally resolve the 
fragments of JPH1 and 2.   
The analysis of JPH1 and 2 in rabbit muscle gives further weight to the experiments 
performed by Guo et al (1994), where they observed increased staining in type II fibre-rich 
muscles using the VF1c antibody. These results confirm this finding, and go further by 
showing that of the muscles tested, the highest amount of JPH1 is detected in EDL muscle, 
followed by latissimus dorsi. This is important to the field, as JPH1 expression corresponds 
loosely with RyR1 expression, which several studies have found to be highest in fast type 
skeletal muscle (Froemming et al 2000, Conti et al, 1996, Protasi et al, 2000). Knowing 
relative levels of JPH 1 and 2 could prove very useful to any future scientist trying to purify 
said proteins. An interesting further study would be the analysis of type 1 RyRs in the same 
samples, and to compare the ratios of JPH1 to RyR1 and DHPRs, or any other interactors, 
such as Caveolin 3 (White et al, 2012). For this analysis to be completed, highly specific 
antibodies targeted to RyR1 and DHPR would be necessary. An important point is that prior 
to homogenisation, the tissue excision, protease addition, homogenisation and freezing 
should be as swift as possible, as EC coupling proteins such as Junctophilins and RyRs are 
readily degraded by proteases (Brule et al, 2010, Murphy et al, 2013).  
As well as the potential for further cleavage of JPH1, differences exist in expression 
levels and molecular weight between the various muscle types. In rabbit diaphragm (and to a 
lesser extent, soleus) had significantly lower JPH1 expression than found in EDL muscle, 
while the intercostal muscles express JPH1 which migrates with a calculated MW of 129 kDa  
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and 88 kDa, while the EDL, GC, SH ,SM muscles have calculated molecular weights of 85 
and 67-70 kDa. Diaphragm muscle expresses JPH1 with an apparent molecular weight of 60 
kDa.  Regarding JPH1 levels in diaphragm and soleus tissue, it is known that muscles with a 
slower phenotype express higher levels of calpain proteolytic enzymes compared to their fast 
fibre type counterparts, and that that μ-calpain (also known as calpain I) is localised to the 
microsomes, as opposed to freely diffusible in the cytoplasm in fast muscle types such as the 
EDL (Sultan et al, 2000). This could account for both the lower molecular weight and 
decreased abundance found in these tissues. As these muscles undergo constant (diaphragm) 
or extended contraction times (soleus, an anti-gravity muscle), it is possible that JPH1 is 
constantly being synthesized and broken down. It should be noted that other proteolytic 
enzymes could also play a factor, if indeed degradation is the cause of the decreased 
molecular weight, and not a muscle-specific splice variant. A splice variant could be the case 
for intercostal muscles, which undergo constant or near constant use. A specific feature of 
intercostal muscles is that they undergo frequent eccentric contractions, and as showed by 
Corona et al (2010), these lengthening contractions of muscle can activate calpain-mediated 
cleavage of JPHs. A possibility is that to prevent continuous damage and repair, a splice 
variant of JPH1 could exist without some of the postulated cleavage areas (see fig 5.1.a), thus 
migrating at a greater molecular weight. Another possibility is that JPH interacting with 
another protein, cellular component or itself could render it less susceptible to proteolytic 
cleavage in this muscle type. Intercostal muscles have also been shown to have altered 
transcription-intiating mechanisms to limb muscle. In field-stimulated FDB and soleus 
muscles, NFAT translocation to the nucleus was increased as expected, but in intercostals 
fibres NFAT translocation was decreased after 90 minutes of stimulation, implying 
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differential regulation of this transcription factor in intercostals muscle tissue (Robison et al, 
2014). The authors postulate that altered regulation of NFAT will have concomitant effect on 
protein expression in this muscle, and thus it is possible that JPH1 and 2 fall under NFATs 
remit. Either way, analysis of various muscle types in rabbit has shown that JPH1 is likely to 
be specifically regulated depending on the function of the muscle, and highlights the 
importance of JPHs in muscle physiology. 
In Fig.5.3.e and f it appears that mAb VF1c and pAb JP1 are interacting with the same 
protein. Despite attempts to characterise JPH1 expression in maturing C2C12 myotubes, 
confounding results were obtained. Junctophilin 1 expression seems to have a biphasic 
expression pattern, peaking 2 or 3 days after differentiation flowed by a decrease to 
undifferentiated levels. As these cells are a widely used tool in EC coupling research and 
especially in analysis of junctophilins, it is important to characterise the expression of JPHs 
in these models (Golini et al, 2011, Hirata et al, 2006). However, an important caveat of 
these experiments is that the state and passage number of these cells can be a confounding 
variable. Another option for studying this protein could be isolated muscle fibres, which can 
also be used for calcium signalling studies, however these are significantlly more expensive 
to get and maintain, as they require whole animals to be sacrificed. Interestingly, in C2C12 
cells the JPH1 protein is a full 90 kDa, as opposed to in skeletal muscle controls where it 
migrates at 75 and 65 kDa. This indicates that a difference in protein processing or cleavage 
exists between these two tissues, and is likely to do with the activity of the cells. As seen in 
chapter 6, exercise can have solubilising effects on the junctophilins, thus a contraction 
protocol followed by JPH analysis in C2C12 cells could be rally interesting (Corona et al, 
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2010; Murphy et al, 2013). It is likely that JPH1 would be detected at a lower molecular 
weight, in its cleaved form after such a protocol. Importantly, C2C12 cells need to be at 
optimum condition and passage, as their expression profile and ability to differentiate 
properly into myotubes decreases at high passage numbers. Further attempts to knock down 
JPH1 expression in C2C12 cell lines proved unsuccessful, due to effects caused by the 
siRNA delivery system (Fig 5.1.3.g). Other researchers have had more reliable results using 
virally delivered siRNA particles and found that knocking down both JPH1 and JPH2 caused 
deformed triads, reduced capacity for SOCE and altered caffeine induced Ca
2+ 
release from 
the SR (Hirata et al, 2006). These results should be interpreted with caution though, as they 
are results of a double knock down. That said, the rabbit muscle expression profile presented 
here describes a more constant role for JPH2, in that its levels are not as variable as JPH1, 
indicating that JPH1 has more of a role in the “fine tuning” of Ca2+ signalling in muscle cells, 
while JPH2 has a largely structural role. A “Fine-tuning” role for JPH1 is logical for several 
reasons. As it is a known contact for DHPR and RyR and participates in orthograde and 
retrograde signalling, JPH1 is well placed to manage Ca
2+ 
and be an active participant in 
calcium ion relese events (Golini et al, 2011). Phimister et al found that JPH1 interacted with 
RyR1 protein in a conformationally dependent manner, and that it may have redox sensing 
abilities (Phimister et al, 2007). This proves that JPH1 can be thought of as “scaffolding that 
talks” instead of a simple, non-reactive structural protein. It is highly likely that JPH1s role in 
retrograde and orthograde Ca
2+ 
signalling will become clearer in the next few years. It will be 
interesting to see if any natural mutations in JPH1 give rise to disease, as they could prove 
invaluable to fully understanding its function. One mutation (R213P) in JPH1 has been linked 
to Charcot-Marie-Tooth disease (CMT), a heritable and progressive neuropathy which affects 
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motor and sensory nerves, and in muscle, can cause varying degress of weakness and or 
atrophy. In CMT one patient with the R213P, mutated JPH1 is unable to rescue SOCE in 
affected tissue, and JPH1 was found lodged in miotchondria which could hint that JPH1 has a 
role in linking RyR-associated and mitochondrial associated complexes (Pla-Martin et al, 
2014). 
As the C2C12 model has proven unreliable, the A7r5 cell line was selected for study with a 
calpain cleavage inhibitor, ALL-N. Future studies using the C2C12 model could delete the 
PEST sequence (the likely area of calpain cleavage of JPH1, see Fig 5.1.3a) and assess 
functional consequences. It is quite likely that decreasing the length of the JPH1 protein 
would have a massive functional effect within muscle, perhaps via orthograde signalling. 
Removal of the PEST sequence could also have very interesting consequences for RyR1 and 
DHPR expression and function. The results presented here show that although skeletal and 
smooth muscle cell lines are similar (in calpain expression at any rate, as smooth muscles 
express calpain I and II as well (Zhang and Johnson, 1992), the A7r5 cell line is not the best 
match for skeletal muscle proteins. However, they do imply that JPH regulation is important 
in smooth muscle contraction, as it can be regulated within hours of addition of  relevant 
substance (e.g. BAPTA AM), and this has implications for smooth muscle biology. That JPH 
levels could be altered by calcium ionophore/chelator addition implies that in resting smooth 
muscle (apart from basal contractions which may be present in cell culture samples), an ideal 
Ca
2+ 
concentration exists for maximum full length JPH1 and 2: a “goldilocks” Ca2+ 
concentration, where full length JPH 1 and 2 out weigh calpain-cleaved JPHs. It is difficult to 
say whether JPHs are being constantly cleaved and regenerated, or if calpain cleavage is an 
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event tied to cell requirements and functions, such as a bout of contractile activity. Recent 
studies in heart and skeletal muscle tissue imply that calpain cleavage of JPH1 and 2 are 
contraction induced, but this may not be the case in smooth muscle (Wehrens et al, 2015 
Murphy et al, 2012).  Some flaws exist in these confounding results, and it may be that 
experimental pitfalls need to be negotiated. These pitfalls include DMSO causing an increase 
in JPH1 and 2 abundance after 3 and 6 hours incubation. This could be due to DMSO passing 
through membranes, and perhaps causing damage. In yeast, DMSO incubation has been 
shown to increase the biosynthesis of membrane components such as phospholipids and to 
thus increase membrane proliferation, and it is possible that this also occurs in the smooth 
muscle cells used in this study (Murata et al, 2003). As JPH proteins interact with plasma 
membranes of cells via their MORN motifs, and that this interaction is crucial to the shape 
and correct functioning of this protein, it is feasible that changes in memebrane structure or 
composition could cause a change in JPH protein levels. High levels of DMSO have also 
been found to allow increased Ca
2+
ions to enter the cell, which could also have affected the 
abundance levels of JPH proteins (Murata et al,2003: de Menovial et al, 2012: Bennett et al, 
2013). DMSO concentration in these experiments did not exceed 0.1% of total volume of 
media added to 6 well plates, but the possibility of incomplete plate closure and thus media 
evaporation or concentration cannot be excluded, however it is very unlikely. Thus it is more 
likely that DMSO has effects on JPH abundance via alterations in Ca
2+
concentration or 
membrane based effects. This could have massive implications for future study of JPH 
proteins in cell culture models, particularly as A7r5s are a popular model for vascular injury. 
It is very interesting that the field of Junctophilin research has focused strongly on cardiac 
and skeletal muscle, while JPH research in smooth muscle is relatively new. In the future, 
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JPHs may be shown to be intrinsic to correct functioning of vascular tissue as well as skeletal 
and cardiac muscle. Interestingly, the N-ter peptides used to introduce siRNA moieties into 
the C2C12 cell lines also caused slight increases in JPH1 expression, despite attempting to do 
the exact opposite (section 5.3.c). It could be that membrane disruption (especially any which 
affect the lipid compostion or integrity of cell membranes) of any sort has an impact on JPH 
expression. This makes sense as removal of JPH1 as seen in KO animals has deleterious 
effects on calcium flux in the cell via RyR and thus on cellular fate, so if the membrane were 
damaged, it would make sense to upregulate JPH proteins which could steady RyR-mediated 
Ca
2+
 release. This bears similarities to what occurs after repetitive eccentric contractions, 
which when performed in mouse cause the upregulation of JPH1 three days after the bout of 
muscle-lengthening exercises (Hirata et al, 2006: Phimister et al, 2007: Corona et al, 2010).   
. 
 An in silico analysis of potential calpain I and II cleavage sites on JPH1 and 2 was 
undertaken, and several sites were found. The most likely cleavage sites for JPH1 and 2 were 
both found in the N terminal region of JPH1 and 2. It is important to note that although the 
FASTA sequences for JPH 1 and 2 (which were analysed here) give computed molecular 
weights of 75 kDa total, in SDS PAGE JPH1 or 2 are rarely if ever found at that apparent 
molecular weight (this is discussed in detail in chapter 6, section 6.4). It should also be noted 
that the fragment readouts given here assume one cleavage event per protein, and that this 
many more cleavage events may occur in vivo. In concordance with in silico efforts 
performed in this work, Gou et al recently found that JP2 protein is indeed cleaved by calpain 
I, and is split into four smaller peptides, at 100, 75, 37 25 and 20 kDa, which supports the 
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work presented in chapter 5 and 6. They confirmed this using fusion proteins of JP2 
fragments, and found that three calpain cleavage sites are N terminal, while one was found in 
the C terminal region, which mutagenesis studies defined as the main calpain cleavage site. 
Similar experiments have not been performed for JP1, however, based on the similarity 
between the results presented here and that from in silico analysis, we can assume that at least 
three calpain cleavage sites exist in JP1 protein.The results shown in fig 5.3.i show that 
although not a perfect model of caplain cleavage sites, many residues were similar to those 
found in Gou et al (2015), so it can be assumed that this in silico analysis is a good starting 
point for further study of calpain interactions of these proteins. As Guo et al found that 
cleavage of JPH2 hindered cardiac contractility (an observation backed up by Murphy et al 
and by the known hypertrophy causing mutations in JPH2), it has been shown that JP1 
cleavage is also detrimental to signalling in skeletal muscle (Corona, et al, 2010, Murphy et 
al, 2013, Guo et al, 2015). Using Biogrid cuckoo calpain hunter and CaMBPD, Guo et al 
predicted calpain cleavage site to be in the region of R565T, consistent with predictions made 
in fig.5.3.i. This is significant for JPH2, as it shows several key facts: i) JPH2 is cleaved as 
part of muscle function  and  ii) JPH2 cleavage has a role in cardiac dysfunction (a fact 
supported by Wu et al, 2014 and Beavers et al, 2013) who showed that RyR2 binds to JP2 
and that a mutation (E169K) causes decreased interaction of these two proteins and increased 
calcium ion leak from the SR) and iii) that extrapolating these results and expanding the 
calpain cleavage knowledge on JPH1 will aid in understanding several muscle disorders 
including those in smooth muscle. Various evidences exist for this: (Murphy et al, 2013: 
Corona et al, 2010). This also supports the work presented in chapter 6, where a burst of 
exercise appeared to cause an increase in JP1 and JP2 cleavage, as determined by western 
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blot. This implies that calpain cleavage has a big role in maintaining EC coupling in skeletal 
muscle cells and Junctophilin levels must be regulated quickly and in response to the activity 
or contraction level of the muscle it is expressed in. Evidence of muscle specific regulation 
can be seen in figures 5.3c, while the changes in JPH total abundance in age and exercise can 
be seen in section 6.3.b.. 
It has been observed that ANGII can affect not only JP2 expression (causing upregulation) 
but the expression of RyR2 also (Gul et al, 2007: Cai et al, 2015). This has implications for 
cardiac disease and hugely, the regulation of RyRs, which is highly complex and has not been 
fully elucidated yet (Cai et al, 2015; Wu et al, 2014). Puerarin, found in a traditional Chinese 
herbal remedy used in cardiovascular medication has also been shown to upregulate JP2 
expression in the heart, as determined by qPCR mediated mRNA analysis. This in tandem 
with up-regulation of Caveolin 3 and other T-Tubule associated proteins imply that 
increasing the amount of JPH2 protein available in the heart, specifically the failing heart is 
beneficial (Wang et al, 2014) 
5.5: Future Studies 
Future work in the area needs to address the levels and functions of JPH1 in disease 
models (see Chapter 6), and to fully understand the role of calpain cleavage and specific 
muscle function has on JPH expression. This could involve mutational studies of the 
postulated PEST or postulated calpain cleavage sequences and subsequent Ca
2+ 
imaging 
studies to assess what function cleaving the junctophilins serves. Murphy et al, (2013) 
suggest that post-stimulatory cleavage of JPH1 in vitro creates a “diffusible fragment” of 
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JPH1, thus disrupting EC coupling and impairing muscle fibre contraction. This would mean 
repeated cleavage and regeneration of JPH1 in skeletal muscle, and warrants further analysis. 
This could be achieved by expressing fragments of JPH1 and incubating with and without 
various calpains followed by SDS page to determine a) If calpain cleavage is at play and b) to 
determine where on the JPH proteins these proteases actually cut.   
Another area worth investigating the role of JPH1 in smooth muscle, and whether it is 
processed the same way as in skeletal muscle. Preliminary data from the current project 
indicate that JPH1 and 2 are not cleaved in smooth muscle embryonic cell line in the same 
way as they are in muscle cells (Appenidix II, A7r5 data Figures 8.2.d and e). This indicates 
that a high degree of cleavage of JPH1 and 2 could be skeletal muscle specific. The role of 
JPHs in smooth muscle, unlike its role in skeletal or cardiac tissue has not been investigated, 
and could be very easily studied using excised vascular tissue and cell line models.  Such 
analyses could include examination of JPH expression patterns in smooth muscle (western 
blot or mRNA analysis), and whether or not JPHs respond to common antihypertensive 
drugs. A simple study would be the comparison of male and female hormones and the effect 
they have, if any, on JPH expression in vascular tissues, as estrogen is reported to have 
protective effects on damaged vascular tissues (Brouchet et al, 2001).  
The phosphorylation of JPH1 by an endogenous kinase, as discovered by Guo et al in 
1994 also warrants further investigation, as this could have huge implications on the 
signalling state of the protein. This could be achieved using 1) bioinformatic approaches to 
identify potential consensus phosphorylation motifs followed by either bacterial expression of 
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clones of this region of JPH1 and kinase assays or 2) tryptic digestion of the isolated JPH1 
followed by phosphopeptide mapping or mass spectrometry. This could provide crucial data 
on how JPH1 interacts with and or regulates other proteins such as RyR1. 
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Chapter 6: Junctophilin 1 and 2 
abundance in models of disease 
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6.1. :Introduction 
 Having established that mAb VF1c detects JPH1, experiments were undertaken to 
analyse JPH1 and JPH2 levels in various disease states such as sarcopenia, chronic 
intermittent hypoxia (CIH) and Duchenne muscular dystrophy (DMD). These disease models 
were chosen as they have been shown or are suspected to have EC coupling irregularities, and 
thus an investigation of JPH expression is fitting. Sarcopenia, DMD and CIH share some 
striking similarities in terms of muscle-specific pathologies, namely altered Ca
2+ 
homeostasis 
and the potential for drastic muscular remodelling (e.g. fibre type switching, fatty tissue 
infiltration).  Because changes in Ca
2+ 
handling or fibre type are known to have repercussions 
for EC coupling proteins, it was prudent to investigate the effects of these pathological states 
on JPH1 and JPH2 abundance in various skeletal muscle groups.  To test this hypothesis, 
Western blot experiments were undertaken to clarify if any such differences in EC coupling 
proteins exist in these disease states.  
 Duchenne muscular dystrophy is an X-linked recessive condition that affects 
approximately 1 in 4000 male births per year (Dooley et al, 2010). It is characterised by 
delayed motor milestones, Gowers sign (using the hands to walk to a standing position from a 
seated position) and progressive muscle atrophy. This atrophy begins in the lower limb 
muscles and progresses to the upper limbs, trunk and diaphragm, which is usually the worst 
affected.  Diaphragm atrophy leads to loss of life in the second decade, usually via respiratory 
failure. DMD is caused by a premature stop codon in the dystrophin gene, causing loss of 
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production or truncated forms of the dystrophin protein (Kunkel et al, 1986; Hoffman et al, 
1987; Bonilla et al, 1988). Dystrophin forms an important link between a complex of 
dystroglycans and sarcoglycans (which mediate contact with the extracellular matrix via 
laminin) and the actin cytoskeleton of cells (see Fig 6.1.1a). It functions almost as a force 
transducer/ shock absorber for the membrane, while also acting as a massive hub for protein-
protein interactions (Davies and Novak, 2006). These interactions are severely perturbed in 
muscles which lack the dystrophin protein, they undergo recurrent degeneration-regeneration 
cycles, as well as immune cell and fatty tissue infiltration, often causing the 
pseudohyertrophy evident in DMD patient calf muscles (an overview of skeletal muscle 
effects can be seen in Fig 6.1.1.b) (Alderton et al, 2000; Jǿrgensen et al, 2009).  As well as 
skeletal muscle pathologies, smooth and cardiac muscle are affected, and there are mild 
cognitive effects.  Because of the massive complex formation at the membrane, the absence 
of dystrophin causes several irregularities in muscle cells including impaired metabolism, 
structural weakness, decreased membrane integrity, fibrosis and increased Ca
2+ 
handling 
abnormalities (Ohlendieck et al, 2012). Ca
2+  
handling is affected in several different ways in 
both DMD patients and in a naturally occurring model, the mdx mouse. Raised intracellular 
calcium levels have been found in both DMD and mdx muscle fibres by Lopez et al (1987). 
Aberrations in RyR receptor signalling and expression have been shown in dystrophic 
myotubes, as well as altered Ca
2+  
sequestering into the SR via SERCA pumps (Schneider et 
al, 2013, Altamirano et al, 2012).  Zhao et al found the dystrophic mdx fibres had increased 
Orai expression compared to WT samples, which as part of the store operated calcium entry 
(SOCE) pathway in muscle cells caused an increase in cytosolic calcium levels. (Zhao et al, 
2012).The Orai calcium channels are recruited and opened in concert with STIM1 proteins, 
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which when overexpressed in mouse myotubes causes a mdx-like phenotype (Goonasekara et 
al, 2014). As JPHs have been linked with RyR regulation and SOCE via STIM and Orai 
mechanisms, it was prudent to examine the abundance of JPH1 and JPH2 in mdx tissue. 
Disruption of the dystrophin complex also affects the interaction of CAV3 with the plasma 
membrane. CAV3 has been shown to interact with JPH2, and is over-expressed in dystrophic 
myotubes (Minetti et al, 1998; Minamisawa et al, 2004). Samples were obtained from the 
mdx mouse, a naturally occurring mutant which lacks dystrophin protein (although it does 
express utrophin, a similar protein which compensates to a small degree) (Tan, Lansman, 
2014).  The mdx mouse is the most widely characterised model of DMD, even though they 
have distinct differences to the human pathology, namely longer life and less severe disease 
progression (Partridge, 2013).   
Irregularities in Ca
2+ 
handling and spark disruption have been described in mouse mdx 
tissue before. Such irregularities include an elevated resting Ca
2+ 
concentration in mdx fibres 
from the EDL muscle as well as increased sensitivity to endurance exercise and osmotic 
shock in comparison to WT muscle fibres (Freyesse et al, 2004;Wang et al 2005).  It has 
been suggested that these Ca
2+ 
handling abnormalities are caused by several mechanisms, 
including: i) increased SOCE and  ii) increased Ca
2+ 
 sparks
, 
caused by a disruption in DHPR-
RyR coupling. Ca 
2+ 
spark frequency is also permanently increased after
 
strenuous exercise or 
osmotic shock in mdx fibres but not WT samples (Wang et al, 2005). Bellinger et al (2009) 
found impaired forces in mdx muscle compared to WT after eccentric contractions (Wang et 
al, 2005; Bellinger et al, 2009) and as this form of exercise is  known to cause deleterious 
effects on JPHs, analysis of these proteins in mdx  muscle is warranted (Corona et al, 2010). 
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To this end, the relative levels of JPH1 and JPH2 proteins in vastus lateralis, diaphragm, 
gastrocnemius and soleus muscles from wildtype and mdx mice were analysed via western 
blot, using pAb JP2 and mAb VF1c antibodies. Results are described in Section 6.3.b. 
 
Figure 6.1.a: A diagram of the dystrophin associated proteins in complex at the cell 
membrane of skeletal muscle cells. Dystrophin interacts with sarcoglycans and 
dystroglycans which together maintain the link between the extracellular matrix and the 
cytoskeleton. This diagram also shows the dystrophin can also act as a hub as it associates 
with CAV3, nNOS (neuronal nitric oxide synthase) and syntrophins. Image adapted from 
(Davies and Novak, 2006).  
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Figure 6.1.b: Overview of muscular effects caused by lack of Dystrophin expression.  
Sarcopenia is a disease of aging, whereby muscle mass and strength decrease 
approximately 4-8 % every decade after the fourth decade of life in humans.  This is 
associated with a reduced force of muscle, which in turn hampers physical activity and well-
being (Mitchell et al, 2012). It is characterised by decreased muscle strength, increased type I 
to type II fibre type ratio and a decrease in fibre type cross-sectional area (Lexell et al, 1988; 
Evans and Lexell, 1995). Due to the increased length of human life, sarcopenia represents a 
major factor in the health and well-being of elderly people, as falls due to muscle weakness 
can be a major cause of loss of independence and morbidity. In addition to frailty and slow 
walking speed increasing the risk of falls, sarcopenia also affects the internal muscles. These 
muscles are particularly important in maintaining structural integrity of the body, especially 
in women. Studies have found that an increased risk of urinary incontinence, vaginal prolapse 
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and thus increased care costs, possible surgeries and a concomitant increase in morbidity are 
associated with weakening of skeletal muscles with age (Morris et al, 2012; Stav et al, 2012). 
By the year 2050, it is estimated that the global population of over-60’s will number 2 billion 
people, thus investigations need to be performed into possible treatments and causes of 
sarcopenia now (Stav et al, 2012). An overview of the effects of sarcopenia on skeletal 
muscle can be seen in Fig 6.1.c.   
So far, although dietary and hormone-replacement based therapies have been 
investigated with mixed results, a resistance exercise regimen has been suggested as the best 
treatment option (Cruz-Jentoft et al, 2014). As well as (or as a feature of) increased weakness 
and decreased muscle mass, aging muscle has several other molecular pathologies including 
motor neuron loss, decreased growth hormone signalling, decreased reactive oxygen species 
(ROS) handling capabilites and dysregulation of Ca
2+
 homeostasis (Mitchell, et al, 2012).  A 
decrease in satellite cell function and number has also been implicated in the pathogenesis of 
sarcopenia, and may be related to altered IL-6 signalling (McKay et al, 2013; Tierney et al, 
2014). The decrease in muscle mass may be due to increased or dysregulated proteolyic 
mechanisms, as both caspase (in EDL but not soleus)  and calpain activity have been shown 
to be increased in aged rodent muscle compared to their young counterparts (Rice and 
Blough, 2006; Brule and Dargelos, 2010). Calcium ion homeostasis has also been shown to 
be dysregulated in aged muscle, and calcium release units (CRUs) are decreased in both fast 
and slow fibre types, and EC–uncoupling has been suggested as a cause (Delbono et al 1995; 
Boncompagani et al, 2006). Interestingly, Ryan and Ohlendieck (2004) found that JSR90 
protein levels were elevated in aged human VL muscle compared to younger samples (Ryan 
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and Ohlendieck, 2004). As we now know that JSR90 is in fact JPH1, further investigation of 
the role of this protein in sarcopenia were undertaken.   
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Figure 6.1.c.: diagram of factors involved in sarcopenia . 
Chronic Intermittent Hypoxia (CIH) is a feature of diseases such as sleep apnoea 
and chronic obstructive pulmonary disorder (COPD), and comprises weakness in the primary 
and secondary muscles used in respiration, leading to apneustic periods. This causes 
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fluctuations in blood oxygen levels, and has wide ranging deleterious effects. While a 
substantial body of work has been done on the loss of function and fibrosis of respiratory 
muscles, little has shown the effect of CIH on peripheral muscles. A widely used rat model of 
intermittent hypoxia uses hypoxic chambers and alternating room and hypoxic air to replicate 
the apnoea seen in the human form of this disease, generating hypoxic animals with similar 
hallmarks to human hypoxic disease seen in COPD and sleep apnoea. CIH has well-
documented effects on muscles of the upper airways, especially the diaphragm where 
remodelling occurs after only one week of CIH treatment in rats (Shortt et al, 2013).  The 
effects of CIH are not limited to respiratory muscles. Chien et al (2010) showed that newly-
diagnosed obstructive sleep apnoea (OSA) patients had decreased functional performance in 
knee extensor muscle (to assess quadriceps function) compared to controls, while Sauleda et 
al (2003) showed that VL samples of OSA patients had altered cytochrome C oxidase activity 
and upregulated phophofructokinase activity, as well as higher protein concentrations and 
increased type II fibre diameter compared to healthy age matched controls (Chien et al, 2010: 
Sauleda et al, 2003).  However, no thorough analysis of the effects of CIH on peripheral 
muscles and EC coupling protein function or levels therein has been performed. To rectify 
this, and to complement mRNA based studies undertaken in the O’Halloran laboratory, EDL 
and soleus samples from rats exposed to CIH for 2 weeks and sham controls were analysed 
for JPH1 and JPH2 protein expression via Western blotting,  section 6.3.c. 
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 6.2: Aims: 
The aims of this chapter were to estimate JPH1 and JPH2 abundance in 8 month old 
mdx mouse; in aged and exercised mouse tissue; and in a 2 week model of intermittent 
hypoxia in rat muscle. These experiments were performed to fully understand the roles of 
JPH1 and JPH2 in models of disease. This also verified that mAb VF1c interacts with the 
JPH1 protein. 
 6.3: Results: 
 
6.3.a: JPH1 and 2 in 8 month old mdx and BL10 (WT )mouse strains 
Four muscle types (vastus lateralis, diaphragm, gastrocnemius and soleus) were 
excised from 8 month old WT and mdx mice, homogenised and subjected to western blotting 
analysis as described in section 3.3 and 3.5. Results are shown in the figures below, and the 
accompanying bar graphs display total abundance and the percentage of cleaved or uncleaved 
JPH protein in each muscle.  In vastus lateralis samples probed with mAb VF1c (against 
JPH1, see Chapter 5) a major band which migrated at 85kDa and a minor band with an 
apparent molecular weight of 65 kDa were detected (see Fig.6.1.3.a.i). When normalised to a 
β-tubulin loading control and expressed as a percentage of WT samples, no significant 
change in the level of JPH1 protein was detected. Similar results were seen when comparing 
JPH2 expression as detected by Western blot. No significant changes were found when 
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comparing WT to mdx samples. (n= 3 mdx, 5 WT: 2 technical replicates, statistical analysis 
was performed using Students’ Unpaired T-test (two tailed). All molecular weights were 
calculated as shown in Appendix I, figure 8.1.a.) 
In diaphragm muscle, no significant differences were found in the abundance of either 
JPH1 or JPH2;(Fig. 6.3.a.ii); however mAb VF1c detected bands of an apparent molecular 
weight 90, 70, 50 and 35 kDa, indicating that may be increased cleavage of JPH1 in this 
tissue (p= 0.7, 0.5, 1, Students’ Unpaired T Test of WT vs mdx for the 90 kDa, 70 kDa and 
50 kDa bands).  JPH2 in the diaphragm migrates as two major bands, detected at 105 and 85 
kDa (left panel, demarcated by arrows) slightly smaller than JPH2 detected in VL or GC, but 
this change in molecular weight was not statistically significant. The level of 100 kDa form 
of JPH2 detected via in mdx diaphragm was slightly increased compared to WT samples, but 
again, this was not statistically significant (p = 0.4, 0.9 Students’ Unpaired T test of WT vs 
mdx 105 and 85 kDa bands). High variability between samples could be a factor. 
 In soleus muscle, JPH1 abundance was detected by mAb VF1c at 90 kDa, 75 kDa and 50 
kDa, and no change in abundance is detectable in mdx tissue compared to WT controls (Fig. 
6.1.3.a.iv, right panel.). This contrasts with JPH2 protein, which appears increased in 
comparison to WT; however statistical significance was not reached (p= 0.1, 0.5, Students’ 
Unpaired T-test of WT vs mdx 110 kDa and 90 kDa bands). A trend towards what is likely to 
be greater cleavage of JPH1 in mdx soleus can be seen (84 % of total JPH1 was found at 85 
kDa in soleus compared to 94% in WT), however JPH2 appears preserved in this muscle, 
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with 57% of mdx total JPH2 being detected at the full length of 100 kDa (Murphy et al, 
2013).  It is possible that higher numbers of experiments could provide more significant data. 
 In gastrocnemius muscles, a decrease in JPH1 protein is again observed in mdx tissue 
compared to WT, but this does not reach significance (p= 0.1, See Fig. 6.3.b.iii)). However, a 
notable difference exists in JPH1 cleavage in this muscle, as only one band was detected, of 
70 kDa apparent molecular weight. Although this is much lower than the 90 kDa form 
detected in the diaphragm or 85 kDa in the soleus samples, comparison of molecular weights 
via Students T-test shows no significant difference. JPH2 was detected as two major bands 
migrating at 110 and 90 kDa. When WT and mdx levels of both forms were compared, a 
significant decrease was found in mdx tissue (p=0.05 (110 kDa WT vs mdx) and  p = 0.04 (90 
kDa WT vs mdx)).  This may reflect the pseudohypertrophy seen in these muscles in mdx 
mice and DMD patients. Interestingly, a difference in cleavage of JPH2 was seen in 
gastrocnemius muscle between mdx and WT muscle. While JPH2 appeared significantly less 
abundant (total protein levels) in mdx  tissue, there was more “full length” JPH2 in mdx 
muscle compared to WT samples. This is very interesting, and may imply that the role of 
calpain cleavage of JPH2 seen in younger mdx mice is less prominent in older mice. It could 
also be indicative of the “steady state” reached in dystrophic mouse models, where the 
degeneration and  regeneration cycles are slower and less destructive than they would be in 
younger mice. 
186 
 
 
Figure 6.3.a.i:  VL muscles of mdx and WT type mice (50μg protein per lane) were 
analysed via western blot for JPH1 and JPH2 expression using mAb VF1c and pAb JP2 
antibodies (mdx n =3, WT n = 4, normalised to β-Tubulin expression, two technical 
replicates). No significant differences in either JPH1 or JPH2 abundance were found in mdx 
samples (mdx n = 3, WT n = 4, 3 technical replicates). 
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Figure 6.3.a.ii: analysis of JPH1 and JPH2 abundance in WT and mdx mouse diaphragm (40 
μg of protein per lane). No significant differences were seen in either JPH1 (detected using 
mAbVF1c) or JPH2 expression in mdx diaphragm compared to WT (mdx n = 3, WT n = 4, 3 
technical replicates).  
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Figure 6.3.a.iii: Analysis of JPH1 and 2 in gastrocnemius muscle of WT and mdx mice 
(50μg of protein per lane). No significant change was observed in JPH1 levels, but there 
was a significant decrease in 85 kDa JPH2 protein (as detected by pAb JP2) in mdx samples 
compared to WT (p= 0.05) (mdx n = 3, WT n = 4, 3 technical replicates). 
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Figure 6.3.a.iv: analysis of JPH1 and 2 expression in mdx and WT soleus 
(30 μg of protein per lane). No significant differences were found between control and mdx 
samples in JPH1 or JPH2.  
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6.3.b: JPH1 and JPH2 in sarcopenia: effect of exercise. 
 The effect of sarcopenia on EC coupling proteins has been touched on before, but few 
studies have looked at JPH expression in aged muscle (Weisleder and Ma, 2007). Thus 
quadriceps muscle (which contains vastus lateralis muscle) and soleus muscle of four groups 
of mice were analysed. The mice were housed and maintained for 12 months (adult) or 24 
months (aged) in the laboratory of Dr. Brian McDonagh in the University of Liverpool. The 
McDonagh group used samples of the muscles listed for proteomic analyses, while I 
performed western blotting of these using the mAb VF1c, pAb JP1 and pAb JP2. The adult 
and aged groups were further split into exercised versus non-exercised controls, (using an in 
vivo isometric regimen prior to snap freezing) to assess any effect this had on the proteins in 
question.  
 In quadriceps muscle, two bands were detected using the mAb VF1c, of 75 and 60 
kDa apparent molecular weight, in adult, aged exercised adult and exercised aged muscles. A 
lower band at 50 kDa was seen in some samples.  No difference in JPH1 total protein 
abundance (measured as cumulative total of bands), however exercised aged quad had 
signidicantly less total JPH1 than its rested counterpart was found between exercised adult 
versus adult(p = 0.0004).  Figure 6.3.b.i also shows the percentages of JPH1 fragments in the 
bar chart on the right hand side. It can be seen that 50% more full length (90 kDa apparent 
MW) protein is found in the un-exercised samples, while those samples subjected to exercise 
protocol have increased JPH1 cleavage, as shown by detection of JPH1 a the lower molecular 
weights (adult versus exercised adult, 75kDa p= 0.031: Aged vs exercised aged samples 75 
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kDa p =0.0001, Students’ T-Test, 2 tailed). This hsows that exercised samples underwent 
significant cleavage of JPH1 protein. 
. 
  
Figure 6.3.b.i: Mouse quadriceps from adult (12 mth) and aged (24 mth) animals 
(exercised and non-exercised) were homogenised and assayed for JPH1 abundance via 
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western blot using the mAb VF1c. Exercised adult and aged quadriceps show a shift in 
molecular weight from 90 kDa in unexercised samples to two bands at 90 and 80 kDa in 
exercised adult and aged quadriceps. All samples to the right of the dashed lines are adult, 
while all samples falling on the left hand side of the dashed line are from aged animals. Blots 
containing exercised samples are on the left hand side (adult samples n = 6, aged samples, n = 
5, 2-3 technical replicates) 
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Figure 6.3.b.ii: Mouse quadriceps from adult, aged, adult excercised and aged 
exercised animals subjected to western blot and immunodectection of JPH2 protein 
using pAb JP2.  In all samples JPH2 was detected as three bands, at 100, 90 and 70 kDa. 
Total abundance of JPH2 protein was significantly increased in exercised adult quad 
compared to its unexercised controls (p=0.04). Differences can also bee seen in the 
percentage of cleaved to full length protein. Both aged samples have less full length 
(100kDa) JPH2 than either adult or exercised adult.  
In the quadriceps muscles, proteins of 100, 90 and 70 kDa were detected in the adult 
and aged tissue (upper panel, demarcated by arrows, figure 6.3.b.ii). Total JPH2 protein 
abundance was significantly increased in exercised adult compared to adult quadriceps 
muscle (p = 0.04,* symbol in Figure 6.3.b.ii). Surprisingly, despite a visible decrease in 
intensity in aged exercised quadriceps compared to unexercised aged controls, this difference 
was not significant (Figure 6.3.b.ii) when normalised to total protein for the corresponding 
lanes, highlighting the importance of controls. Looking at the percentage cleavage pattern for 
this protein, (right hand side of graph) it is clear that unexercised adult samples have higher 
percantages of full length JPH2 than either of the aged samples (Adult versus aged samples 
had a p value of 0.034) while it is interesting that a significant increase in JPH2  at 100 kDa 
was seen in exercised adult compared to its rested counterpart (Adult versus exercised adult: 
p= 0.031). This implies that exercise might increase or enhance the detection of JPH2 by 
western blot, perhaps by increasing solubility. 
Using pAb JP1, greater abundance of JPH1 protein was detected in adult muscle 
compared to aged muscle, (p= 0.02). As pAb interacts with the C-terminal region JPH1 
protein, it is likely that the bands detected at 75 kDa are “full length” JPH1 (For a comparison 
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of VF1c and JP1antibodies, please refer to figure 8.3.f). Decreased total abundance was  seen 
in exercised aged samples compared to adult excersied samples, but this was not found to be 
significant using this antibody.  
 
Figure 6.3.b.iii: Adult, aged, exercised adult and exercised aged mouse soleus 
muscles were analysed for JPH1 total abundance via western blot. Using the mAb VF1c, 
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total JPH1 abundance was determined in each tissue, normalised to total protein content via  
Coomassie staining. Aged soleus has significantly increased JPH1 total abundance compared 
to adult counterparts (Students’T Test, p=0.0) No shift in molecular weight of JPH1 was 
detected in soleus muscle samples of exercised versus non exercised controls. 
In soleus muscles samples, there is no detectable difference in JPH1 abundance as 
detected by pAb JP1 between aged and adult JPH1 levels, and no significant changes were 
found when aged exercised samples were compared with adult exercised or adult 
(unexercised) JPH1abundance levels. However, exercised soleus samples all showed an 
increase in a probable cleavage event (two bands visible at 90 and 55 kDa) while unexercised 
soleus muscle displays JPH1 protein at 90 kDa.These comparisons did not reach significance 
however.  A diagram of cleavage can be seen in figure 8.3.f. 
In the soleus, pAb JP2 detects proteins at 100, 75 and 60 kDa, which are lower molecular 
weights than those found in quad muscles, although comparisons using Students’ T-tests 
show that these differences in apparent molecular weight are non-significant. A significant 
decrease in JPH2 abundance was found in aged samples compared to adult samples (p=0.050, 
Students’ T-Test).  No other significant differences in abundance were found, however some 
interesting changes in molecular weight are visible. There is increased 100 kDa JPH2 
detected in exercised adult samples compared to rested adult samples (p=0.035), implying a 
direct effect of exercise. Aged soleus samples displayed the lowest amount of full length 
JPH2.  
In the soleus muscles, the mAb VF1c detects a doublet with a molecular weight of 65 kDa, as 
compared with molecular weight markers (Figure 6.3.b.iv). A significant increase in total 
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JPH1 protein is found in aged soleus compared to adult samples (p= 0.02, Students’ unpaired 
T-test), and this is paralleled by a similar but non-significant increase in JPH1 abundance in 
exercised aged soleus compared to exercised adult. This echoes the increase in total 
abundance detected in aged quad samples versus adult controls, and shows that a global 
increase in JPH1 abundance is occurring in limb muscles with aging.  Cross-comparison of 
muscles found that aged soleus has significantly higher amounts of JPH1 protein than aged 
quad, when normalised to total protein staining (p= 0.04). This could be indicative of a 
compensatory mechanism in slow, gravity bearing muscles.  
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Figure 6.3.b.iv: Soleus from adult, aged, adult exercised and aged exercised 
samples were analysed for JPH1 protein content using the VF1c mAb.  One main 
band(has doublet appearance in some samples) is detected in all samples at 65 kDa. The total 
abundance of this protein was compared among the smples tested, and aged soleus had higher 
amount of total JPH1 abundance (p=0.02) 
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Figure 6.3.b. iv: Soleus muscle from Adult, aged, adult exerdcised and aged 
exercised animals subjected to western blotting and immunodetection using pAb JP1. 
The pAb JP1 antibody detected only one band, at 65 kDa (n=5 and 6 for each group, 2 
technical replicates, compared using Students T-test). Increased protein cleavage was seen in 
exercised samples compared to rested controls. 
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Figure 6.1.3.b.vi: Soleus muscles from adult, aged, adult exercised and aged exercised 
mice were analysed for JPH2 expression via Western blot. Aged soleus had less abundant 
JPH2 than adult soleus muscle, (#, p< 0.05) while the highest amount of 100kDa JPH2 (full; 
length) was found in adult exercised soleus. Aged soleus had the lowest amount of full length 
JPH2. There is a significant increase in 90kDa JPH2 in exercised versus adult muscle (p= 
0.035, Students’T Test) 
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6.3.c: JPH1 and 2 expression in the 2 week CIH rat 
 Male Wistar rats underwent two weeks of chronic intermittent hypoxia (CIH) or sham 
treatment as described in section 3.2 and by Shortt et al  (Shortt et al, 2013). Extensor 
digitorum longus (EDL) and soleus muscles were analysed for JPH1 and 2abundance. In 
EDL muscle, CIH animals display an apparent decrease in JPH1 protein levels (detected 
using VF1c and JP1 antibodies) compared to Sham treated controls, but this was not 
significantly different (Student’s T-test, p= 0.4528 and 0.1259 for CIH vs Sham animals in 
mAb VF1c and pAb JP1 immunoreactivity respectively, normalised to total protein via 
Coomassie staining, Figure 6.3.c.i and Fig 6.3.c.ii). In both pAb JP1 and mAb VF1c blots, 
bands were detected at 70 kDa, reconfirming that the mAb VF1c interacts with the JPH1 
protein. No difference was found in molecular weight of JPH1 between CIH and sham 
animals. In EDL muscle, JPH2 protein was detected as two bands with apparent molecular 
weights of 95 and 76 kDa. Despite an apparent decrease in protein levels of both 90 and 76 
kDa bands in CIH treated animals compared to controls, this difference was also non-
significant (p= 0.2789 and 0.1258, for CIH vs Sham 90 and 70 kDa respectively, Student’s T-
test) (Figure 6.3.c.ii).  
 In the soleus muscle, JP1 and VF1c antibodies both detected bands at 73 kDa. When 
comparing CIH and Sham treated samples, an increase was again seen in Sham tissue but this 
did not reach statistical significance (p= 0.6154 (mAb VF1c) and p = 0.8033 (JP1 antibody)). 
In the case of JPH2 abundance (Figure 6.3.c.iii.), two bands were again detected, this time at 
100 and 76 kDa, a slightly higher molecular weight than that seen with JPH2 in EDL muscle.  
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No changes were seen in abundance for either band when CIH and Sham muscles were 
compared (p= 0.6371 and 0.2208 for 100 and 76 kDa bands respectively). 
When comparing the JPH1 expression of EDL to soleus muscles with and without 
CIH treatment, both muscle types showed similar levels of JPH1 protein, both of which were 
non-significantly decreased compared to their Sham counterparts. In contrast, full length 
JPH2 displayed a downward trend in CIH treated EDL compared to IH treated soleus but this 
was just below the threshold for significance (p = 0.054). However, when comparing levels 
of 76 kDa JPH2 in CIH EDL and soleus muscle, soleus muscle showed a significant increase 
compared to EDL (p = 0.01),  (Figure 6.3.c.iii). No differences were found between Sham 
and CIH EDL and soleus at either molecular weight.  
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Figure 6.3.c.i: CIH and sham rat EDL muscle analysed using mAb VF1c (30μg/well). 
Although variation existed between the sham and CIH group, this difference was not 
significant. The bands detected  match closely with those detected using pAb JP1, confirming 
the interaction of mAb VF1c with this protein.  
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Figure 6.3.c.i: EDL muscle from Sham and CIH treated rat was analysed for JPH1 and 
JPH2 expression (30μg protein per lane).  mAb VF1c and pAb JP1 antibodies both detect a 
band at 70 kDa, and despite a trend towards increased JPH1 in tissue from sham-treated rats, 
this was non-significant. Similar results are seen in JP2 blots, where two bands at 95 and 76 
kDa were detected.   
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Figure 6.3.c.ii: Sham and CIH treated rat soleus were analysed via western blot for 
JPH1 and JPH2 expression (30μg protein/lane). In soleus, one band was detected in both 
JP1 and VF1c blots at 70 kDa, while in JP2 exposed blots, two bands were detected at 100 
kDa and 76 kDa, slightly higher than those found in EDL. No significant changes were found 
in either JPH1 or JPH2 when Sham treated animals were compared to CIH samples. 
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Figure 6.3.c.iii: Graphs showing comparison of JPH1 (mAb VF1c and pAb JP1) and 
JPH2 (pAb JP2) abundance in EDL and soleus muscle from CIH and Sham–treated 
rats (30μg protein/lane). A significant increase in 76 kDa JPH2 protein is observed in CIH 
treated soleus compared to EDL muscle (p>0.05, #). No differences were seen in JPH1 
abundance when CIH and sham EDL and soleus were compared.   
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 6.4: Discussion 
 
6.4.a: JPH1 and JPH2 abundance in mdx and WT mouse muscle.  
 Although no significant changes in JPH1 or JPH2 were seen in VL, soleus or 
diaphragm at 8 months of age, JPH2 protein levels were significantly decreased in mdx 
gastrocnemius compared to WT controls. This could be because of the increased 
psuedohypertrophy and necrotic tissue found in what is a comparatively large muscle, or 
perhaps another facet of the disease. Such inputs could include increased reactive oxygen 
species generation influencing JPH2 synthesis or dysregulated Ca
2+
 causing this decrease. 
Either way, it is interesting that while JPH2 is affected, uncleaved JPH1 levels are unchanged 
at this age, and further highlights the muscle specific regulation of each JPH protein. Taken 
together the results of this study show non-significant changes in diaphragm, VL and soleus, 
which is surprising as diaphragm is often the worst affected muscle in this disease 
(respiratory failure is very often a cause of death in DMD patients), as well as in this model. 
The decreased JPH2 expression in gastrocnemius muscle could be related to increased store 
operated Ca
2+
 entry, found to be elevated in mdx fibres, perhaps as a compensatory 
mechanism for leaky SR (Wang et al, 2005). As JPH2 has been suggested to interact in some 
way with the SR Ca 
2+
 sensor STIM1 and its associated store operated channel, Orai it is 
plausible that an increase in Ca
2+
 entry could affect either cleavage or expression of JPH2 
(Woo et al, 2012). These results are in contrast to previous studies by Murphy et al (2013), 
who found that increased JPH2 expression in TA muscles of 2.5 month old mdx mice. They 
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also noted that increased proteolysis of both JPH1 and JPH2 (from 90 to 75 kDa) were found 
in mdx muscles compared to WT controls, with markedly increased proteolytic cleavage of 
JPH1 in 7 month old diaphragm compared to WT, but unfortunately do not comment on 
abundance of total protein of either JPH1 or JPH2 in this tissue.The amounts of proteolytic 
cleavage of JPH1 and 2 were also analysed in these studies, and no significant differences in 
proteolytic cleavage were found (as measured by Students’ T-Test). It may be possible that 
by 8 months of age in the mdx mouse, a steady state of JPH expression has been reached, and 
that disease pathology is not as marked as it would be in their human counterparts, who 
display necrosis and psuedohypertrophy (infiltration of fibrotic, non-contractile tissue in to 
muscle) in the lower limb muscles before others are affected. A temporal gene expression 
analysis of mdx mouse muscle tissue from animals ranging from 2 weeks to 1 year in age 
found that in the diaphragm, but not in hindlimb muscle, RyR1 levels were altered compared 
to control mice, and that the mdx mouse had different alterations in comparison to biopsies 
from DMD patients (Rouger et al, 2002). Carberry et al noted that in proteomic analysis of 
muscles from mdx mice that different proteins (such as parvalbumin, a calcium binding 
protein in the cytosol of fast muscles which was increased in flexor digitorum brevis (FDB) 
and interosseus muscles but not in EDL or soleus) are differentially regulated, which further 
corroborates the hypothesis that different muscles regulate their protein content and 
modification based on activity and disease progression (Carberry et al, 2013). 
 It should be noted that the mdx mouse is not a perfect model of Duchenne muscular 
dystrophy, as the mice live longer and are protected in part by a natural overexpression of a 
compensatory protein, utrophin. It has been suggested by Capote et al that knock-out of the 
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utrophin protein in the mdx model generates a more faithful representation of the human 
disease.(Larcher et al, 2014, Capote et al, 2010), or the use of  Transcription-Activator Like 
Effector Nucleases (TALEN) generated mdx rats could provide a better model for this 
disease.  
6.4.b: JPH1 and 2 in exercised and unexercised adult and aged mice 
 As shown in section 6.1.3.a, JPH1 protein is increased in aged soleus muscle but not 
in quadriceps muscle in aged compared to adult controls. It is possible that this increase is a 
compensatory response to EC uncoupling, a documented process in aged skeletal muscle, or 
as a regulatory response to hypernitrosylated and leaky RyRs found in aged skeletal muscle 
(Boncompagani et al, 2006; Andersson et al, 2011). Increased JPH1 is also likely tied to the 
described decrease in DHPR α1S subunits in aged muscle. As this subunit of DHPR is known 
to interact with both JPH1 and JPH2, compensatory efforts to overcome DHPR decrease via 
JPH1 upregulation are plausible (O’Connell et al, 2008; Golini et al, 2011). Other EC 
coupling proteins including RyR1 and interestingly, RyR2 are altered in aged skeletal muscle. 
Gheorge et al (2014) performed proteomic analysis of aged and adult human muscle, and 
found that Ca
2+ 
homoestasis and lipid metabolism protein expression levels were altered 
before those involved in mitochondria and apoptosis signalling, which may imply that Ca
2+ 
 
homeostasis dysregulation occurs before ROS-mediated perturbations, and may explain why 
progressive aging and defective ROS signalling lead to leaky RyR1 channels in aged skeletal 
muscle. They also found that RyR2 and JPH2 were upregulated in aged VL muscles 
compared to adult controls. Increased expression of RyR1 was also found in the 
gastrocnemius muscles of aged mice compared to adult controls. This implies that the 
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alteration seen in Ca
2+  
levels in aged tissue may represent a larger reliance on calcium 
induced calcium release, which given the decreased L-type calcium current influx (due to 
decreased DHPR subunit expression) makes sense. It may also explain why JPH levels have 
to change in ageing muscle, as a shift from RyR1 to RyR2 expression in aged tissue would 
necessitate the concomitant increase or decrease in regulatory proteins (Gheorghe et al, 2014; 
Hwang et al, 2013). This indicates that exercise may have a solubilising effect on the muscle, 
perhaps allowing increased release of JPH1 from membranes and thus increasing detection of 
said protein. Detection using the pAb JP1 was very difficult, and persistant background may 
have obscured some results using this antibody, similar to that seen in A7r5 experiments.  
 The change in JPH2 levels could be due to alterations in PM-ER interaction sites, and 
implies that JPH1 and JPH2 are separately regulated within muscle types, or could be linked 
to RyR isoform expression in this muscle. A three-fold increase in JPH2 in exercised versus 
unexercised adult quad muscle along with the shift in molecular weight could imply that 
strenuous exercise might have a solubilising effect on JPH2, thus making the protein more 
detectable by freeing it from the SR membrane. This is akin to what occurs after exercise in 
JPH1 protein, as suggested by Murphy et al (2013) , who stated that after exercise JPH1 was 
cleaved by calpains into a 75 kDa soluble fraction and a 15 kDa C-terminal segment which 
stays embedded in the SR membrane (Murphy et al, 2013). After bouts of  exercise, and in 
some aged samples both JPH1 and  JPH2 exhibited altered molecular weights, indicating that 
increased calpain cleavage (or cleavage by another proteolytic enzyme) of these proteins 
could indeed be a factor in aging. This is prominent in JPH2 molecular weights seen in 
soleus, where adult muscle which was subjected to the exercise protocol had significantly 
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increased cleavage of JPH2 (p=0.035) compared to its  rested counterpart. This corroborates 
previous studies where increased cleavage of JPH2 was found in skeletal muscle after 
exercise. Alterations in proteolytic activity and calpain cleavage activity have been shown to 
occur in aged muscle samples and to display fibre type specificity (Dargelos et al, 2007). A 
comparison of 3, 6, 30 and 36 month old rat EDL and soleus muscle found that caspase 
cleavage increased dramatically in aged soleus compared to younger counterparts, but that 
this did not occur to the same extent in EDL muscle (Rice and Blough, 2006). Brule and 
Dargelos (2010) also found that RyR1 cleavage by calpains (μ- and m subtypes) was 
significantly increased in aged rat muscle, and likely contributed to Ca
2+ 
handling 
irregularities therein (Brule and Dargelos, 2010). Taken together, the results described in 
Section 6.1.3.b imply that JPHs are differentially regulated in aging and after exercise, and 
are likely effected by the altered intracellular calcium levels, increased proteolytic activity 
and changes in EC coupling protein expression which occur in aging. Further analysis will 
have to be performed to fully elucidate the exact effects up or down regulation (as well as the 
change in molecular weight) of JPHs have in aged and exercised muscle. 
 
6.4.c: JPH1 and JPH2 in CIH and sham treated rat EDL and Soleus Muscles 
  As a foundation for the study of EC coupling protein in a model of intermittent 
hypoxia, these results provide some interesting results; namely that JPH1 is not changed in 
rat EDL or soleus muscles after two weeks of CIH treatment compared to sham controls. 
JPH2 is unchanged in EDL and soleus compared to SHAM muscles, however 76 kDa JPH2 
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protein is more abundant in CIH treated soleus compared to EDL muscle. This is very 
interesting, as it is vastly different from previous results in other animal models which show 
that soleus typically has a decreased amount of both JPH1 and JPH2 compared to EDL 
muscle, although soleus muscle do tend to show higher rates of suspected JPH proteolytic 
cleavage (see Chapter 5). Perhaps this slight increase may make the muscle more efficient, or 
perhaps it is indicative of increased calcium ion dysregulation. Intermittent hypoxia training 
is utilised by athletes to improve performance, (a “Live high, train low” hypothesis) but 
several studies have questioned its efficacy (Katayama et al, 2003). Vogt et al (2001) found 
altered levels of VEGF, HIF1α and myoglobin mRNA in muscle biopsies of endurance 
athletes trained at simulated hypoxia compared to normoxic controls. However Nordsborg et 
al (2012) and Siebenmann et al (2012) found no difference in endurance performance or VO2 
max in hypoxic-trained endurance cyclists compared to normoxic controls. So far, little work 
has been performed on EC coupling proteins in hypoxia treated skeletal muscle, although 
some work on cardiac muscle has shown increased activity and expression of RyR2, CASQ2 
and SERCA2 in rat hearts after two weeks of CIH exposure facilitating an improvement in 
Ca
2+
 handling (Li et al,  2009). In isolated cardiomyocytes from neonatal rats, four days of 
CIH caused an increase in Ca
2+ 
extrusion from the cell and a small increase in ROS 
generation along with an increase in SERCA2 and RyR2 expression and activity (Chen et al, 
2014). This implies that CIH can cause changes to both Ca
2+ 
handling and EC coupling 
protein level, and this deserves to be investigated further in skeletal muscle.  Sun et al (2013) 
also found that pO2 levels of skeletal muscle were linked to RyR1 S-nitrosylation, where low 
pO2 levels were shown to correspond to lower levels of cysteine oxidation on the RyR1 
monomers. An increase in S-oxidation (at higher pO2 levels) of RyR1 was also found to 
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increase RyR1 activity (Sun et al, 2013). Hence, Ca
2+ 
release via RyR1 in skeletal muscle can 
be shaped by the pO2 concentration, and implies that hypoxia may have an effect on EC 
coupling proteins via post translational modification, expression changes and alterations in 
activity levels. It is likely that an increase in the exposure time of CIH or the analysis of other 
muscles could provide more data on the subject of JPH regulation in CIH treatment.  
It is interesting that in CIH tissue and mdx muscle (both of which are reported to 
undergo increased ROS activity) both showed non-significant changes in JPH1 expression, 
even though it is known that oxidation status can affect the interaction of RyR1 with JPH1 
(Phimister et al, 2010). This contrasts with aged muscle, where increased ROS activity are 
cited as a pathological pathway in sarcopenia, and implies that perhaps that cumulative 
effects of calcium dysregulation combined with overactive ROS lead to a sharper change in 
regulation of JPHs, and that these events could occur at different times or feed into the 
worsening of disease (Gheorghe et al 2014).  
 
6.5: Future studies 
It would be beneficial to include intercostal muscle into further analysis of EC 
proteins in further analysis of DMD/mdx model muscle samples as DMD causes 
kyphoscoliosis (an abnormal curve of the spine), in part due to intercostals muscle weakness. 
As it is known that these muscles have specialized Ca
2+
 handling mechanisms it is likely that 
JPHs or RyRs could be altered. Further analysis could include the use of different mdx 
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models such as the mdx rat, which is reported to be more in-keeping with the human form of 
the disease (Larcher et al, 2014). It would also be relevant to analyse the effects of DMD on 
cardiac muscle JPH2 and RyR2 levels, as cardiomyopathy is a significant pathology in this 
disease and there is evidence of enhanced post-translational modifications of RyR2 in DMD 
models (Kyrychenko et al, 2013)   
Further analysis of EC coupling proteins in CIH models is required to fully elucidate 
the effect this treatment has on protein levels, activities and post-translational modifications. 
This would require the use of a standardized model of CIH, as many different lab groups use 
different levels and timeframes of hypoxia treatment. The effect of exercise training under 
CIH conditions on skeletal muscle should also be clarified, perhaps with a large scale 
proteomics based study to identify any proteins which are differentially expressed to those 
normally found in trained muscle. It is also possible that as shown in the differing levels of 
the 76 kDa fragment of JPH2 in EDL and soleus muscles in response to IH, muscle specific 
responses to hypoxia could be worth studying, as it may explain some deleterious effects seen 
in obstructive sleep apnoea and COPD patients.  
 In sarcopenia research, investigations into the field of EC coupling proteins could be 
expanded by characterising the effect of increased JPH1 in the soleus of aged muscles and 
clarifying whether this is a compensatory response or an effect of the disease. This could be 
accomplished via single fibre studies of aged versus adult studies combined with Ca
2+
 
imaging studies to assess any effect this upregulation has on RyR gating. Comparison of 
effects across muscle fibre types would be useful here also. Another method would be to use 
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inducible knock-out of JPH1 or JPH2 in aged animals (such as that demonstrated by Hirata et 
al, 2006) which could be very interesting. Further analysis of the postulated JPH cleavage 
after exercise could be performed in two ways; using a muscle cell line or isolated myocytes 
and either using molecular techniques to delete potential proteolytic cleavage sites within 
junctophilins, thereby inhibiting calpain mediated cleavage and assessing the effect on RyR 
gating and Ca
2+
 homeostasis; or by incubating cells under contraction-inducing conditions 
with and without specific calpain inhibitors. Either way, although some work has shown that 
JPHs are cleaved by calpains in muscle cells after contractions (Corona et al, 2010; Murphy 
et al, 2013) there is plenty of scope for further analysis. 
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Chapter 7: Discussion 
217 
 
 
7.1: Introduction 
The results outlined in chapters 4, 5 and 6 together illustrate interesting aspects of SR channel 
function, especially in regard to type 1 ryanodine receptors. Over all, a potential novel 
interaction between RyR1 and GRB2 has been found in rat muscle using pull-down of the 
RyR complex followed by western blotting. It has also been confirmed that mAb VF1c, 
originally generated against the junctional sarcoplasmic reticulum protein of 90 kDa, actually 
interacts with the junctophilin 1 protein. JPH1 has been shown to be differentially regulated 
in different skeletal muscles, and to be expressed (although as a minor subtype) in smooth 
muscle. Characterisation of JPH1 and JPH2 expression in disease models has shown 
increased abundance of JPH1 in aged soleus, but not quadriceps of male mice, and that 
exercise has an effect on the molecular weight of the protein (as determined by SDS-PAGE). 
It was also found that there are no differences in abundance of JPH1 or JPH2 in limb muscles 
from 8 month mdx versus wild type mice, with the exception of decreased levels of an 85kDa 
form of the JPH2 protein in mdx GC muscle. No difference was seen in rats which underwent 
2 weeks of chronic intermittent hypoxia. The implications of these results will be discussed 
below.  
218 
 
7.2: GRB2-RyR1 interaction 
In chapter 4, it was found that peptide analogs of the proline rich region are difficult 
to use experimentally, but that the proline rich region of RyR1 may interact with the GRB2 
adapter protein. As this protein is especially important in cell signalling, specifically via the 
MAP-kinase pathway, an interaction with RyR1 could give badly needed clues as to its 
regulation or wider effects on muscle cells, as have been seen in hippocampal neurons 
(Aronson et al, 1997; Huddleston et al, 2008).  
It is important to note that much further work remains to be done to characterise this 
interaction. It must be clarified whether or not this protein interacts with ion channels related 
to RyR1, such as RyR2 or RyR3, or even InsP3 Receptors. This could give clues as to the 
function and site of this interaction.  
The GRB2-RyR1 interaction must be validated: the use of molecular and genomic strategies, 
such as CRISPR/CAS-9 or other molecular tool could be used to mutate the proline rich 
region of RyR1, or indeed one of the SH3 domains located on GRB2, to determine the effect 
this would have on this interaction. This could also allow for functional work, to determine 
what effect inhibiting this interaction would have on the health of the cell, Ca
2+ 
release and 
abundance of SR related proteins. 
Postulated functions for the GRB2-RyR1 interaction include a myriad of possibilities. 
GRB2 is a linker protein, and is likely facilitating the interaction of RyR1 with other proteins, 
probably proteins close to the cell membrane or in the cytosol, due to the location of the 
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candidate binding site. It is possible that the interaction of GRB2 and RyR1 is linking a 
protein already known to interact with RyR1, but the interaction domain is unclear. However, 
it is also possible that GRB2 is bringing regulatory effectors to the surface of RyR1, and that 
these interactions could be fleeting, such as that seen between Bin 1 and actin and myosin in 
sarcomere assembly (Fernando et al, 2009). Various cellular conditions such as alterations in 
pH or nearby ionic composition which could encourage such an interaction could be analysed 
to see if they promote or hinder the GRB2-RyR1 interaction, and for this a human muscle-
derived cell line that expresses both proteins would be advantageous. It also remains to be 
seen whether GRB2 interacts with RyR1 (or the RyR1 associated complex) in other cell and 
muscle types. The experiments outlined in chapter 4 were performed using mixed muscle 
from rat hindlimb, which contains muscles with a high proportion of type II (fast) fibres 
(Kohn and Myburgh, 2007). This interaction could very well be specific to conditions 
favoured in fast type muscles (such as gene regulation etc), and this could be checked by 
performing pull down experiments using fast and slow muscles (e.g. EDL and Soleus) or 
indeed cell lines from the respective muscle types, although these would have to be from the 
same species. It could also be confirmed that this interaction occurs in human muscle using 
easily accessible VL biopsies, or banked tissue and co-localization and immunoprecipitation 
studies. A caveat here is that reliable antibodies which detect RyR1 consistently and 
sensitively are a necessity.  
  It is interesting that the interaction of RyR1 with PLCγ1 and PTN were not 
confirmed in this instance, and highlights the need to experimentally validate in silico data. 
However it would be ideal to validate such interactions under a wider range of conditions, to 
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fully test whether these proteins do in fact interact under certain circumstances these 
experiments could be improved by chemically cross-linking proteins pulled out of solution in 
complex with RyR, thus preserving and aiding visualisation of any such interaction, or by 
examining the RyR complex and  its putative interactions under a wider range of conditions, 
such as altered ionic strength, high and low Ca
2+ 
concentration, or under varying pH 
conditions, all of which could contribute to the interactions of proteins with this complex. It 
is necessary to study putative interactions of the RyR channel under open and closed 
conditions, as suggested by Phimister et al, who noted that JP1 is more likely to interact with 
RyR1 when it is in the open conformation (Phimister et al., 2007).  
 The interaction of GRB2 with RyR1 protein complex provides very interesting 
avenue for research, and scope for the role of RyR1 in signalling events other than Ca
2+
 
release. Indeed, purely because of its size, the RyR1 complex may indeed act as massive hubs 
for protein interactions that may or may not be related to the function of the protein, and is 
reported to have other roles such as glutathione transport (Banhegyi et al, 2003). Due to the 
many roles of GRB2 in signalling pathways (e.g. insulin receptor signalling, fibroblast 
growth receptor signalling, activation of the MAP kinase pathway etc), this is a possibility, 
although unlikely. It would be tempting to speculate that the GRB2-RyR1 complex 
interaction could be involved in the insulin receptor pathway, which might facilitate easy 
coordination of insulin-based signalling and RyR1 (and therefore muscle contraction) 
activity. It is also entirely possible that the GRB2 protein is not the only SH3-domain 
containing adapter protein to potentially interact with the proline rich region of RyR1, and it 
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is also feasible that GRB2 could form dimers to block activity, as seen with the fibroblast 
growth factor receptor (Lin et al, 2012). 
 Altogether, the interaction of GRB2 with the RyR1 complex opens up a new avenue 
for RyR research, and demonstrates that a huge amount of work remains to be done on RyR 
interaction partners and their roles in calcium signalling. It may also provide clues as to the 
role of RyRs in non-muscle tissue. 
 
7.3: Characterisation of mAb VF1c. 
Chapter 5 shows the results of the mAb VF1c characterisation experiments, where, 
building on previous work performed in this laboratory, mAb VF1c was shown to interact 
with the junctophilin 1 protein. This allows the alignment of previous research using this 
antibody, meaning that it is now known that JPH1 is phosphorylated by an endogenous 
kinase, is non-glycosylated and is increased in abundance after chronic low frequency 
stimulation (Campbell et al, 1987; Guo et al, 1994; Froemming et al, 1999; Froemming et al, 
2000). This was elaborated further by showing that JPH1 protein abundance was increased in 
fast type muscle fibres (such as those found in EDL and VL muscles), as detected by western 
blotting. It was also shown, in collaboration with the Sorrentino group that mAb VF1c binds 
to a region between amino acids 369-460 of JPH1, although attempts to narrow this further 
were hampered by rogue secondary antibody binding to peptide arrays. It is possible that the 
mAb VF1c binds to a conformational epitope on this protein.  
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The implications of these results are far-ranging. The amalgamation of old and new 
knowledge on JPH1 function can add to the field, although regrettably we do not yet know 
which kinase is involved in phosphorylating it, or the effect this has on the protein and its 
binding partners.  
Uncovering the binding region for mAb VF1c allows the drawing of some interesting 
conclusions: for instance in western blots of rabbit muscle, the JPH1 protein as detected with 
mAb VF1c can be seen as two bands at  90 and 80 kDa. As neither of these bands are visible 
in secondary only controls, a logical conclusion is that the JPH1 protein is in some way 
cleaved within the region of 369-460, or that shorter splice variants of JPH1 exist in skeletal 
muscle. This provides an interesting starting point for why and how is JPH1 cleaved. 
Although Murphy et al suggested that JPH1 and JPH2 are subject to calpain cleavage via μ-
calpain, it remains to be fully investigated (Murphy et al, 2013). It is tempting to think that 
cleavage of JPH1 or 2 may be linked to activity and or regulation in some way, and thus 
alterations in calpains acting upon these proteins could have very serious ramifications for 
muscular disorders, or that variances in molecular weight of these proteins could exert 
differing effects on their interaction partners as seen with the 45 kDa junctional Sarcoplasmic 
reticulum protein, JSRP1/ JSRP 45 (Yasuda et al, 2013). If the action of proteolytic enzymes 
on the JPH protein is also relevant to those expressed in neuronal tissue, these ramifications 
could be necessary to understand diseases of these tissues as well, such as Huntingtons like 
disease 2(HLD2)(Nishi et al., 2002)(Margolis, 2003). JPH1 has also been implicated in 
Charcot-Marie-Tooth disease, a peripheral neuropathy of varying severity caused by 
mutations in the GDAP1 (ganglioside induced differentiation associated protein 1) gene (Pla-
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Martin et al., 2014). Thus the investigation of proteins which act upon JPH1 and 2 are 
necessary.   
The characterisation of mAb VF1c also confirmed previous reports of increased 
abundance of JSR-90 (JPH1) in type II muscle fibres (Froemming et al  2000). JSR-90 was 
found to be decreased in rabbit tibialis anterior, a predominantly fast muscle, after chronic 
low frequency stimulation, and this was paralleled in the work presented here via Western 
blotting of several muscle types (Froemming et al,  2000). The soleus muscle types in both 
rabbit and rat both displayed lower abundance of JPH1 and JPH2 compared to faster muscles 
such as EDL, and may represent a matched expression level to that found for RyR1 in fast 
and slow muscle types (Froemming et al ,2000; Salanova et al, 2008). It is also possible that 
this differential of JPH1 and JPH2 expression in skeletal muscle is a reflection of the varying 
embryonic origins of the muscle groups. This could definitely be the case for the intercostal 
and diaphragm muscles, which arise from a separate somite to the limb buds in embryonic 
differentiation, and require slightly altered levels of muscle differentiation factors MyoD and 
Myf-5 (Kablar et al,1997). 
Chapter 5 also demonstrates the need for carefully controlled data, particularly when 
examining cell culture samples by Western blot. The expression of JPH1 and JPH2 protein 
were demonstrated in A7r5 and C2C12 cell lines. The C2C12 mouse myoblast cell line must 
be used at as low a passage number as possible, and unfortunately did not provide a clear 
timeline of JPH expression during myotube differentiation. It is also difficult to transfect 
these cells once they have been differentiated. Interesting results were obtained using the 
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A7r5 cell line, where both JPH1 and JPH2 (the major isoform in smooth muscle) are 
expressed. It is noteworthy that JPH1 is expressed in this cell line, and may hint that these 
proteins have distinct roles in smooth muscle, which has already been shown in skeletal and 
cardiac muscle (Beavers et al., 2013; Jayasinghe et al., 2014). It has been shown that 
application of cholesterol oxidation products, also known as oxysterols, onto A7r5 cell had 
no effect on JPH1 abundance (Hammoud et al, 2012), but it would be interesting to analyse 
JPH2 under the same conditions, especially as JPH2 alterations have been noted in 
hypertensive states, as well as hypertrophic cariomyopathy (Cai et al, 2015:Guo et al, 2015). 
It was also seen that JPH1 and JPH2 in A7r5 cells do not undergo the same cleavage events 
as they do in skeletal muscle (both proteins were detected at approx. 90 kDa in A7r5 lysates), 
despite expressing the same calpain cleavage proteins (μ and M-calpain, also known as 
calpains I and II, respectively) reported  to act on JPH1 and JPH2 (Ariyoshi et al,2007; Kar et 
al,2007; Murphy et al, 2012).  
Another important point when examining these data is the issue of molecular weight. 
Calpain cleavage aside, full length JPH1 is detected in some tissues at a molecular weight of 
90 kDa, despite having a predicted molecular weight of 72 kDa. Given that we know JPH1 is 
not glycosylated (Froemming et al, 1999) and that even though JPH1 is phosphorylated by an 
as yet unkown kinase, this does not account for the almost 20 kDa upward shift in molecular 
weight as seen in SDS PAGE and western blots of this protein. A possibility is that JPH 
structure is affecting its apparent molecular weight. All junctophilins posess membrane 
binding regions (MORN motifs), a middle α-helical region and a C-terminal membrane 
spanning domain. These attributes have been shown in other proteins to affect the relative 
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mobility in SDS PAGE gels. Rath et al state that in CFTR (Cystic Fibrosis transmembrane 
conductance regulator channels, chloride channels associated with cystic fibrosis) mutants 
with added helical turns, relative mobility could be slowed in the same gel by up to thirty 
percent, and they postulate that this is due to the uneven SDS binding of these helices and 
membrane spanning regions, which in some cases have been shown to bind twice the amount 
of SDS as other non-helical soluble proteins. Abberant SDS binding was also shown to 
encourage the partial refolding of proteins, which if it occurred in any of the data shown here 
could explain unusual binding patterns seen with some antibodies, particularly pAb JP1. It 
was also shown that proten-lipid interactions could be a factor in altering relative mobility in 
gels, and as all junctophilin proteins contain lipid binding motifs, and have been shown to 
change shape depending on the compositiionof the lipids they interact with, this could 
account for some of the disparites in measured molecular weights (Rath et al., 2009: Bennet 
et al., 2013).  Transmembrane regions have also been shown to be responsible for detergent 
resistant dimerization, as occurs in the glycoporin A protein, and if the C terminal region of 
JPHs are cleaved off and free, it is possible that they dimerize and could account for 30 kDa 
bands seen in some gels (Furthmyer and Marchesi, 1976: Li et al., 2012). It has been 
suggested by Rath et al that when analysing proteins with potentially troublesome regions 
such as α-helices and TM domains that specialised molecular weight markers be used, 
perhaps as specific set of helical proteins could be bacterially expressed (Rath et a.l, 2013).  
This chapter also demonstrated that JPH1 and 2 are expressed in A7r5 rat aortic cell 
line, and that they can be of (limited) use in studying calpain cleavage of said proteins. 
DMSO (in A7r5s) and N-ter peptides, both membrane disrupting compounds had 
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upregulatory effects on JPH1 and 2 expression. This is probably due to either a change in 
lipid composition around/ near JPHs proteins, which may have affected either transcriopption 
or nmay have solubilised or “freed” the protein from the membranes, allowing it to be more 
easily detected via western blot. Interestingly, BAPTA-AM and A23187 had opposing effects 
depending on the timescale, and may hint at time and calcium based regulation of JPH1 and 2 
expression in smooth muscle. A contraction study would be an excellent follow up to these 
data. An in silico analysis showed that the most likely calpain cleavage sites on JPH1 in the N 
terminal portion at approximately 150-160 aa and in the C terminal region, at approximately 
600-610, in rabbit, rat, mouse and human JPH1 and 2. This corroborates Guo et al, who  
found that the primary calpain cleavage site is found at the C-terminal end of JPH2. JPH 
proteins are necessary for T-tubule arrangement and calcium  release, and increased cleavage 
of both JPH1 and 2 have been implicated in skeletal muscle myopathy, aging and 
cardiopathies. (Murphy et al., 2013: Wu et al., 2014, Guo et al., 2015). Thus the in silico 
analysis presented here will provide a frim basis for future inhibitory work using compound 
such as ALL-N or via mutagenesis of suspected cleavage sites, similar to the experiemtns 
performed in Gou et al (2015).  
  Taken together, these data imply that the regulation of JPH1 and JPH2 protein levels 
is muscle specific, and that JPH1 is cleaved between the amino acids 369 and 460. This 
provides a new reliable antibody to aid the study of JPH1 protein, and may yet yield valuable 
clues as to if and why it is cleaved in skeletal muscle cells, but not in smooth muscle. Further 
study will clarify the role this protein has in maintenance of health and its role in disease. 
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7.4: JPH1 and JPH2 in disease models. 
Experiments were performed to analyse the abundance of JPH1 and JPH2 in rodent models of 
aging, chronic intermittent hypoxia (CIH) and Duchenne muscular dystrophy (DMD). While 
no differences were found in JPH1 or JPH2 protein abundance in CIH compared to controls, 
a decrease in the abundance of the 85 kDa form of JPH2 was found in mdx compared to wild 
type GC muscle. Similarly in CIH EDL and soleus muscles, no change in JPH1 abundance 
was found, whereas a small non-significant decrease in JPH2 was found in CIH EDL 
compared to sham animals. In the study of aged and exercised mouse soleus and quadriceps, 
some intriguing results were obtained. Firstly, when aged soleus and aged quadriceps were 
compared, an increase in JPH1 abundance (detected with mAb VF1c) was found in aged 
soleus compared to aged quadriceps and adult soleus samples. Detection of JPH1 abundance 
using pAb JP1 found decreased abundance in aged quads compared to adult quadriceps, and 
that that abundance of JPH1 was increased in exercised aged quadriceps compared to aged 
quadriceps. Interestingly, a decrease in JPH1 abundance in exercised aged soleus was 
detected compared to exercised aged quadriceps. JPH2 abundance was found to be lower in 
aged soleus compared to aged quadriceps, contrasting the increase found in JPH1 levels. 
Following on from this, JPH2 abundance was also decreased in exercised aged soleus 
compared to exercised and aged quadriceps samples. This was different to the results found 
with adult exercised samples, where JPH2 abundance was higher in exercised adult 
quadriceps compared to adult quadriceps. It is possible that exercising the muscle may have 
caused increased liberation of JPH2 from the SR membrane, thus increasing detection.  
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 In CIH tissue compared to control tissue, it is noteworthy that there was no change in JPH1 
abundance as detected by western blotting. As these samples were collected after two weeks 
of CIH treatment, it is entirely possible that the effects seen in limb muscles from this 
treatment occur after a longer period of time. Either way, it is a poorly-explored avenue of 
research, as plenty of work exists on the whole-body or diaphragmatic effects of CIH, but 
very little on the molecular effects in limb muscle. It has been shown that alterations in RyR 
function and modification (e.g. oxidation of Cys residues) occur in hypoxic tissue, and it 
follows that interacting proteins would incur similar effects (Sun et al, 2013). In this instance, 
a change in the oxidation status of the cysteine residues on RyR1 can affect the interaction of 
RyR1 with JPH1 (Phimister et al 2007).  In the case of JPH1, it is likely that it would be 
affected by any form of hypoxia as this has been shown to have an effect on metabolism of 
the cell and thus of redox potential at the SR membrane. As increasing hypoxic status also 
increases inflammatory effects in muscle cells, raised levels of membrane alterations and 
increased reactive oxygen species could certainly have an effect on JPH1 abundance and the 
status of the protein (Phimister et al, 2007). 
Ideally, one would perform a long term study of in limb, smooth and respiratory muscles 
under hypoxic conditions and examine a range of EC coupling related proteins.  This would 
allow the pinpointing of when CIH-mediated limb dysfunction arises, and if any EC coupling 
proteins are involved.  
The comparison of mdx mouse with wild type showed no difference in JPH1 abundance in 
animals of 8 months of age. This contrasts to previous results obtained by Murphy et al, 
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although the mice sampled in their study were of a different age group (Murphy et al, 2012). 
It is possible that by 8 months, the degeneration and regeneration seen in mdx muscle has 
reached a steady state, a stark contrast to the progression of the disease seen in the human 
disease Duchenne muscular dystrophy. An exception to this is the decrease seen in abundance 
of the 85 kDa form of JPH2 in mdx gastrocnemius muscle compared to wild type controls, 
and this could be a parallel of the pseudohypertrophic effect seen in DMD calf muscle, but 
confirmation of this would need further experimentation. Alterations in skeletal muscle 
hypertrophy have been linked to a mutation in JPH2, and this could add to the pathology of 
the disease (Woo et al, 2010). As dystrophin is absent in DMD and in the mdx mouse, and as 
the dystrophin protein is in complex with CAV3, a protein known to interact with JPH2, the 
decrease in JPH2 abundance could be linked to this (Woo et al, 2010).  It is very possible that 
the decrease in JPH2 has an implication for (or is because of) the structural defects seen in 
mdx muscle. Future studies could include the analysis of JPH1 and JPH2 abundance and 
monitoring of their molecular weight in an animal model of DMD, or preferably in DMD 
patient biopsies. The investigation of the effects of decreased JPH2 abundance on calcium 
signalling could also be further elucidated, perhaps in single fibre studies using calcium 
imaging. 
 Further work must also be performed on JPH expression in aged and exercised 
skeletal muscle. Considering that the population of those over 60 years of age is going to 
increase in the coming decades, sarcopenia is and will become a significant burden to patients 
and healthcare systems alike (Cruz-Jentoft et al., 2010; Cruz-Jentoft et al., 2014). The 
increases found in JPH expression in aged soleus compared to quadriceps muscles indicate 
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that use- or perhaps pathway-dependent factors are at play in aged muscle. It is also quite 
likely that the increase in soleus JPH1 levels is a compensatory measure to attempt to 
alleviate EC uncoupling, found to be increased in aged muscle (Boncompagnani et al., 2006). 
It is also possible that defective or ablated T-tubule or altered SR geometry could be part of 
the reason for the changes in JPH abundance. In the soleus, a predominantly type I muscle 
with many mitochondria, it is feasible that the increased ROS-mediated signalling associated 
with aging could result in a requirement for higher abundance of JPH1 to help regulate RyR1 
and minimise aberrant Ca
2+ 
release, as increased reactive oxygen species in muscle have been 
shown to have an effect on RyR1 (Sun et al., 2013). The increase in JPH1 may also give 
clues as to the regulation of junctophilins in muscle tissue, but this would require further 
study to fully elucidate the mechanism involved. The increased JPH1 abundance in soleus 
compared to quadriceps muscle may also be due to the bigger role this muscle has in anti-
gravity functions, which may be even more relevant in bipedal humans.   The exercised 
samples showed interesting results, whereby the JPH2 abundance was found to be increased 
in exercised quadriceps compared to unexercised adult controls. This may be due to a 
solubilising effect of exercise on the JPH proteins (Murphy et al., 2013). The decrease in 
JPH2 abundance in exercised quadriceps could also be due structural rearrangements in 
sarcopenic muscle. Taken together, these results have interesting implications for the field of 
aging research. Although further work is necessary, the alterations in JPH2 and JPH1 are of 
interest. The differential regulation of JPH1 and JPH2 during aging could not only be linked 
to RyR mediated calcium release, but also to interacting proteins such as STIM and Orai, 
TRPC3 and CAV3. It is possible that as Ca
2+
 dysregulation progresses, the compensatory 
drive to maintain intact RyR1 signalling is increased, while the need for accessory Ca
2+
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influx (such as SOCE channel and sensor Orai and STIM) decreases.  Ideally, several groups 
of aged animals could be treated with superoxide dismutase inhibitors, an exercise regime 
and controls the pathways affecting sarcopenia and thus JPH regulation could be 
disentangled. If there was also a pharmacological, molecular or physiological method of 
altering JPH expression in muscles susceptible to sarcopenia this could alleviate some portion 
of the aberrant Ca
2+
 signalling in this disease. Exercise would be an excellent method of 
doing this. Previous work has shown that after acute bouts of eccentric (lengthening 
contractions), JPH1 expression was decreased; however there are no data commenting on 
JPH1 or JPH2 expression after chronic training programs. It would be worth investigating as 
this could lead to a rationally designed exercise regime specifically created to stave off the 
adverse effects of sarcopenia on skeletal muscles. In designing such an exercise regime it 
would be important to consider the muscle specific differences and to encourage exercise of 
trunk and core muscles. This could greatly improve not only the devastating and often 
expensive effects of sarcopenia, but also ward off the often-overlooked complications of this 
disease. 
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7.5: Conclusions: 
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RyR1 is a rapidly expanding hub of protein-protein interactions necessary to regulate the 
movement of Ca
2+
 in a wide variety of cell types. In the work presented here, RyR1 has been 
shown to form a complex with GRB2, an adapter protein crucial to many signalling 
pathways. It is likely that one of the SH3 domains on the GRB2 protein interacts with the 
proline rich region in RyR1. GRB2 may bring the RyR complex into close approximation 
with a number of other protein networks, such as those involved in MAPK signalling or the 
dyrophin-dystroglycan complexes. GRB2 is likely to exert different roles and may bring RyR 
into conmtact with different intracellular pathways in non-muscle tissues, such as in B-cells. 
Further analysis is necessary to characterise other potential interactors of this complex, and to 
assess any effect they have on RyR1 gating or regulation.  
 This work also demonstrated that another interactor of RyR1, junctophilin 1, can be 
detected using the mAb VF1c. It was shown that this antibody binds to a region located 
between amino acids 369-450, and that this may be a conformational epitope.  This allows 
the cohesion of previous data using the mAb VF1c, and thus provides novel information 
about the JPH1 protein, namely that this protein is phosphorylated by an endogenous kinase 
and is non-glycosylated. It was also found that both JPH1 and JPH2 are differentially 
expressed in skeletal muscle of rabbit limb and trunk, and that this difference in abundance 
may depend on muscle developmental origin or may be use-dependent. This has massive 
implications for the study of EC coupling in many muscle types, and potentially on the 
selection of muscle types best suited for the future of JPH-based research. Calpain cleavage 
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studies confirmed the action of calpains on JPH1 and 2, and in silico studies suggested the 
amino acids likely to be cleaved by calpains I or II. It was seen that memebrane disrupting 
compounds such as DMSO and N-ter peptide siRNA transfection system may cause 
upregulation of JPH1 and 2 proteins.  
  The effects of sarcopenia on soleus and quadriceps muscle were found to be different, 
and to have opposing effects on JPH1 and JPH2 expression. Aged soleus showed increased 
JPH1 abundance compared to aged quadriceps, and this is likely to compensate for increased 
EC uncoupling found in skeletal muscle. In contrast, JPH2 decreased in aged soleus 
compared to aged quadriceps, in exercised and non exercised samples, while JPH2 abundance 
was increased in exercised adult quadriceps compared to non-exercised adult quadriceps. 
Taken together, these results imply that alterations in muscle structure and EC coupling 
proteins are implicated in the pathology of sarcopenia, and that exercise may have a 
solubilising effect on JPH proteins. Further analysis is needed to ascertain the exact effect 
these changes in JPH1 and JPH2 have on Ca
2+
 release in the muscle cell. 
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8.1: Appendices 
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A549 8 0.145 -4.533 5.17 147.51
JEG 3 8 0.145 -4.533 5.17 147.51
A7r5 8 0.145 -4.533 5.17 147.51
ShSy 5y 8 0.145 -4.533 5.17 147.51
JURKAT -
U937 8 0.145 -4.533 5.17 147.51
HL-60 -
C2C12 8 0.145 -4.533 5.17 147.51
"75 kDa band"
A549 16.5 0.3 -4.378 4.99 98.3
JEG 3 16.5 0.3 -4.378 4.99 98.3
A7r5 16.5 0.3 -4.378 4.99 98.3
ShSy 5y 16.5 0.3 -4.378 4.99 98.3
JURKAT -
U937 14 0.254545 -4.4234545 5.04 110.77
HL-60 16.5 0.3 -4.378 4.99 98.3
C2C12 16.5 0.3 -4.378 4.99 98.3
-0.200
 
Figure 8.1.b: MW calculation of cell culture screen: SH3B blot. Bands have apparent 
molecular weight of 147 kDa and 98 kDa, except for U937 cells, which have bands at 147and 
110 kDa. 
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      A549 homogenate "150 kDa" protein  average kDa "75 kDa" protein  Average kDa 
Cell screen 147.51 143.23 98.3 90.27   
Peptide Optimisation 132.8   83.27     
Hydroxyapatite  149.37   89.234     
Table 8.1.a: average of molecular weights of proteins detected using SH3B peptide  
calculated from cell culture screen, peptide optimisation and hydroxyapatite 
experiments. 
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Table 8.1.c: TagIdent (expasy.org) search using parameters defined by experimental 
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results from section 4.3.a-g. TagIdent was searched using molecular weight of 146 kDa (+/- 
20%) and a pI of 4-5, with a keyword of “SH3”, and limited to homo sapiens. Of the proteins 
returned by the search, PLCγ1 is a protein suggested by data from Wu et al (2007).  
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Figure 8.1.d: Rf  calculations for FKBP12 pull down experiments. Apparent molecular 
weights were calculated using the same method as described in Fig8.1.a.  
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Figure 8.1.e: FKBP 12 pull down of rat Brain and muscle, probed with anti- mouse or 
anti-Rabbit secondary antibody only. Brain and muscle homogenate, post solubilisation 
(PO), GST control flowthrough (GST FT), FKBP12 FT, GST-post solubilised (brain/muscle 
gst beads plus post solubilisation material), FKBP 12 –PO (brain/muscle incubated post 
solubilisation sample with FKBP 12 beads)  samples were run on 10% SDS PAGE gels 
followed by wet transfer as described in materials and methods.  
Blots were probed with 1:1000 anti mouse or anti rabbit secondary and exposed to film. The 
anti- mouse blot (A) shows a background band at 30 kDa, marked with an asterisk. No 
background bands were seen with the anti-rabbit only control.   
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Figure 8.1.f: OPHID search using “RyR1” as input method returns 38 known or 
predicted interactors. Notable described interactors (e.g. PLCγ1, GRB2 and NCK) are 
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described in Wu et al (2007). Some descrepancies exist, e.g., absence of Junctophilin, a 
known RyR1 interaction partner. The experiments in section 4.4 describe tests to validate 
some of these interactions.  
 
 
 
 
 
 
 
 
 
Figure 8.1.g: Diagram of hypothetical role for GRB2-RyR1 interaction. GRB2 may 
facilitate the interaction of RyR1 with receptor Tyrosine kinases, such as Insulin receptors, 
which may allow linking of intracellular calium ion concentrations with extracellular 
signalling eents, allowing a concerted mitogenic response via the MAPK pathway.  
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Figure 8.1.h: another possible role for GRB2-RyR1 complex. GRB2 has been shown to 
interact with the dystrophin complex in muscle cells, and it is feasible that it may act as an 
anchor to tether this complex to RyR rich areas.  Junctophilin 1, which interacts with RyR1, 
has also been shown to associate with CAV3, which is part of the dystrophin complex in 
skeletal muscle. Anchoring large protein complexes could be purely structural or have 
implications for signalling, especially in muscle afflicted Duchenne muscular dystrophy.  
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8.2: Appendix II 
Peptide Array Data 
 
Figure 8.2.a: Peptide array of amino acid fragments from JPH1 probed with VF1c and 
with secondary antibody only. VF1c interacts with spot 9, which contains the sequence 
QAALAARQECDIARAVAR. This result is confounded by the secondary only control 
which displays strong interaction with spots 1, 4, 9, 14, 18, 24, 25 and 26. It is possible that 
VF1c antibody binds a conformational epitope, and that this region of JPH1 resembles an 
antibody binding protein. 
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Spot 
no. Peptide Sequence 
Interacts with 
VF1c antibody  
Interacts with 
Secondary 
alone 
1 MARTKVEIANSRTAHARA   √ 
2 TKVEIANSRTAHARAKAD   √ 
3 EIANSRTAHARAKADAAD   √ 
4 NSRTAHARAKADAADQAA   √ 
5 TAHARAKADAADQAALAA   √ 
6 ARAKADAADQAALAARQE   √ 
7 KADAADQAALAARQECDI   √ 
8 AADQAALAARQECDIARA   √ 
9 QAALAARQECDIARAVAR √ √ 
10 LAARQECDIARAVARELS   √ 
11 RQECDIARAVARELSPDF   √ 
12 CDIARAVARELSPDFYQP   √ 
13 ARAVARELSPDFYQPGPD   √ 
14 VARELSPDFYQPGPDYIK   √ 
15 ELSPDFYQPGPDYIKQRL   √ 
16 PDFYQPGPDYIKQRLQEG   √ 
17 YQPGPDYIKQRLQEGVDA   √ 
18 GPDYIIKQRLQEGVDAKEN   √ 
19 YIKQRLQEGVDAKENPEE   √ 
20 QRLQEGVDAKENPEEKVP   √ 
21 QEGVDAKENPEEKVPAKP   √ 
22 VDAKENPEEKVPAKPPTP   √ 
23 KENPEEKVPAKPPTPKES   √ 
24 PEEKVPAKPPTPKESPHF   √ 
25 KVPAKPPTPKESPHFYRK   √ 
26 PAKPPTPKESPHFYRKGT   √ 
 
Table 8.2.a: Amino acids from JPH1 (VF1c interacting region 369-460) synthesised via 
fmoc chemistry and probed with VF1c antibody. Coloured bars indicate the spots that 
VF1c interacted with. Blue bars indicate strong interaction, green indicate medium 
interactions with the secondary alone while red bars denote interaction with the VF1c 
antibody. the VF1c antibody detects a spot corresponding to 393-410. It is possible that VF1c 
binds to the JPH1 protein in a conformational manner. 
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Rabbit pAb JP1, JP2 and VF1c screen : Coomassie loading controls and secondary 
antibody controls 
 
Figure 8.2.b: Post antibody detection via ECl and Film, rabbit tissue blots were stained 
with Coomassie for densitometric analysis. Signals obtained from each antibody were 
normalised to total protein per lane.  
 
Table 8.2.b: Calculated molecular weight of JPH1 and JPH2 in various rabbit skeletal 
muscle.  
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Figure 8.2.c: Rabbit muscle secondary only blots. Fresh rabbit tissue blots were probed 
with anti-rabbit or anti mouse secondary antibodies only. Anti-Rabbit blots contain a 
background band at 45kDa which was then excluded from analysis of JPH1 and 2. The VF1c 
antibody was detected using the anti-mouse secondary, thus no extraneous bands were seen. 
Alternatives to using the anti-rabbit secondary are tagging the primary JPH1 and 2  antibodies 
with fluorescent probes or HRP enzyme and detecting them directly, without the use of a 
secondary.  
A7r5 Calpain Cleavage Study 
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Figure 8.2.f:A7r5 secondary only controls. A7r5 cells were incubated with media only, 
0.1% DMSO, ALL-N, A23187 and BAPTA-AM. Western blotting was performed and blots 
were incubated with anti-mouse and anti-rabbit secondary antibodies only. Background bands 
can be seen at 220 and 100 kDa in the left hand panel, and at 60 50 and 45 kDa in the right 
hand panel.   
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Figure 8.2.g: Clustal Ω alignment of protein sequences from JPH1 and JPH2 from 
human, rabbit, rat and mouse.  
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Figure 8.2.h: antibody to N-terminal end of JPH1 was used to probe C2C12 cells.The 
only available antibody to JPH1 (Santa Cruz biotechnology) was purchased and used to probe 
C2C12 differentiation samples. Despite multiple attempts and trials with many secondary 
antibody concentrations, different muscle tissue and buffer controls, this antibody was 
determined to be completely ineffectual, thus the lab wsa refunded by the SCBT. This is 
unfortunate an N-terminal targeting antibody would have provided for a clear and concise 
study of JPH1 via western blot or other methods such as ELISA or immunohistological study. 
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8.3: Appendix III 
 
 
Figure 8.3.a: Western blot of rat muscle and organ tissue probed with anti-mouse 
secondary antibody only. Two bands are seen in rat muscle samples (VL, soleus, 
diaphragm, sternohyoid and intercostals). A band at 220 kDa can be seen in pancreas sample 
and in A7r5 cell lysates.  
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Table 8.3.a: Rf of proteins analysed from rat muscle as detected with anti mouse 
secondary antibodies. Blots probed with other antibodies raised in mouse were then 
carefully analysed to ensure no rogue secondary antibody was detected as a valid interaction.   
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Figure 8.3.b: Rat muscle and organ samples probed with anti-rabbit antibody. Western 
blot of rat muscle (VL, soleus, diaphragm, sternohyoid and intercostals) and organs (brain, 
heart, lung, liver, pancreas, spleen, adrenal gland) and A7r5 cell line were incubated with 
anti-rabbit secondary only. No bands were detected. 
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Figure 8.3.c: Anti-rabbit secondary control of Mouse organ and muscle tissue. Mouse 
organ tissue (brain, heart, lung, liver, pancreas, spleen) and muscle samples (diaphragm, 
intercostals, Vast lateralis, EDL, Gastrocnemuis, soleus) were analysed by western blot and 
incubated with anti-rabbit secondary antibody. Some bands were detected in lung, liver and 
spleen samples. No bands were detected in muscle samples.  
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Figure 8.3.d: Anti-Mouse secondary control western blot of mouse organ and muscle.  
Organ tissue (brain, heart, lung, liver, pancreas, spleen) and muscle samples (diaphragm, 
intercostals, vastus lateralis, EDL, gastrocnemius, soleus) were subjected to SDS-PAGE  and 
western blot procedures and probed with anti mouse secondary antibodies. No bands were 
detected in any of the samples analysed.  
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Figure 8.3.e: Quadriceps from adult and aged exercised and unexercised mouse probed 
with mAb VF1c and pAb JP1 antibodies. Blots were aligned visually using the molecular 
weight markers. A and C are the sme blot probed first with pAb JP1, stripped and reprobed 
with mAb VF1c. Blot B is exercised adult and aged samples.When lined up, it can be seen 
the two antibodies detect the same protein at different molecular weights. pAb JP1 detects 
full length JPH1, seen here at 75 kDa, and occasionally as a doublet. There is much more 
background detected with this antibody and it required long exposure. mAb VF1c detects 
several bands, at 75 kDa (full length), 65 kDa  and much lower at 50 kDa(cleaved JPH1)  The 
JP1 and VF1c bands line up at an apparent MW of 75 kDa  in A and C, while the exercised 
samples in B shoe=w two main bands. Given that we know the binding locations of these 
anitibodies (Cterminal for JP1 and mid-region for VF1c) we can say that a cleavage effect is 
occurring due to exercise, which cleaved the JPH1 protein in the somewhere along the middle 
to C terminal portion.   
 
Figure 8.3.f:  Diagram of possible cleavage of JPH1 protein (dashed lines). mAb VF1c 
and pAb JP1 binding regions are shown as well. Cleavage in the region of the dashed lines 
would account for the staining pattern seen using these antibodies, and is corroborated by the 
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calpain cleavage studies in chapter 5. If the caleage domains are conserved between JPH1 
and 2 we can assume that the main calpain cleavage in JPH1 is also C terminal, as described 
for JPH2 in (Guo et al, 2015). This is supported by the experimental data shown in chapters 5 
and 6.   
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